

Supporting Information

Photo-Hydroacylation: 1-Tetralones from ortho-Allylbenzaldehydes

Veronika Schmalz and Ulrich Koert*

Table of Contents

1	Methods and Materials	2
2	Optimization & Effect of Reaction Conditions.....	3
3	Emission Spectra of Employed Light Source.....	4
4	Sensitivity Assessment.....	5
5	Substrate Synthesis	6
5.1	Isomerisation Reaction of S7.....	8
6	General Procedures I – III: Substrate Synthesis.....	10
7	General Procedures IV – VI: Substrate Synthesis.....	20
8	General Procedure VII-X: Substrate Synthesis.....	24
9	General Procedure XI: Photocyclization to Tetralones.....	30
9.1	Limitation of the Substrate Scope.....	37
10	Synthesis of Prolonged Sidechain	39
11	Synthesis of Deuterated Compounds	40
12	Mechanistic Studies	41
12.1	Deuteration Studies	41
12.2	Deuterium Scrambling Experiment.....	42
12.3	Quantum Yield Determination.....	43
12.4	UV-Vis Measurements	43
13	Author Contributions	142

1 Methods and Materials

All **non-aqueous reactions** were carried out under argon atmosphere using oven-dried glassware unless noted otherwise. All solvents were distilled by rotary evaporation prior to use. Solvents for non-aqueous reactions were dried as follows prior to use, unless noted otherwise: THF was dried and degassed with KOH and subsequently distilled from sodium/benzophenone or Solvona® under nitrogen atmosphere. CH₂Cl₂ and acetonitrile were dried and degassed by distillation from CaH₂ under nitrogen atmosphere. MeOH was dried and degassed by distillation from Mg-turnings (5 g/L) under nitrogen atmosphere. Toluene was dried and degassed with Solvona® and distilled from it under nitrogen atmosphere. All commercially available reagents and reactants were used without purification unless otherwise noted.

Certain sections of this paper were written with the assistance of an AI language model. Specifically, selected paragraphs were refined using the ChatGPT language model, developed by OpenAI. The AI model's role was solely to provide language generation support and should not be considered as an author or contributor to the scientific work. The authors take full responsibility for the final content presented in this paper.

Thin layer chromatography (TLC) was performed to monitor reactions using MERCK silica gel 60 F₂₄₅ plates. Visualization was performed by fluorescence quenching under UV-light (254, 365 nm) or using a cerium sulfate/phosphomolybdic acid stain. **Chromatographic purification** of products was performed using Merck silica gel 60 (230 – 400 mesh) by application of positive pressure. Concentration under reduced pressure was performed by rotary evaporation at 40 °C and by exposing to high vacuum at room temperature if necessary.

NMR spectra were recorded on a Bruker AV II 300 MHz, AV III 500 MHz or AV III HD 500 MHz spectrometer at room temperature. The signals were referenced to residual solvent and chemical shifts are reported in ppm. Signal patterns are reported based on appearance as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet.

Mass spectra were recorded by the mass service department of the Philipps-Universität Marburg. HR-ESI and APCI mass spectra were acquired with an LTQ-FT Ultra mass spectrometer (Thermo Fischer Scientific). The resolution was set to 100.000.


IR spectra were recorded on a Bruker IFS 200 spectrometer. Intensities are reported as follows: s = strong, m = medium, w = weak. Absorption bands are given in wave numbers (cm⁻¹).

Melting points were determined on a Mettler Toledo MP70 using one end closed capillary tubes.

Photochemical reactions were run in 25 mL round bottom flasks made of borosilicate glass (Duran®) unless noted otherwise, placed 6 – 7 cm away from the irradiation source. Irradiation was performed with a 365 nm LED lamp (7 LEDs, 200 mW each) over a stirring plate with two cooling fans.

2 Optimization & Effect of Reaction Conditions


Table 1: Conversion of starting material in different solvents.



entry	solvent	Yield [%]	Recovered starting material [%]
1	MeCN	55	40
2	toluene	27	73
3	acetone	48	21
4	<i>i</i> -PrOH	28	n.d.
5	CH ₂ Cl ₂	67	33
6	CH ₂ Cl ₂ (55 mM)	68	32
7	CH ₂ Cl ₂ (45 mM)	72	27
8	CH ₂ Cl ₂ (200 mM), 150 min	78	22
9	CH ₂ Cl ₂ (20 mM), 150 min	88	-
10	CH ₂ Cl ₂ (15 mM), 180 min	93	-


The reactions were carried out at 0.15 mmol scale. Product and starting material were isolated.

Table 2: Deviation from standard conditions in solvents and concentration.



entry	variation from conditions	Yield [%]	Recovered starting material [%]
1	none	93	-
2	10 mM instead of 15 mM	91	-
3	MeCN instead of CH ₂ Cl ₂	88	-

Table 3: Control experiments.



entry	variation from standard conditions	Yield [%]	Recovered starting material [%]
1	no light	0	100
2	2.5 h instead of 3 h	91	2

3 Emission Spectra of Employed Light Source





Figure S1: Emission spectra and plot of the 365 nm LED lamp.

The normalized overlay of the measured emission spectra of the lamp confirms an increased emission intensity at 365 nm (Figure S1).

4 Sensitivity Assessment



The sensitivity assessment was conducted according to studies reported by GLORIUS *et al.*^[1] The diagram shown in Figure S2 was made using the template provided by GLORIUS *et al.*^[1]

Table 4: results of the sensitivity assessment.

entry	experiment	variation from standard conditions	yield [%]	recovered starting material (*)
1	High <i>c</i>	$V_{\text{rxn}} - 10\% V_{\text{rxn}}$	-11	no
2	Low <i>c</i>	$V_{\text{rxn}} + 10\% V_{\text{rxn}}$	-6	no
3	H ₂ O	+ H ₂ O; $V_{\text{H}_2\text{O}} = 1.00$ equiv	-11	no
4	Low O ₂	degassed, freeze-pump-thaw	-16	no
5	High O ₂	+ air; $V_{\text{air}} = 1.3 \cdot V_{\text{rxn}}$	-19	no
6	Low T	$T - 10\text{ }^\circ\text{C}$	-13	no
7	High T	$T + 10\text{ }^\circ\text{C}$	-22	no
8	Low I	distance / 2	-73	yes
9	High I	distance \cdot 2	-14	no





Figure S2: Radar diagram illustrating the results of the sensitivity assessment. C = concentration of starting material, T = temperature, I = light intensity, * = incomplete conversion.


5 Substrate Synthesis

(3-methylbut-2-en-1-yl)boronic acid **S1**



was obtained according to a protocol reported by PARK *et al.*^[2] The concentration was determined according to the protocol using naphthalene.

methyl 2-(3-methylbut-2-en-1-yl)nicotinate **S2**,




A solution of boronic acid **S1** (0.22 M in CHCl₃, 26.9 mL, 6.00 mmol, 2.00 equiv) was transferred into a SCHLENK-flask and the solvent was evaporated under stirring *in vacuo*. Methyl 2-bromonicotinate (648 mg, 3.00 mmol, 1.00 equiv), K₂CO₃ (1.66 mg, 12.0 mmol, 4.00 equiv), Pd(PPh₃)₄ (173 mg, 0.15 mmol, 0.05 equiv) and dioxane (9.0 mL) were added successively. The mixture was degassed and stirred at 100 °C for 12 h. The crude was diluted with

CH₂Cl₂ 5 mL and 10 mL sat. NaHCO₃ solution. The aqueous phase was extracted with CH₂Cl₂ (3 x 20 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane/EtOAc 10:1 → 8:1 → 6:1) to give the product **S2** (288 mg, 1.41 mmol, 47%) as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.65 (dd, *J* = 4.8, 1.8 Hz, 1H, CH_{arom}), 8.13 (dd, *J* = 7.9, 1.8 Hz, 1H, CH_{arom}), 7.19 (dd, *J* = 7.9, 4.8 Hz, 1H, CH_{arom}), 5.37 (tp, *J* = 6.9, 1.4 Hz, 1H, CH_{olef}), 3.92 (d, *J* = 7.4 Hz, 2H, CH₂), 3.91 (s, 3H, COOCH₃), 1.75 (d, *J* = 1.3 Hz, 3H, CH₃), 1.72 (q, *J* = 1.4 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 167.4, 162.5, 152.1, 138.6, 133.5, 125.6, 121.4, 121.0, 52.5, 36.2, 26.0, 18.4 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2952 (w), 2915 (w), 2857 (w), 1727 (s), 1583 (w), 1568 (m), 1430 (s), 1376 (w), 1264 (s), 1189 (w), 1128 (s), 1101 (w), 1080 (s), 1060 (w), 964 (w), 923 (w), 875 (w), 838 (w), 786 (w), 758 (m), 608 (w), 551 (w), 449 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₅NO₂H 206.1176, Found 206.1172.

(2-(3-methylbut-2-en-1-yl)pyridin-3-yl)methanol **S3**,




Pyridine **S2** (287 mg, 1.40 mmol, 1.00 equiv) was dissolved in anhydrous MeOH (1.40 mL). NaOMe solution (25% in MeOH, 0.02 mL, 0.07 mmol, 0.05 equiv) and NaBH₄ (132 mg, 3.50 mmol, 2.50 equiv) was added successively and the mixture was stirred for 12 h at rt. The mixture was diluted with 5 mL sat. NaHCO₃-solution and 10 mL CH₂Cl₂.

The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane/EtOAc 4:1 → 1:1 → 1:2 → 0:1) to give the product **S3** (95.2 mg, 0.54 mmol, 38%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.46 (dd, *J* = 4.9, 1.8 Hz, 1H, CH_{arom}), 7.74 – 7.69 (m, 1H, CH_{arom}), 7.15 (dd, *J* = 7.6, 4.9 Hz, 1H, CH_{arom}), 5.32 (tp, *J* = 6.9, 1.4 Hz, 1H, CH_{olef}), 4.72 (s, 2H, CH₂OH), 3.58 (dt, *J* = 6.9, 1.2 Hz, 1H, CH₂), 1.97 (s, 1H, OH), 1.78 – 1.76 (m, 3H, CH₃), 1.73 (q, *J* = 1.5 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 159.2 (C_{arom}), 148.4 (C_{arom}), 135.6 (C_{arom}), 134.0 (C_{arom}), 133.5 (C_{olef}), 121.6 (C_{arom}), 121.4 (CH_{olef}), 62.2 (CH₂OH), 34.9 (CH₂), 25.9 (CH₃), 18.3 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3225 (w), 3059 (w), 2967 (w), 2914 (m), 2856 (w), 1728 (m), 1671 (w), 1579 (m), 1434 (s), 1405 (w), 1376 (w), 1357 (w), 1266 (m), 1129 (w), 1100 (w), 1082 (w), 1043 (s), 922 (w), 874 (w), 836 (w), 790 (s), 760 (w), 687 (w), 616 (w), 554 (w), 450 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₁H₁₆NOH 178.1223, Found 178.1226.

2-(3-methylbut-2-en-1-yl)nicotinaldehyde **4h**,




Pyridine **S3** (95.2 mg, 0.54 mmol, 1.00 equiv) was dissolved in anhydrous CH₂Cl₂ (2.6 mL) and the mixture was stirred for 12 h at rt. The mixture was diluted with 5 mL sat. NaHCO₃-solution and 10 mL CH₂Cl₂. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude

was purified by column chromatography (*n*-pentane/EtOAc 5:1) to give the product **4h** (57.0 mg, 0.33 mmol, 61%) as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.33 (s, 1H, CHO), 8.71 (dd, *J* = 4.8, 1.9 Hz, 1H, CH_{arom}), 8.12 (dd, *J* = 7.8, 1.9 Hz, 1H, CH_{arom}), 7.31 (dd, *J* = 7.8, 4.8 Hz, 1H, CH_{arom}), 5.35 (tp, *J* = 6.9, 1.4 Hz, 1H, CH_{olef}), 3.94 (dt, *J* = 6.8, 1.2 Hz, 2H, CH₂), 1.78 – 1.77 (m, 3H, CH₃), 1.72 (q, *J* = 1.5 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 191.3 (CHO), 163.7 (C_{arom}), 153.7 (C_{arom}), 137.6 (C_{arom}), 134.1 (C_{olef}), 129.4 (C_{arom}), 122.0 (C_{arom}), 121.2 (CH_{olef}), 34.7 (CH₂), 25.9 (CH₃), 18.4 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3050 (w), 2969 (w), 2914 (w), 2859 (w), 2748 (w), 1965 (w), 1693 (s), 1581 (s), 1564 (w), 1439 (m), 1391 (m), 1377 (w), 1278 (w), 1254 (w), 1217 (m), 1196 (w),

1153 (w), 1101 (w), 1061 (w), 984 (w), 923 (w), 891 (w), 875 (w), 840 (w), 796 (m), 754 (w), 729 (w), 668 (w), 634 (w), 607 (w), 549 (w), 451 (w), 416 (w). **HRMS** (ESI+) m/z: [M+H]⁺ Calcd for C₁₁H₁₃NOH 176.1070, Found 176.1067.


methyl 3-(3-methylbut-2-en-1-yl)isonicotinate **S4**,



A solution of boronic acid **S1** (0.47 M in CHCl₃, 4.00 mmol, 2.00 equiv) was transferred into a SCHLENK-flask and the solvent was evaporated under stirring *in vacuo*. Methyl 3-bromoisonicotinate (432 mg, 2.00 mmol, 1.00 equiv), K₂CO₃ (1.11 g, 8.00 mmol, 4.00 equiv) Pd(PPh₃)₄ (115 mg, 0.10 mmol, 0.05 equiv) and dioxane (6.0 mL) were added successively. The mixture was degassed and stirred at 100 °C for 12 h. The crude was diluted with CH₂Cl₂ 5 mL and 10 mL sat. NaHCO₃ solution. The aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane/EtOAc 5:1) to give the product **S4** (365 mg, 1.78 mmol, 89%) as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.58 (s, 1H, CH_{arom}), 8.55 (d, J = 5.0 Hz, 1H, CH_{arom}), 7.61 (d, J = 5.0 Hz, 1H, CH_{arom}), 5.23 (tp, J = 7.1, 1.5 Hz, 1H, CH_{olef}), 3.92 (s, 3H, COOCH₃), 3.66 (d, J = 7.1 Hz, 2H, CH₂), 1.73 (d, J = 1.2 Hz, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 167.0 (COOCH₃), 152.4 (C_{arom}), 147.9 (C_{arom}), 136.8 (C_{arom}), 136.7 (C_{olef}), 133.9 (C_{arom}), 123.2 (C_{arom}), 121.7 (CH_{olef}), 52.7 (COOCH₃), 30.1 (CH₂), 25.9 (CH₃), 18.1 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3214 (m), 3052 (w), 2968 (w), 2915 (w), 1731 (s), 1589 (w), 1482 (w), 1435 (s), 1406 (w), 1274 (s), 1194 (w), 1145 (w), 1118 (w), 1100 (m), 1062 (w), 1027 (w), 965 (w), 883 (w), 848 (w), 834 (w), 786 (w), 748 (w), 720 (m), 696 (w), 673 (w), 643 (w), 542 (m), 513 (w), 478 (w), 450 (w). **HRMS** (ESI+) m/z: [M+Na]⁺ Calcd for C₁₂H₁₅NO₂H 206.1176, Found 206.1171.


(3-(3-methylbut-2-en-1-yl)pyridin-4-yl)methanol **S5**,



Pyridine **S4** (363 mg, 1.77 mmol, 1.00 equiv) was dissolved in anhydrous MeOH (1.80 mL). NaOMe solution (25% in MeOH, 0.02 mL, 0.09 mmol, 0.05 equiv) and NaBH₄ (167 mg, 4.43 mmol, 2.50 equiv) was added successively and the mixture was stirred for 12 h at rt. The mixture was diluted with 5 mL sat. NaHCO₃-solution and 10 mL CH₂Cl₂. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane/EtOAc 1:1→1:2) to give the product **S5** (89.9 mg, 0.51 mmol, 29%) as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ 8.41 (d, J = 5.0 Hz, 1H, CH_{arom}), 8.32 (s, 1H, CH_{arom}), 7.42 (d, J = 5.0 Hz, 1H, CH_{arom}), 5.14 (tp, J = 7.1, 1.5 Hz, 1H, CH_{olef}), 4.72 (s, 2H, CH₂OH), 3.29 (d, J = 7.0 Hz, 2H, CH₂), 3.07 (br s, 1H, OH), 1.74 – 1.70 (m, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 149.7 (C_{arom}), 148.2 (C_{arom}), 147.9 (C_{arom}), 134.0 (C_{olef}), 133.8 (C_{arom}), 121.2 (C_{arom}), 121.0 (CH_{olef}), 61.2 (CH₂OH), 29.1 (CH₂), 25.8 (CH₃), 18.0 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3476 (w), 2971 (w), 2914 (w), 2858 (w), 2360 (m), 2310 (w), 2276 (w), 1626 (m), 1493 (w), 1434 (s), 1377 (w), 1217 (w), 1160 (s), 1095 (m), 1058 (s), 984 (w), 924 (w), 901 (w), 833 (s), 774 (w), 718 (w), 678 (w), 537 (w), 491 (w), 448 (w). **HRMS** (ESI+) m/z: [M+Na]⁺ Calcd for C₁₁H₁₅NOH 178.1232, Found 178.1224.


3-(3-methylbut-2-en-1-yl)isonicotinaldehyde **4i**,



Pyridine **S5** (89.9 mg, 0.51 mmol, 1.00 equiv) was dissolved in anhydrous CH₂Cl₂ (2.4 mL) and the mixture was stirred for 12 h at rt. The mixture was diluted with 5 mL sat. NaHCO₃-solution and 10 mL CH₂Cl₂. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layer was washed with brine (20 mL) dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane/EtOAc 5:1) to give the product **4i** (34.0 mg, 0.19 mmol, 38%) as a yellow oil.


¹H NMR: (500 MHz, CDCl₃) δ = 10.33 (s, 1H, CHO), 8.69 (d, J = 5.0 Hz, 1H, CH_{arom}), 8.65 (s, 1H, CH_{arom}), 7.61 (d, J = 5.0 Hz, 1H, CH_{arom}), 5.24 (tp, J = 7.1, 1.5 Hz, 1H, CH_{olef}), 3.73 (d, J = 7.1 Hz, 2H, CH₂), 1.76 – 1.74 (m, 3H, CH₃), 1.73 (q, J = 1.4 Hz, 3H, CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 191.9 (CHO), 152.8 (C_{arom}), 149.0 (C_{arom}), 139.0 (C_{arom}), 137.0 (C_{arom}), 134.3 (C_{olef}), 122.3 (C_{arom}), 121.7 (CH_{olef}), 28.9 (CH₂), 25.8 (CH₃), 18.2 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3028 (w), 2971 (w), 2915 (w), 2858 (w), 2749 (w), 1705 (s), 1561 (w), 1482 (w), 1449 (w), 1409 (m), 1377 (w), 1310 (w), 1284 (w), 1220 (m), 1200 (w), 1133 (w), 1099 (w), 1054 (w), 984 (w), 829 (m), 800 (w), 773 (w), 738 (w), 658 (m), 438 (w). **HRMS** (ESI+) m/z: [M+H]⁺ Calcd for C₁₁H₁₃NOH 176.1070, Found 176.1068.

methyl (*E*)-4-(2-formylphenyl)but-2-enoate **S6**




was obtained according to a protocol reported by DIXON *et al.*^[3]

methyl (*E*)-3-(2-formylphenoxy)acrylate **S7**



was obtained according to a protocol reported by KOKETSU *et al.*^[4]

5.1 Isomerisation Reaction of **S7**



S7 (64.3 mg, 0.29 mmol, 0.015 M) was irradiated in CH₂Cl₂ (19.5 mL) with 365 nm UV-Light for 3 h. The solvent was removed under reduced pressure. The isomer mixture was obtained in a 1:0.82 *E/Z*-ratio (see Figure 4).




Figure 3: Stacked ¹H-NMR spectra of **S7**-(*E*)-isomer (blue), **S7**-isomer mixture after irradiation (green), **S7**-(*Z*)-isomer (red).





Figure 4: ¹H-NMR spectrum of irradiation mixture of **S7**. *E*-isomer (blue) and *Z*-isomer (red) marked.

6 General Procedures I – III: Substrate Synthesis



General Procedure I: Acetylation

The acetylation was carried out according to a protocol reported by NISHIBAYASHI *et al.*^[5]

2-Bromobenzaldehyde **3S** (1.00 equiv) and anhydrous MeOH (17 M) were placed in a SCHLENK-flask under inert atmosphere. Trimethyl orthoformate (4.00 equiv) and *p*TsOH x H₂O (0.01 equiv) were added and the reaction mixture was stirred for 2 h at rt. The mixture was concentrated under reduced pressure. Sat. NaHCO₃-solution was added and the mixture was extracted with Et₂O (3 x). The combined organic layers were washed with water (2 x) and brine, dried over Na₂SO₄. The product was purified as indicated.

General Procedure II A: Alkylation

Unless otherwise noted the alkylation was carried out with the following protocol.

To a solution of *ortho*-bromo acetal **3S** (1.00 equiv) in anhydrous THF (0.3 M) at -78 °C *n*-BuLi (1.10 equiv, 2.5 M) were added dropwise and the solution was stirred for 1 h. R¹,R²-Allylbromide (1.30 equiv) was added to the solution and the mixture was allowed to warm to rt for 2 h. The reaction was quenched with sat. NaHCO₃-solution and extracted with Et₂O (3 x). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure. Unless otherwise noted, the obtained acetal was used in the next reaction without further purification and characterization due to instability on the column chromatography.

General Procedure II B: Alkylation


Unless otherwise noted the alkylation was carried out with the following protocol.

To a solution of *ortho*-bromo acetal **3S** (1.00 equiv) in anhydrous THF (0.3 M) at -78 °C *n*-BuLi (1.10 equiv, 2.5 M) were added dropwise and the solution was stirred for 1 h. CuBr x Me₂S (0.5 equiv) were added and the reaction was allowed to warm to -40 °C and stirred at -40 °C for 40 min. R¹,R²-Allylbromide (1.30 equiv) was added to the solution and the mixture was allowed to warm to rt over night. The reaction was quenched with sat. NaHCO₃-solution and extracted with Et₂O (3 x). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure. Unless otherwise noted, the obtained acetal was used in the next reaction without further purification and characterization due to instability on the column chromatography.

General Procedure III: Acetal Cleavage


Acetal **3S** (1.00 equiv) was dissolved in acetone (0.075 M) and *p*TsOH x H₂O (0.05 equiv) was added. The solution was stirred for 2 h at rt. Et₂O and sat. NaHCO₃-solution were added and the mixture was extracted with Et₂O (3 x). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure. The residue was purified by column chromatography to give **4** as a colorless oil

1-bromo-2-(dimethoxymethyl)benzene **3S1**



was obtained according to general procedure I, a protocol reported by NISHIBAYASHI *et al.*^[5]


2-(but-2-en-1-yl)benzaldehyde **4k**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S1** (2.31 g, 10.0 mmol) and crotyl bromide (1.34 mL, 13.0 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4k** (1.21 mg, 7.57 mmol, 76% over two steps, *E/Z* 86:14) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.29 (s, 1H, CHO), 7.86 – 7.82 (m, 1H, CH_{arom}), 7.53 (s, 1H, CH_{arom}), 7.37 (tdd, *J* = 7.7, 1.2, 0.4 Hz, 1H, CH_{arom}), 7.33 – 7.31 (m, 0.14H, CH_{arom,minor}), 7.29 (ddd, *J* = 7.6, 1.3, 0.7 Hz, 0.86H, CH_{arom,major}), 5.67 – 5.51 (m, 1.23H, CH_{olef}, CH_{olef,minor}), 5.48 – 5.40 (m, 0.86H, CH_{olef,major}), 3.84 (d, *J* = 6.9 Hz, 0.28H, CH_{2,minor}), 3.75 (dt, *J* = 6.3, 1.6 Hz, 1.75H, CH_{2,major}), 1.75 (ddt, *J* = 6.6, 1.6, 0.9 Hz, 0.41H, CH_{3,minor}), 1.66 (dq, *J* = 6.4, 1.5 Hz, 2.60H, CH_{2,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.6 (CHO_{minor}), 192.5 (CHO_{major}), 143.6 (C_{arom,major}), 134.1 (C_{arom,major}), 134.0 (C_{arom,minor}), 131.8 (C_{arom,minor}), 131.2 (C_{arom,major}), 131.1 (C_{arom,major}), 130.7 (C_{arom,minor}), 129.8 (CH_{olef,major}), 128.6 (C_{arom,minor}), 127.3 (CH_{olef,major}), 126.9 (C_{arom,major}), 126.8 (C_{arom,minor}), 125.5 (C_{arom,minor}), 35.5 (CH_{2,major}), 30.2 (CH_{2,minor}), 18.0 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3024 (w), 2916 (w), 2855 (w), 2733 (w), 1692 (s), 1598 (m), 1573 (w), 1485 (w), 1451 (w), 1401 (w), 1377 (w), 1287 (w), 1264 (w), 1206 (m), 1159 (w), 1112 (w), 1088 (w), 1057 (w), 1044 (w), 1029 (w), 967 (m), 899 (w), 858 (w), 832 (w), 808 (w), 752 (s), 687 (w), 660 (w), 635 (w), 587 (w), 547 (w), 468 (w), 435 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₁H₁₂O 161.0961, Found 161.0960.


2-(3-methylbut-2-en-1-yl)benzaldehyde **4l**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S1** (1.16 g, 5.00 mmol) and prenyl bromide (0.75 mL, 6.50 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4l** (418 mg, 2.40 mmol, 48% over two steps) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 10.29 (s, 1H, CHO), 7.84 (dd, *J* = 7.6, 1.7 Hz, 1H, CH_{arom}), 7.51 (td, *J* = 7.6, 1.6 Hz, 1H, CH_{arom}), 7.42 – 7.26 (m, 2H, 2 x CH_{arom}), 5.27 (ddp, *J* = 7.0, 5.7, 1.5 Hz, 1H, CH_{olef}), 3.76 (d, *J* = 7.1 Hz, 2H, CH₂), 1.74 (s, 2H, CH₃), 1.73 (s, 3H, CH₃) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 192.7 (CHO), 144.7, 134.2, 134.0, 133.3, 131.4, 130.8, 126.7, 122.9, 31.5, 25.9, 18.2 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3367 (w), 2978 (w), 2934 (w), 1694 (s), 1601 (w), 1464 (w), 1378 (w), 1328 (w), 1285 (w), 1206 (m), 1156 (w), 1093 (w), 1034 (w), 976 (w), 842 (w), 753 (s), 711 (w), 686 (w), 637 (w), 591 (w), 467 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₂H₁₄O 175.1117, Found 175.0750.

2-allylbenzaldehyde **4m**,




To a solution of *ortho*-bromo acetal **3S1** (466 mg, 1.90 mmol) in anhydrous THF (5.8 mL) at -78 °C *n*-BuLi (0.87 mL, 2.5 M) were added dropwise and the solution was stirred for 30 min. To the solution CuBr x Me₂S (195 mg, 0.95 mmol) was added and the mixture was warmed to -40 °C for 1 h. Allylbromide (0.22 mL, 2.47 mmol) was added dropwise and the reaction was stirred for 18 h at rt. To the mixture sat. ammonium chloride solution (10 mL) was added carefully.

The mixture was extracted with Et₂O (3 x 15 mL). The combined organic phases were washed with brine, dried with Na₂SO₄, filtered and concentrated under reduced pressure. The crude was then treated according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4m** (166 mg, 1.14 mmol, 60% over two steps) as a colorless oil.


¹H NMR: (500 MHz, CDCl₃) δ = 10.26 (s, 1H, CHO), 7.85 (dd, *J* = 7.6, 1.6 Hz, 1H, CH_{arom}), 7.54 (td, *J* = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.40 (td, *J* = 7.5, 1.3 Hz, 1H, CH_{arom}), 7.30 (dd, *J* = 7.6, 1.1 Hz, 1H, CH_{arom}), 6.04 (ddt, *J* = 17.1, 10.1, 6.2 Hz, 1H, CH_{olef}), 5.09 (dq, *J* = 10.1, 1.5 Hz, 1H, CHH_{olef}), 4.98 (dq, *J* = 17.1, 1.7 Hz, 1H, CHH_{olef}), 3.83 (dt, *J* = 6.3, 1.8 Hz, 2H, CH₂) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.5 (CHO), 142.4 (C_{arom}), 137.1 (C_{arom}), 134.1 (C_{arom}), 134.0 (C_{arom}), 131.7 (C_{arom}), 131.2 (C_{arom}), 127.1 (C_{arom}), 116.6 (C_{arom}), 36.7 (CH₂) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3076 (w), 3008 (w), 2979 (w), 2859 (w), 2735 (w), 1694 (s), 1637 (w), 1599 (m), 1574 (w), 1485 (w), 1452 (w), 1404 (w), 1287 (w), 1208 (m), 1190 (w), 1161 (w), 1093 (w), 995 (w), 916 (w), 856 (w), 835 (w), 803 (w), 780 (w), 753 (s), 661 (w), 635 (w), 555 (w), 512 (w), 441 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₀H₁₀O 147.0804, Found 147.0807.

3-bromocyclopent-1-ene **S8**



was obtained according to a protocol reported by TAN *et al.*^[6]


2-(cyclopent-2-en-1-yl)benzaldehyde **4o**



was obtained utilizing first the general procedure II B, using corresponding aryl bromide **3S1** (0.70 g, 3.00 mmol) and 3-bromocyclopent-1-ene **S8** (0.74 mL, 6.50 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4o** (42.0 mg, 0.24 mmol, 16% over two steps) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.39 (s, 1H, CHO), 7.86 – 7.80 (m, 1H, CH_{arom}), 7.52 (td, *J* = 7.6, 1.5 Hz, 1H, CH_{arom}), 7.40 – 7.31 (m, 1H, CH_{arom}), 6.02 (dq, *J* = 5.8, 2.4 Hz, 1H, CH_{olef}), 5.79 (dq, *J* = 5.7, 2.1 Hz, 1H, CH_{olef}), 4.84 (ddt, *J* = 9.1, 4.5, 2.3 Hz, 1H, CH_{benzylic}), 2.61 – 2.52 (m, 1H, CHH), 2.52 – 2.41 (m, 2H, CH₂), 1.66 (ddt, *J* = 12.5, 8.6, 6.7 Hz, 1H, CHH) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 192.7 (CHO), 149.0 (C_{arom}), 134.2 (C_{arom}), 133.5 (C_{arom}), 133.2 (CH_{olef}), 133.1 (CH_{olef}), 131.6 (C_{arom}), 127.9 (C_{arom}), 126.6 (C_{arom}), 46.1 (CH), 34.1 (CH₂), 32.5 (CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3369 (w), 3056 (w), 2937 (w), 2850 (w), 2733 (w), 1691 (s), 1597 (m), 1572 (w), 1483 (w), 1453 (w), 1406 (w), 1353 (w), 1292 (w), 1207 (w), 1189 (w), 1162 (w), 1109 (w), 1012 (w), 952 (w), 915 (w), 849 (w), 823 (w), 758 (s), 657 (w), 575 (w), 535 (w), 441 (w). **HRMS** (APCI+) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₂O 173.0961, Found 173.0958.


1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde **4p**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S1** (577 mg, 2.50 mmol) and cyclohexenyl bromide (0.37 mL, 3.25 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 50:1 (*n*-pentane/Et₂O) afforded **4p** (0.14 g, 0.72 mmol, 29% over two steps) as a colorless oil.


¹H NMR: (300 MHz, CDCl₃) δ = 10.36 (s, 1H, CHO), 7.84 (d, *J* = 7.6 Hz, 1H, CH_{arom}), 7.54 (t, *J* = 7.6 Hz, 1H, CH_{arom}), 7.44 – 7.34 (m, 2H, 2 x CH_{arom}), 5.98 (ddd, *J* = 10.1, 3.6, 2.5 Hz, 1H, CH_{olef}), 5.75 – 5.66 (m, 1H, CH_{olef}), 4.40 (dq, *J* = 5.5, 2.9 Hz, 1H, CH_{benzylic}), 2.19 – 2.08 (m, 3H, 1.5 x CH₂), 1.79 – 1.65 (m, 2H, CH₂), 1.58 – 1.48 (m, 1H, 0.5 x CH₂) ppm. **¹³C NMR**: (75 MHz, CDCl₃) δ = 192.6 (CHO), 149.2 (C_{arom}), 133.9 (C_{arom}), 133.5 (C_{arom}), 131.9 (C_{arom}), 129.6 (C_{arom}), 129.4 (C_{olef}), 129.3 (C_{olef}), 126.6 (C_{arom}), 36.7 (CH), 32.9 (CH₂), 25.1 (CH₂), 21.3 (CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3020 (w), 2928 (m), 2858 (w), 2836 (w), 2732 (w), 1691 (s), 1598 (m), 1572 (w), 1483 (w), 1449 (w), 1407 (w), 1320 (w), 1291 (w), 1248 (w), 1191 (m), 1161 (w), 1135 (w), 1105 (w), 984 (w), 932 (w), 900 (w), 853 (w), 822 (w), 786 (w), 758 (s), 722 (w), 640 (w), 602 (w), 539 (w), 442 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₄O₁Na 187.1114, Found 187.1117.

3-bromocyclohept-1-ene **S9**



was obtained according to a protocol reported by TAN *et al.*^[6]


2-(cyclohept-2-en-1-yl)benzaldehyde **4q**



was obtained utilizing first the general procedure II B, using corresponding aryl bromide **3S1** (0.35 g, 1.50 mmol) and 3-bromocyclohept-1-ene **S9** (0.29 mL, 1.95 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4q** (122 mg, 0.49 mmol, 33% over two steps) as a colorless oil.


¹H NMR: (300 MHz, CDCl₃) δ = 10.38 (s, 1H, CHO), 7.84 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 7.54 (d, *J* = 7.6 Hz, 1H, CH_{arom}), 7.43 (d, *J* = 6.7 Hz, 1H, CH_{arom}), 7.36 (d, *J* = 7.5 Hz, 1H, CH_{arom}), 5.94 – 5.84 (m, 1H, CH_{olef}), 5.79 – 5.71 (m, 1H, CH_{olef}), 4.53 – 4.44 (m, 1H, CH_{benzylic}), 2.34 – 2.22 (m, 2H, CH₂), 2.03 – 1.94 (m, 1H, 0.5 x CH₂), 1.89 – 1.71 (m, 4H, 2 x CHH, 2 x CHH), 1.53 – 1.43 (m, 1H, 0.5 x CH₂) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 192.5 (CHO), 150.5 (C_{arom}), 136.3 (CH_{olef}), 134.1 (C_{arom}), 133.0 (C_{arom}), 132.3 (CH_{olef}), 131.2 (C_{arom}), 128.8 (C_{arom}), 126.5 (C_{arom}), 41.9 (CH_{benzylic}), 36.8 (CH₂), 30.5 (CH₂), 29.0 (CH₂), 27.1 (CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3032 (w), 2927 (m), 2855 (w), 2739 (w), 1693 (s), 1599 (m), 1574 (w), 1482 (w), 1446 (w), 1401 (w), 1291 (w), 1262 (w), 1240 (w), 1185 (m), 1162 (w), 1080 (w), 1030 (w), 908 (w), 835 (w), 819 (w), 756 (s), 684 (w), 656 (w), 621 (w), 606 (w), 539 (w), 481 (w), 443 (w). **HRMS** (EI+) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₆O 200.12011, Found 200.12066.

1-(bromomethyl)cyclopent-1-ene **S10**



was obtained according to a protocol reported by WERZ *et al.*^[7]

2-(cyclopent-1-en-1-ylmethyl)benzaldehyde **4t**




was prepared according to a protocol reported by DIXON *et al.*^[3]

Magnesium turnings (120 mg, 4.93 mmol, 1.14 equiv) and iodine crystals were degassed and stirred in THF (2 mL) at rt until mixture did the color disappeared. A solution of aryl bromide **3S1** (1.00 g, 4.33 mmol, 1.00 equiv) in THF (5 mL) was added and stirred for 10 min before being cooled to $-78\text{ }^{\circ}\text{C}$ and stirred for 1 h. 8 mL THF were added, followed by $\text{CuBr} \times \text{Me}_2\text{S}$ (44.5 mg, 0.22 mmol, 0.05 equiv) and stirred for 10 min. Bromide **S10** (0.66 mL, 5.63 mmol, 1.30 equiv) was added and the mixture was allowed to warm to rt over 16 h. The reaction mixture was quenched by sat. NH_4Cl solution (15 mL) and extracted with CH_2Cl_2 (3 x 15 mL). The combined organic layer was washed with brine (20 mL), dried over Na_2SO_4 and the solvent was removed under reduced pressure. The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/ Et_2O) afforded **4t** (126 mg, 0.67 mmol, 16% over two steps) as a colorless oil.


$^1\text{H NMR}$: (300 MHz, CDCl_3) δ 10.26 (s, 1H, CHO), 7.87 (d, $J = 7.6$ Hz, 1H, CH_{arom}), 7.51 (td, $J = 7.5, 1.7$ Hz, 1H, CH_{arom}), 7.37 (t, $J = 7.5$ Hz, 1H, CH_{arom}), 7.27 (d, $J = 7.6$ Hz, 1H, CH_{arom}), 5.12 (s, 1H, CH_{olef}), 3.77 (s, 2H, CH_2), 2.27 (t, $J = 7.3$ Hz, 4H, 2 x CH_2), 1.86 (p, $J = 7.4$ Hz, 2H, CH_2) ppm. **$^{13}\text{C NMR}$** : (75 MHz, CDCl_3) $\delta = 192.2$ (C=O), 144.1 (C_{olef}), 142.9 (C_{arom}), 134.2 (C_{arom}), 133.9 (C_{arom}), 131.5 (C_{arom}), 130.1 (C_{arom}), 126.9 (C_{arom}), 126.5 (CH_{olef}), 35.5 (CH_2), 34.4 (CH_2 , benzylic), 32.6 (CH_2), 23.5 (CH_2) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3049 (w), 2923 (w), 2893 (w), 2845 (m), 2755 (w), 1693 (s), 1598 (m), 1573 (w), 1484 (w), 1450 (w), 1400 (w), 1286 (w), 1205 (m), 1160 (w), 1127 (w), 1088 (w), 1036 (w), 962 (w), 861 (w), 840 (w), 805 (w), 758 (s), 662 (w), 637 (w), 585 (w), 472 (w), 437 (w). **HRMS** (ESI+) m/z : [M]⁺ Calcd for $\text{C}_{13}\text{H}_{14}\text{O}$ 187.1117, Found 187.1113.

1-(bromomethyl)cyclohex-1-ene **S11**



was obtained according to a protocol reported by BOWER *et al.*^[8]


2-(cyclohex-1-en-1-ylmethyl)benzaldehyde **4u**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S1** (185 mg, 0.80 mmol) and 1-(bromomethyl)cyclohex-1-ene **S11** (0.14 mL, 1.04 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 50:1 (*n*-pentane/ Et_2O) afforded **4u** (106 mg, 0.53 mmol, 98% over two steps) as a colorless oil.


$^1\text{H NMR}$: (300 MHz, CDCl_3) $\delta = 10.28$ (s, 1H, CHO), 7.87 (d, $J = 7.6$ Hz, 1H, CH_{arom}), 7.51 (t, $J = 7.5$ Hz, 1H, CH_{arom}), 7.36 (t, $J = 7.5$ Hz, 1H, CH_{arom}), 7.26 (d, $J = 7.6$ Hz, 1H, CH_{arom}), 5.25 – 5.17 (m, 1H, CH_{olef}), 3.65 (s, 2H, CH_2 , benzylic), 2.02 – 1.89 (m, 4H, 2 x CH_2 , cyclohex), 1.68 – 1.46 (m, 4H, 2 x CH_2 , cyclohex) ppm. **$^{13}\text{C NMR}$** : (75 MHz, CDCl_3) $\delta = 192.2$ (CHO), 142.9 (C_{arom}), 137.7 (C_{olef}), 134.6 (C_{arom}), 133.9 (C_{arom}), 131.7 (C_{arom}), 129.8 (C_{arom}), 126.9 (C_{arom}), 124.0 (CH_{olef}), 40.3 (CH_2), 29.0 (CH_2 , cyclohex), 25.4 (CH_2 , cyclohex), 23.0 (CH_2 , cyclohex), 22.5 (CH_2 , cyclohex) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3000 (w), 2925 (m), 2855 (w), 2834 (w), 2755 (w), 1692 (s), 1598 (m), 1573 (w), 1484 (w), 1449 (w), 1399 (w), 1373 (w), 1342 (w), 1292 (w), 1242 (w), 1206 (m), 1159 (w), 1134 (w), 1077 (w), 1046 (w), 999 (w), 955 (w), 920 (w), 865 (w), 838 (w), 805 (w), 750 (s), 636 (m), 596 (w), 514 (w), 473 (w), 435 (w). **HRMS** (EI+) m/z : [M]⁺ Calcd for $\text{C}_{14}\text{H}_{16}\text{O}$ 200.12011, Found 200.11818.

1-bromo-2-(1,1-dimethoxyethyl)benzene **S12**



was obtained according to a protocol reported by YANG *et al.*^[9]


1-(2-(but-2-en-1-yl)phenyl)ethan-1-one **S13**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **S12** (2.50 g, 10.2 mmol) and crotyl bromide (1.36 mL, 13.3 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **S13** (1.13 mg, 6.47 mmol, *E/Z* 86:14, 56% over two steps) as a colorless oil.


¹H NMR: (500 MHz, CDCl₃) δ = 7.61 (d, *J* = 1.2 Hz, 1H, CH_{arom}), 7.40 (td, *J* = 7.7, 1.4 Hz, 1H, CH_{arom}), 7.31 – 7.25 (m, 2H, 2 x CH_{arom}), 5.47 (s, 2H, 2 x CH_{olef}), 3.65 (d, *J* = 7.5 Hz, 0.29H, CH_{2,minor}), 3.56 (d, *J* = 8.0 Hz, 1.71H, CH_{2,major}), 2.58 (s, 0.44H, C=OCH_{3,minor}), 2.56 (s, 2.52H, C=OCH_{3,major}), 1.72 – 1.70 (m, 0.44H, CH_{olef}CH_{3,minor}), 1.66 (dq, *J* = 6.3, 1.3 Hz, 2.56H, CH_{olef}CH_{3,major}) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 202.6 (C=O_{major}), 202.5 (C=O_{minor}), 141.0 (C_{arom,minor}), 140.8 (C_{arom,major}), 138.3 (C_{arom,minor}), 138.3 (C_{arom,major}), 131.6 (C_{arom,ffminor}), 131.5 (C_{arom,major}), 131.2 (C_{arom,major}), 130.8 (C_{arom,minor}), 130.0 (CH_{olef,major}), 129.0 (C_{arom,minor}), 129.0 (CH_{olef,minor}), 128.9 (C_{arom,major}), 126.6 (CH_{olef,major}), 126.0 (C_{arom,major}), 126.0 (C_{arom,minor}), 125.2 (CH_{olef,minor}), 36.9 (CH_{2,major}), 31.4 (CH_{2,minor}), 30.1 (COCH_{3,major}), 30.0 (COCH_{3,minor}), 18.1 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3023 (w), 2963 (w), 2916 (w), 2855 (w), 1683 (s), 1599 (w), 1571 (w), 1484 (w), 1435 (w), 1354 (m), 1287 (w), 1249 (s), 1186 (w), 1165 (w), 1124 (w), 1071 (w), 1041 (w), 1014 (w), 967 (m), 938 (w), 757 (s), 718 (w), 685 (w), 600 (s), 543 (w), 458 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₄O 175.1117, Found 175.1117.

1,3-dibromo-2-(dimethoxymethyl)benzene **3S2**



was obtained according to a protocol reported by HALL *et al.*^[10]


1-bromo-3-(but-2-en-1-yl)-2-(dimethoxymethyl)benzene **S14**



was obtained according to general procedure II A, using corresponding aryl bromide **3S2** (326 g, 1.05 mmol) and crotyl bromide (0.12 mL, 1.16 mmol). Purification by column chromatography using 100:1:5 (*n*-pentane/Et₂O/Et₃N) afforded **S14** (260 mg, 0.91 mmol, 87%, *E/Z* 83:17) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.38 (dd, *J* = 7.9, 1.3 Hz, 1H, CH_{arom}), 7.20 (ddd, *J* = 7.7, 1.3, 0.5 Hz, 1H, CH_{arom}), 7.08 (t, *J* = 7.8 Hz, 1H, CH_{arom}), 5.86 (s, 0.17H, C(OCH₃)₂H_{minor}), 5.83 (s, 0.83H, C(OCH₃)₂H_{major}), 5.60 – 5.47 (m, 2H, 2 x CH_{olef}), 3.76 – 3.74 (m, 0.34H, CH_{2,minor}), 3.66 – 3.64 (m, 1.66H CH_{2,major}), 3.46 (s, 1.01H, 2 x OCH_{3,minor}), 3.45 (s, 4.99H, 2 x OCH_{3,major}), 1.74 – 1.72 (m, 0.56H, CH_{3,minor}), 1.69 – 1.67 (m, 2.47H, CH_{3,major}) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 143.8 (C_{arom,minor}), 143.6 (C_{arom,major}), 134.7 (C_{arom,minor}), 134.6 (C_{arom,major}), 130.8 (C_{arom,major}), 130.7 (C_{arom,major}), 130.7 (C_{arom,major}), 130.6 (C_{arom,minor}), 130.4 (CH_{olef,major}), 129.9 (C_{arom,minor}), 129.8 (CH_{olef,minor}), 129.8 (C_{arom,major}), 126.2 (CH_{olef,major}), 124.5 (C_{arom,minor}), 124.5 (C_{arom,minor}), 124.4 (CH_{olef,minor}), 107.9 (CH(OCH₃)_{2,minor}), 107.8 (CH(OCH₃)_{2,major}), 56.0 (2 x OCH₃), 35.8 (CH_{2,major}), 30.0 (CH_{2,minor}), 18.1 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2989 (w), 2930 (w), 2855 (w), 2828 (w), 1591 (w), 1562 (w), 1450 (w), 1378 (w), 1213 (m), 1185 (w), 1125 (w), 1102 (w), 1067 (s), 993 (w), 964 (m), 910 (w), 890 (w), 817 (w), 777 (m), 743 (w), 706 (w), 689 (w), 601 (w), 567 (w), 545 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₇BrO₂Na 307.0304, 309.0285 Found 307.0301, 309.0279.


2-bromo-6-(but-2-en-1-yl)benzaldehyde **4j**



was obtained according to general procedure III using **S14** (85.6 mg, 0.30 mmol). Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4j** (65.7mg, 0.27 mmol, 92%) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 10.49 (s, 0.2H, CHO_{minor}), 10.47 (s, 0.8H, CHO_{major}), 7.51 (dd, *J* = 7.5, 1.7 Hz, 1H, CH_{arom}), 7.33 – 7.21 (m, 2H, 2 x CH_{arom}), 5.63 – 5.39 (m, 2H, 2 x CH_{olef}), 3.73 (d, *J* = 7.2 Hz, 0.4H, CH_{2,minor}), 3.63 (d, *J* = 6.2 Hz, 1.60H CH_{2,major}), 1.70 (ddt, *J* = 6.7, 1.9, 0.9 Hz, 0.6H, CH_{3,minor}), 1.70 – 1.61 (m, 2.42H, CH_{3,major}) ppm. **¹³C NMR**: (75 MHz, CDCl₃) δ = 194.6 (CHO_{minor}), 194.4 (CHO_{major}), 145.4 (C_{arom,minor}), 145.3 (C_{arom,major}), 133.8 (C_{arom,major}), 133.8 (C_{arom,major}), 133.7 (C_{arom,minor}), 132.1 (C_{arom,minor}), 132.0 (C_{arom,major}), 131.9 (C_{arom,minor}), 131.8 (C_{arom,minor}), 130.6 (C_{arom,major}), 130.2 (C_{arom,minor}), 129.1 (CH_{olef,major}), 127.9 (CH_{olef,minor}), 127.7 (C_{arom,major}), 127.3 (CH_{olef,major}), 126.0 (CH_{olef,minor}), 36.4 (CH_{2,major}), 30.8 (CH_{2,minor}), 18.0 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3024 (w), 2963 (w), 2917 (w), 2854 (w), 2764 (w), 1697 (s), 1587 (w), 1557 (w), 1449 (m), 1401 (w), 1377 (w), 1248 (w), 1185 (w), 1132 (w), 1102 (w), 1054 (w), 968 (w), 943 (w), 858 (w), 779 (m), 726 (w), 680 (w), 603 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₁H₁₁BrO 239.0066, 241.0046, Found 239.0064, 241.0044.


2-(but-2-en-1-yl)-6-(trimethylsilyl)benzaldehyde **4f**



Aryl bromide **S14** (150 mg, 0.53 mmol, 1.00 equiv) was dissolved in anhydrous THF (1.6 mL), cooled to $-78\text{ }^{\circ}\text{C}$, *n*-BuLi (2.5 M, 0.23 mL, 0.58 mmol, 1.10 equiv) was added dropwise and stirred for 1 h. A solution of TMSCl (0.08 mL, 0.63 mmol, 1.20 equiv) in 1 mL THF was added dropwise to the reaction mixture. The reaction was allowed to warm to rt over 3 h. Water (10 mL) was added and the mixture was diluted with Et₂O (5 mL). The aqueous phase was extracted with Et₂O (3 x 10 mL) and the combined organic phases were washed with brine (15 mL), dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was used according to procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4j** (25.3 mg, 0.28 mmol, 52%, *E/Z* 83:17) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.50 (s, 0.17H, CHO_{minor}), 10.49 (s, 0.83H, CHO_{major}), 7.61 – 7.58 (m, 1H, CH_{arom}), 7.48 – 7.44 (m, 1H, CH_{arom}), 7.33 – 7.31 (m, 0.17H, CH_{arom,minor}), 7.29 – 7.27 (m, 0.83H, CH_{arom,major}), 5.68 – 5.39 (m, 2H, 2xCH_{olef}), 3.80 – 3.78 (m, 0.34H, CH_{2,minor}), 3.71 (dt, *J* = 6.3, 1.6 Hz, 1.66H, CH_{2,minor}), 1.76 – 1.74 (m, 0.51H CH_{3,minor}), 1.67 (dq, *J* = 6.5, 1.5 Hz, 2.50H, CH_{3,major}), 0.32 (s, 9H, Si(CH₃)₃). ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 193.4 (CHO_{minor}), 193.3 (CHO_{major}), 144.3 (C_{arom,major}), 143.9 (C_{arom,minor}), 143.6 (C_{arom,major}), 138.6 (C_{arom,major}), 135.5 (C_{arom,minor}), 134.1 (C_{arom,major}), 134.0 (C_{arom,minor}), 132.7 (C_{arom,major}), 132.6 (C_{arom,minor}), 132.1 (C_{arom,major}), 131.8 (C_{arom,minor}), 130.1 (CH_{olef,major}), 129.0 (CH_{olef,minor}), 127.3 (CH_{olef,major}), 125.3 (CH_{olef,minor}), 36.4 (CH_{2,major}), 31.1 (CH_{2,minor}), 18.1 (CH_{3,major}), 13.2 (CH_{3,minor}), 0.7 (Si(CH₃)_{3,minor}), 0.6 (Si(CH₃)_{3,major}) ppm. One ¹³C-signal of the minor isomer could not be found due to the noise to signal ratio. **⁶⁰Si NMR**: (60 MHz, CDCl₃) δ = -3.5 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3023 (w), 2949 (w), 2764 (w), 1693 (s), 1573 (w), 1454 (w), 1395 (w), 1284 (w), 1247 (m), 1211 (w), 1172 (w), 1136 (w), 1079 (w), 968 (w), 867 (w), 839 (s), 795 (w), 763 (m), 676 (w), 625 (w), 488 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₄H₂₁OSiH 233.1356, Found 233.1356.


1-bromo-2-(dimethoxymethyl)-3-fluorobenzene **3S3**



was obtained according to general procedure I, aldehyde **S15** (1.00 g, 4.93 mmol). Purification by column chromatography using 2:1:0.01 (*n*-pentane/Et₂O/Et₃N) afforded **3S3** (1.11 mg, 4.46 mmol, 91%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.37 (dt, *J* = 8.0, 1.1 Hz, 1H, CH_{arom}), 7.16 (td, *J* = 8.2, 5.6 Hz, 1H, CH_{arom}), 7.05 (ddd, *J* = 10.5, 8.3, 1.2 Hz, 1H, CH_{arom}), 5.71 (d, *J* = 1.3 Hz, 1H, CH), 3.49 (s, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 161.52 (d, *J* = 256.5 Hz, FC_{arom}), 130.94 (d, *J* = 10.0 Hz, C_{arom}), 129.18 (d, *J* = 3.8 Hz, C_{arom}), 125.39 (d, *J* = 14.3 Hz, C_{arom}), 123.50 (d, *J* = 5.2 Hz, C_{arom}), 116.17 (d, *J* = 22.9 Hz, C_{arom}) 104.85 (CH), 55.70 (2 x OCH₃) ppm. **¹⁹F NMR**: (282 MHz, CDCl₃) δ = -111.12 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2993 (w), 2932 (w), 2830 (w), 1601 (w), 1572 (m), 1454 (m), 1375 (w), 1276 (w), 1248 (m), 1201 (w), 1175 (w), 1137 (w), 1103 (w), 1059 (s), 968 (m), 892 (s), 846 (w), 816 (w), 782 (s), 730 (m), 689 (w), 571 (w), 535 (w), 501 (w), 471 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₉H₁₀BrFO₂Na 270.9740, 272.9721, Found 270.9739, 272.9719.


2-fluoro-6-(3-methylbut-2-en-1-yl)benzaldehyde **4d**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S3** (1.10 g, 4.42 mmol) and prenyl bromide (0.74 mL, 5.74 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 20:1 (*n*-pentane/Et₂O) afforded **4d** (473 mg, 2.46 mmol, 56% over two steps) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.52 (s, 1H, CHO), 7.45 (td, *J* = 8.1, 5.8 Hz, 1H, CH_{arom}), 7.09 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 7.00 (dd, *J* = 10.9, 8.3 Hz, 1H, CH_{arom}), 5.25 (ddq, *J* = 8.7, 5.8, 1.5 Hz, 1H, CH_{olef}), 3.74 (d, *J* = 7.2 Hz, 2H CH₂), 1.72 (d, *J* = 13.3 Hz, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 189.4 (d, *J* = 10.5 Hz, CHO), 166.2 (d, *J* = 257.5 Hz, FC_{arom}), 146.2 (C_{arom}) 135.3 (d, *J* = 10.5 Hz, C_{arom}), 133.9 (C_{olef}), 126.2 (d, *J* = 3.8 Hz, C_{arom}), 122.3 (d, *J* = 5.7 Hz, C_{arom}), 121.4 (CH_{olef}), 114.0 (d, *J* = 21.9 Hz, C_{arom}), 32.0 (CH₂), 25.9 (CH₃), 18.1 (CH₃). ppm. **¹⁹F NMR**: (282 MHz, CDCl₃) δ = -120.80 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2970 (w), 2915 (w), 2881 (w), 2780 (w), 1695 (s), 1610 (m), 1571 (m), 1469 (m), 1450 (w), 1414 (w), 1378 (w), 1285 (w), 1258 (w), 1240 (m), 1186 (w), 1159 (w), 1101 (w), 1070 (w), 986 (w), 922 (w), 888 (w), 850 (w), 826 (m), 792 (s), 771 (w), 729 (w), 709 (w), 625 (w), 595 (w), 511 (w), 449 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₃FONa 215.0800, Found 215.0842.


2-bromo-1-(dimethoxymethyl)-4-methylbenzene **3S4**



was obtained according to general procedure I using the corresponding aldehyde **S16** (0.80 g, 4.00 mmol). Purification by column chromatography using 2:1:0.01 (*n*-pentane/Et₂O/Et₃N) afforded **3S4** (873 mg, 3.56 mmol, 89%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.47 (d, *J* = 7.9 Hz, 1H, CH_{arom}), 7.41 – 7.37 (m, 1H, CH_{arom}), 7.13 (dtd, *J* = 7.9, 1.3, 0.6 Hz, 1H, CH_{arom}), 5.53 (s, 1H, CH), 3.37 (s, 6H, 2 x OCH₃), 2.32 (s, 3H, C_{arom}CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 140.5, 133.9, 133.4, 128.2, 128.1, 122.8, 103.0, 53.9, 20.8 (C_{arom}CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2989 (w), 2930 (w), 2828 (w), 1607 (w), 1563 (w), 1488 (w), 1446 (w), 1389 (w), 1361 (m), 1279 (w), 1209 (m), 1189 (w), 1140 (w), 1104 (m), 1055 (s), 978 (m), 912 (w), 874 (w), 833 (w), 811 (m), 714 (w), 674 (w), 651 (w), 594 (w), 568 (w), 551 (w), 478 (w), 439 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₀H₁₃BrO₂Na 266.9991, 268.9971, Found 266.9992, 268.9971.


4-methyl-2-(3-methylbut-2-en-1-yl)benzaldehyde **4e**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S4** (613 mg, 2.50 mmol) and prenyl bromide (0.33 mL, 3.25 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4e** (194 mg, 1.03 mmol, 41% over two steps) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.22 (s, 1H, CHO), 7.73 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 7.16 (dd, *J* = 7.8, 1.9 Hz, 1H, CH_{arom}), 7.09 (d, *J* = 1.7 Hz, 1H, CH_{arom}), 5.26 (tp, *J* = 7.1, 1.4 Hz, 1H, CH_{olef}), 3.73 (d, *J* = 7.1 Hz, 2H, CH₂), 2.39 (s, 3H, CH₃), 1.74 (d, *J* = 1.3 Hz, 3H, C_{olef}CH₃), 1.73 (q, *J* = 1.4 Hz, 3H, C_{olef}CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.2 (CHO), 145.0 (C_{arom}), 144.7 (C_{olef,quant}), 133.0 (C_{arom}), 131.7 (C_{arom}), 131.7 (C_{arom}), 131.4 (C_{arom}), 127.4 (C_{arom}), 122.9 (CH_{olef}), 31.3 (CH₂), 25.9 (CH₃), 22.0 (C_{arom}CH₃), 18.1 (CH₃)f ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2970 (w), 2916 (w), 2857 (w), 2730 (w), 1691 (s), 1606 (m), 1569 (w), 1494 (w), 1448 (w), 1398 (w), 1377 (w), 1293 (w), 1198 (w), 1101 (w), 1037 (w), 927 (w), 885 (w), 816 (w), 735 (w), 446 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₆O₂Na 211.1093, Found 211.1095.


1-bromo-4-chloro-2-(dimethoxymethyl)benzene **3S5**



was obtained according to general procedure I using the corresponding aldehyde **S17** (0.50 g, 2.28 mmol). Purification by column chromatography using 20:1:0.02 (*n*-pentane/Et₂O/Et₃N) afforded **3S5** (519 mg, 1.96 mmol, 86%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.60 (d, *J* = 2.7 Hz, 1H, CH_{arom}), 7.48 (d, *J* = 8.5 Hz, 1H, CH_{arom}), 7.18 (dd, *J* = 8.5, 2.7 Hz, 1H, CH_{arom}), 5.50 (s, 1H, CH), 3.38 (s, 6H, 2 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 138.7 (CH_{arom}), 134.1 (CH_{arom}), 133.7 (CH_{arom}), 130.2 (CH_{arom}), 128.8 (CH_{arom}), 120.8 (CH_{arom}), 102.4 (CH), 54.0 (2 x OCH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3089 (w), 2993 (w), 2933 (w), 2830 (w), 1562 (w), 1456 (m), 1390 (w), 1359 (m), 1254 (w), 1195 (m), 1155 (w), 1129 (w), 1105 (w), 1094 (w), 1054 (s), 1031 (w), 981 (m), 914 (w), 877 (m), 813 (m), 761 (w), 742 (w), 705 (w), 644 (w), 614 (w), 568 (w), 512 (m), 456 (w). **HRMS** (EI+) *m/z*: [M]⁺ Calcd for C₉H₁₀BrClO₂ 263.95527, 265.95322, Found 263.95650, 265.95415.

1-(but-2-en-1-yl)-4-chloro-2-(dimethoxymethyl)benzene **S18**




was obtained according to general procedure II A, using corresponding aryl bromide **3S5** (0.51 g, 1.92 mmol) and crotyl bromide (0.30 mL, 2.50 mmol). Purification by column chromatography using 100:1:1 (*n*-pentane/Et₂O/Et₃N) afforded **S18** (818 mg, 3.43 mmol, 78%, *E/Z* 79:21) as a yellow oil.

¹H NMR: (300 MHz, CDCl₃) δ = 7.56 (d, *J* = 2.3 Hz, 1H, CH_{arom}), 7.23 (dd, *J* = 8.2, 2.4 Hz, 1H, CH_{arom}), 7.12 (dd, *J* = 8.2, 5.3 Hz, 1H, CH_{arom}), 5.63 – 5.39 (m, 2H, 2 x CH_{olef}), 5.46 (s, 0.21H, CH(OCH₃)_{2,minor}), 5.46 (s, 0.79H, CH(OCH₃)_{2,major}), 3.45 (d, *J* = 7.1 Hz, 0.42H, CH_{2,minor}), 3.37 (dd, *J* = 7.3, 1.3 Hz, 1.60H, CH_{2,major}), 3.31 (s, 1.38H, CH(OCH₃)_{2,minor}), 3.31 (s, 4.64H, CH(OCH₃)_{2,major}), 1.72 (ddt, *J* = 6.8, 1.8, 0.9 Hz, 0.70H, CH_{3,minor}), 1.69 – 1.65 (m, 2.31H, CH_{3,major}) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 137.8 (C_{arom,minor}), 137.4 (C_{arom,major}), 137.3 (C_{arom,major}), 131.8 (C_{arom,minor}), 131.7 (C_{arom,minor}), 131.2 (C_{arom,major}), 130.7 (C_{arom,minor}), 129.2 (CH_{olef,major}), 128.6 (C_{arom,minor}), 128.5 (C_{arom,major}), 128.3 (CH_{olef,minor}), 127.7 (CH_{olef,major}), 127.0 (C_{arom,minor}), 126.9 (C_{arom,major}), 126.8 (C_{arom,major}), 125.3 (CH_{olef,minor}), 100.6 (CH(OCH₃)_{2,minor}), 100.5 (CH(OCH₃)_{2,major}), 53.1 (CH(OCH₃)_{2,major}), 53.0 (CH(OCH₃)_{2,minor}), 34.6 (CH_{2,major}),

29.1(CH_{2,minor}), 17.9 (CH_{3,major}), 12.9 (CH_{3,minor}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3024 (w), 2918 (w), 2856 (w), 2732 (w), 1692 (s), 1592 (w), 1563 (w), 1479 (m), 1451 (w), 1398 (w), 1298 (w), 1279 (w), 1259 (w), 1197 (s), 1109 (w), 1055 (w), 968 (m), 939 (w), 898 (m), 832 (w), 811 (w), 790 (w), 737 (w), 691 (w), 648 (w), 557 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₃H₁₇ClO₂H 241.0990, Found 241.0987.


2-(but-2-en-1-yl)-5-chlorobenzaldehyde **4a**



was obtained according to general procedure III using **S18** (250 mg, 1.04 mmol). Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4a** (149 mg, 0.77 mmol, 74%, 77:23 *E/Z*) as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ 10.23 (s, 1H, CHO), 7.81 (t, *J* = 2.8 Hz, 1H, CH_{arom}), 7.47 (dd, *J* = 8.2, 2.4 Hz, 1H, CH_{arom}), 7.25 (dd, *J* = 11.3, 8.1 Hz, 1H, CH_{arom}), 5.65 – 5.36 (m, 2H, 2 x CH_{olef}), 3.78 (d, *J* = 7.1 Hz, 0.66H, CH_{2,minor}), 3.69 (dt, *J* = 6.2, 1.6 Hz, 1.34H, CH_{2,major}), 1.75 – 1.71 (m, 0.99H, CH_{3,minor}), 1.66 (dq, *J* = 6.2, 1.5 Hz, 2.02H, CH_{3,major}) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 191.0 (CHO_{minor}), 190.9 (CHO_{major}), 142.2 (C_{arom,minor}), 141.8 (C_{arom,major}), 135.1 (C_{arom,minor}), 135.1 (C_{arom,major}), 133.9 (C_{arom,major}), 133.1 (C_{arom,major}), 133.0 (C_{arom,minor}), 132.6 (C_{arom,major}), 132.2 (C_{arom,minor}), 130.9 (C_{arom,minor}), 130.3 (C_{arom,major}), 129.3 (CH_{olef,major}), 128.4 (C_{arom,minor}), 128.0 (CH_{olef,minor}), 127.8 (CH_{olef,major}), 126.1 (CH_{olef,minor}), 34.8 (CH_{2,major}), 29.6 (CH_{2,minor}), 18.0 (CH_{3,major}), 13.0 (CH_{3,minor}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3023 (w), 2918 (w), 2855 (w), 2732 (w), 1689 (s), 1604 (m), 1569 (w), 1495 (w), 1450 (w), 1398 (w), 1380 (w), 1290 (w), 1267 (w), 1232 (w), 1202 (m), 1125 (w), 1039 (w), 968 (m), 866 (w), 816 (m), 778 (w), 713 (w), 693 (w), 672 (w), 616 (w), 535 (w), 488 (w), 442 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₄ONa 197.0937, Found 197.0936.


3-bromo-2-(dimethoxymethyl)phenol **3S6**



was obtained according to general procedure I using the corresponding aldehyde **S19** (5.03 g, 25.0 mmol). Aqueous workup afforded **3S6** (6.00 g, 24.3 mmol, 97%) as a brown oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.71 (s, 1H, CH_{arom}), 7.12 – 7.03 (m, 1H, CH_{arom}), 6.84 (dd, *J* = 7.6, 1.8 Hz, 1H, CH_{arom}), 5.83 (s, 1H, CH), 3.48 (s, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 157.8 (C_{arom}), 131.2 (C_{arom}), 124.5 (C_{arom}), 123.5 (C_{arom}), 120.1 (C_{arom}), 117.1 (C_{arom}), 106.8 (CH), 54.6 (2 x CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3316 (w), 2936 (w), 2833 (w), 1608 (w), 1571 (m), 1452 (s), 1356 (m), 1290 (w), 1244 (m), 1191 (w), 1163 (m), 1132 (w), 1096 (m), 1047 (s), 988 (w), 951 (m), 893 (s), 835 (w), 817 (w), 780 (m), 730 (m), 688 (w), 654 (w), 539 (w), 471 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₉H₁₁BrO₃Na 268.9784, 270.9764, Found 268.9775, 270.9753.

(3-bromo-2-(dimethoxymethyl)phenoxy)(tert-butyl)dimethylsilane **3S7**,




Alcohol **3S6** (6.00 g, 24.3 mmol), imidazole (3.14 g, 46.2 mmol, 1.90 equiv.) were dissolved in anhydrous THF (24 mL), TBSCl (4.38 g, 29.2 mmol, 1.20 equiv.) was added and stirred at rt for 18 h. 15 mL water and 15 mL Et₂O were added and the aqueous phase was extracted with Et₂O (3 x 20 mL). The combined organic phase was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. Purification by column chromatography

using 100:1 (*n*-pentane/Et₂O) afforded the silyl ether **3S7** (7.77 g, 21.5 mmol, 89%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.60 (d, *J* = 2.7 Hz, 1H, CH_{arom}), 7.19 (dd, *J* = 8.0, 1.1 Hz, 1H, CH_{arom}), 7.00 (t, *J* = 8.1 Hz, 1H, CH_{arom}), 6.76 (dd, *J* = 8.2, 1.1 Hz, 1H, CH_{arom}), 5.76 (s, 1H, CH), 3.42 (s, 6H, 2 x OCH₃), 1.03 (s, 9H, (CH₃)₃SiC(CH₃)₃), 0.25 (s, 6H, (CH₃)₃SiC(CH₃)₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 155.4 (C_{arom}), 130.0 (C_{arom}), 127.9 (C_{arom}), 127.2 (C_{arom}), 123.0 (C_{arom}), 118.6 (C_{arom}), 103.3 (CH), 55.6 (2 x OCH₃), 25.9 ((CH₃)₃SiC(CH₃)₃), 18.5 (C_{quant}), -4.1((CH₃)₃SiC(CH₃)₃) ppm. **²⁹Si NMR**: (60 MHz, CDCl₃) δ = 22.0. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2955 (w), 2931 (m), 2886 (w), 2859 (w), 1703 (s), 1586 (s), 1562 (w), 1448 (s), 1402 (w), 1363 (w), 1291 (m), 1255 (m), 1210 (w), 1181 (w), 1165 (w), 1136 (w), 1103 (w), 1075 (w), 936 (s), 840 (s), 811 (w), 784 (m), 732 (w), 667 (w), 578 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₅H₂₅BrO₃SiNe 383.0654, 385.0630, Found 383.0634, 385.0610.


2-((tert-butyldimethylsilyloxy)-6-(3-methylbut-2-en-1-yl)benzaldehyde **4S1**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S7** (7.67 g, 21.2 mmol) and prenyl bromide (2.99 mL, 25.5 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4S1** (4.98 g, 16.0 mmol, 75% over two steps) as a colorless oil.


¹H NMR: (500 MHz, CDCl₃) δ = 10.63 (s, 1H, CHO), 7.31 (t, *J* = 8.0 Hz, 1H, CH_{arom}), 6.87 (dt, *J* = 7.7, 1.1 Hz, 1H, CH_{arom}), 5.27 (tp, *J* = 7.2, 1.4 Hz, 1H, CH_{olef}), 3.70 (d, 2H, CH_{2,benzylic}), 1.73 (q, *J* = 1.4 Hz, 3H, CH=CCH₃CH₃), 1.70 (s, 3H, CH=CCH₃CH₃), 1.01 (s, 9H, (CH₃)₂SiC(CH₃)₃), 0.27 (s, 6H, (CH₃)₂SiC(CH₃)₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 193.0 (CHO), 160.2 (C_{arom}), 145.6 (C_{arom}), 134.5 (C_{arom}), 132.9 (C_{olef}), 125.5 (C_{arom}), 123.2 (C_{arom}), 122.7 (CH_{olef}), 117.7 (C_{arom}), 32.2 (CH₂), 25.9 (CH₃), 25.9 ((CH₃)₂SiC(CH₃)₃), 18.5 (C_{quart}), 18.1 (CH₃), -4.1 ((CH₃)₂SiC(CH₃)₃) ppm. **²⁹Si NMR:** (60 MHz, CDCl₃) δ = 23.0. **IR (ATR) $\tilde{\nu}$ (cm⁻¹)** = 2956 (w), 2930 (m), 2859 (w), 2772 (w), 1688 (s), 1591 (m), 1574 (w), 1465 (s), 1443 (w), 1404 (m), 1293 (w), 1253 (s), 1182 (w), 1162 (w), 1102 (w), 1078 (w), 1031 (m), 1004 (w), 926 (w), 859 (w), 838 (w), 810 (w), 780 (s), 730 (w), 702 (w), 666 (w), 611 (w), 575 (w), 462 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₈H₂₈O₂SiNa 327.1751, Found 327.1737.

1-bromo-2-(dimethoxymethyl)-4,5-dimethoxybenzene **3S8**



was obtained according to a protocol reported by GREETS *et al.*^[11]


2-(but-2-en-1-yl)-4,5-dimethoxybenzaldehyde **4S2**



was obtained utilizing first the general procedure II A, using corresponding aryl bromide **3S8** (501 mg, 1.72 mmol) and crotyl bromide (0.27 mL, 2.24 mmol). The reaction mixture was quenched with sat. NH₄Cl solution (5 mL) and extracted with CH₂Cl₂ (3 x 15 mL). The combined organic layer was washed with brine (15 mL), dried over Na₂SO₄ and the solvent was removed under reduced pressure. Purification by column chromatography using 20:1→10:1 (*n*-pentane/EtOAc) afforded **4S2** (353 mg, 1.60 mmol, 93%, *E/Z* 75:25) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.20 (s, 0.25H, CHO_{minor}), 10.19 (s, 0.75H, CHO_{major}), 7.38 (s, 0.74H, CH_{arom,major}), 7.37 (s, 0.26H, CH_{arom,minor}), 6.73 (s, 0.24H, CH_{arom,minor}), 6.69 (s, 0.76H, CH_{arom,major}), 5.65 – 5.37 (m, 2H, 2xCH_{olef,major+minor}), 3.95 – 3.94 (m, 3H, OCH₃), 3.91 (s, 3H, OCH₃), 3.77 – 3.74 (m, 0.51H, CH_{2,minor}), 3.68 – 3.65 (m, 1.52H, CH_{2,major}), 1.76 – 1.73 (m, 0.75H, CH_{3,minor}), 1.67 – 1.64 (m, 2.25H, CH_{3,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 190.2 (C=O), 154.0 (C_{arom,major}), 154.0 (C_{arom,minor}), 147.9 (C_{arom,major}), 147.8 (C_{arom,minor}), 139.4 (C_{arom,minor}), 138.9 (C_{arom,major}), 130.1 (CH_{olef,major}), 128.9 (CH_{olef,minor}), 127.2 (CH_{olef,major}), 126.9 (C_{arom,major}), 126.8 (C_{arom,minor}), 125.3 (CH_{olef,minor}), 112.9 (C_{arom,major}), 112.5 (C_{arom,minor}), 111.1 (C_{arom,minor}), 110.6 (C_{arom,major}), 56.2 (OCH₃), 56.1 (OCH₃), 34.7 (CH_{2,major}), 29.3 (CH_{2,minor}), 18.0 (CH_{3,major}), 13.2 (CH_{3,minor}) ppm. **IR (ATR) $\tilde{\nu}$ (cm⁻¹)** = 3422 (w), 2936 (w), 2856 (w), 1672 (m), 1595 (s), 1510 (s), 1461 (m), 1406 (w), 1352 (w), 1312 (w), 1262 (s), 1226 (w), 1176 (w), 1104 (s), 1035 (w), 998 (w), 968 (w), 871 (m), 786 (w), 747 (m), 693 (w), 662 (w), 581 (m), 452 (w). **HRMS (APCI+)** *m/z*: [M+H]⁺ Calcd for C₁₃H₁₆O₃H 221.1172, Found 221.1167.


1-bromo-2-(dimethoxymethyl)naphthalene **3S9**



was obtained according to general procedure I using the corresponding aldehyde **S28** (156 mg, 0.66 mmol). **3S9** was afforded (184 mg, 0.65 mmol, 99%) as a colorless solid.

¹H NMR: (500 MHz, CDCl₃) δ = 8.38 (d, *J* = 9.2 Hz, 1H, CH_{arom}), 7.83 (d, *J* = 8.4 Hz, 2H, 2xCH_{arom}), 7.72 (d, *J* = 8.5 Hz, 1H, CH_{arom}), 7.61 (ddd, *J* = 8.5, 6.8, 1.4 Hz, 1H, CH_{arom}), 7.55 (ddd, *J* = 8.1, 6.8, 1.3 Hz, 1H, CH_{arom}), 5.88 (s, 1H, CH), 3.45 (s, 6H, 2xOCH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 135.3 (C_{arom}), 134.8 (C_{arom}), 132.3 (C_{arom}), 128.3 (C_{arom}), 127.8 (C_{arom}), 127.7 (C_{arom}), 127.6 (C_{arom}), 127.2 (C_{arom}), 124.9 (C_{arom}), 123.7 (C_{arom}), 104.2 (CH), 54.4 (OCH₃) ppm. **IR (ATR) $\tilde{\nu}$ (cm⁻¹)** = 3063 (w), 2990 (w), 2931 (w), 2828 (w), 1557 (w), 1501 (w), 1461 (w), 1380 (w), 1324 (m), 1258 (w), 1221 (w), 1209 (w), 1189 (m), 1149 (w), 1133 (w), 1106 (m), 1054 (s), 1000 (w), 967 (m), 917 (w), 890 (w), 864 (w), 823 (m), 801 (w), 769 (m), 746 (m), 657 (w), 532 (m), 414 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₃BrO₂Na 302.9991, 304.9972, Found 302.9993, 304.9972. **m.p.** 53.9– 54.9°C (CH₂Cl₂).


1-(but-2-en-1-yl)-2-naphthaldehyde **4g**



was obtained according to general procedure II A using **3S9** (178 mg, 0.63 mmol). The crude was then used according to general procedure III. Purification by column chromatography using 40:1 (*n*-pentane/Et₂O) afforded **4g** (64 mg, 0.34 mmol, 66% *E/Z* 80:20) as a pale yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.61 (s, 0.2H, CHO_{minor}), 10.60 (s, 0.80H, CHO_{major}), 8.26 – 8.18 (m, 1H, CH_{arom}), 7.98 – 7.92 (m, 1H, CH_{arom}), 7.90 – 7.84 (m, 1H, CH_{arom}), 7.80 (d, J = 8.8 Hz, 1H, CH_{arom}), 7.65 – 7.55 (m, 2H, 2xCH_{arom}), 5.82 – 5.33 (m, 2H, 2xCH_{olef}), 4.33 – 4.29 (m, 0.39H, CH_{2,minor}), 4.24 (dt, J = 5.8, 1.8 Hz, 1.61H CH_{2,major}), 1.93 – 1.88 (m, 0.59H, CH_{3,minor}), 1.62 (dq, J = 6.5, 1.7 Hz, 2.41H, CH_{3,major}). ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.2 (CHO_{minor}), 192.1 (CHO_{major}), 143.6 (C_{arom,minor}), 142.7 (C_{arom,major}), 137.7 (C_{arom,minor}), 136.5 (C_{arom,major}), 132.2 (C_{arom,major}), 131.2 (C_{arom,major}), 131.1 (C_{arom,minor}), 129.2 (CH_{olef,major}), 129.1 (C_{arom,minor}), 129.0 (C_{arom,major}), 128.8 (C_{arom,minor}), 128.8 (C_{arom,minor}), 128.7 (C_{arom,major}), 127.7 (CH_{olef,major}), 127.6 (C_{arom,major}), 127.5 (C_{arom,minor}), 127.0 (C_{arom,major}), 125.6 (C_{arom,major}), 125.5 (C_{arom,minor}), 125.0 (CH_{olef,minor}), 124.3 (C_{arom,minor}), 124.1 (C_{arom,major}), 29.5 (CH_{2,major}), 24.9 (CH_{2,minor}), 18.1 (CH_{3,major}), 13.5 (CH_{3,minor}) ppm. Two ¹³C-signals of the minor isomer could not be found due to the noise to signal ratio. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3058 (w), 3022 (w), 2916 (w), 2856 (w), 2735 (w), 1678 (s), 1620 (w), 1597 (w), 1566 (w), 1511 (w), 1470 (w), 1451 (w), 1431 (w), 1378 (w), 1342 (w), 1261 (w), 1225 (m), 1190 (w), 1165 (w), 1145 (w), 1105 (w), 1067 (w), 1033 (w), 966 (w), 910 (w), 865 (w), 817 (m), 790 (w), 763 (w), 745 (m), 663 (w), 611 (w), 564 (w), 523 (w), 482 (w), 438 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₄O 211.1117, Found 211.1117.

7 General Procedures IV – VI: Substrate Synthesis



General Procedure IV: Tetrahydropyran Protection

The reduction was carried out according to a protocol reported by KOERT *et al.*

To a solution of *ortho*-bromo benzyl alcohol (1.00 equiv) and PPTS (0.05 equiv) in anhydrous CH_2Cl_2 (0.2 M) DHP was added and stirred for 2 h at rt. The mixture was diluted with CH_2Cl_2 , washed with water (2 x) and brine and dried over Na_2SO_4 . The solvent was removed under reduced pressure. The product was afforded as an oil and used without further purification.

General Procedure II A: Alkylation

To a solution of acetal (1.00 equiv) in anhydrous THF (0.3 M) at $-78\text{ }^\circ\text{C}$ *n*-BuLi (1.10 equiv, 2.5 M) were added dropwise and the solution was stirred for 30 min. R^1, R^2 -Allylbromide (1.30 equiv) was added to the solution and the mixture was allowed to warm to rt for 2 h. The reaction was quenched with sat. NaHCO_3 -solution and extracted with Et_2O (3 x). The combined organic layers were washed with brine and dried over Na_2SO_4 . The solvent was removed under reduced pressure. The residue was purified by column chromatography (*n*-pentane/ Et_2O / Et_3N 40:1:0.5, unless otherwise noted) to give the product as a colorless oil.


General Procedure V: Tetrahydropyran Deprotection

Alkylated acetal (1.00 equiv) and PPTS (0.05 equiv) were dissolved in MeOH (0.5 M) and stirred at rt overnight. The mixture was extracted with Et_2O (3x). The combined organic layers were washed with water (2 x), followed by brine and dried over Na_2SO_4 . The solvent was removed under reduced pressure. The residue was purified by column chromatography (*n*-pentane/ EtOAc 10:1, unless otherwise noted) to give the product as a colorless oil.

General Procedure VI: Oxidation to Benzaldehyde

To a solution of alcohol (1.00 equiv) in CH_2Cl_2 (0.2 M) DMP (1.10 equiv) was added and stirred at rt overnight. The mixture was diluted with sat. NaHCO_3 -solution and extracted with Et_2O (3 x). The combined organic layers were washed with water, followed by brine and dried over Na_2SO_4 . The solvent was removed under reduced pressure. The residue was purified by column chromatography (*n*-pentane/ Et_2O 100:1, unless otherwise noted) to give the product as a colorless oil.

2-((2-bromo-4-fluorobenzyl)oxy)tetrahydro-2H-pyran **S20**



was obtained according to general procedure IV, using the corresponding alcohol **S21** (1.00 g, 4.90 mmol).

Purification by column chromatography afforded **S20** (1.41 mg, 4.90 mmol, 99%) as a colorless oil.


$^1\text{H NMR}$: (300 MHz, CDCl_3) δ = 7.48 (dd, J = 8.6, 6.1 Hz, 1H, CH_{arom}), 7.30 (dd, J = 8.2, 2.6 Hz, 1H, CH_{arom}), 7.03 (td, J = 8.4, 2.6 Hz, 1H, CH_{arom}), 4.82 – 4.74 (m, 2H, OCHO and $\text{CHH}_{\text{benzylic}}$), 4.53 (d, J = 13.0 Hz, 1H, $\text{CHH}_{\text{benzylic}}$),

3.91 (ddd, J = 11.4, 8.8, 3.5 Hz, 1H, OCHH_{THP}), 3.57 (dtd, J = 11.3, 4.3, 1.4 Hz, 1H, OCHH_{THP}), 1.92 – 1.52 (m, 6H, 3 x CH_2_{THP}) ppm.

$^{13}\text{C NMR}$: (75 MHz, CDCl_3) δ = 161.8 (d, J = 250.1 Hz, CF_{arom}), 133.9 (d, J = 3.6 Hz, C_{arom}), 130.3 (d, J = 8.3 Hz, C_{arom}), 122.9 (d, J = 9.6 Hz, C_{arom}), 119.9 (d, J = 24.5 Hz, C_{arom}), 114.5 (d, J = 20.6 Hz, C_{arom}), 98.6 (OCHO), 68.2 ($\text{CH}_2_{\text{benzylic}}$), 62.4 (CH_2_{THP}), 30.7 (CH_2_{THP}), 25.6 (CH_2_{THP}), 19.5 (CH_2_{THP}) ppm. **$^{19}\text{F NMR}$** : (282 MHz, CDCl_3) δ = -113.44 ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 2942 (m), 2870 (w), 1600 (m),

1589 (w), 1488 (s), 1455 (w), 1441 (w), 1386 (w), 1350 (w), 1323 (w), 1261 (w), 1230 (m), 1201 (w), 1183 (w), 1155 (w), 1126 (m), 1069 (m), 1037 (w), 1028 (s), 973 (m), 906 (w), 874 (m), 859 (w), 815 (m), 769 (w), 430 (w). **HRMS** (ESI+) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{12}\text{H}_{14}\text{BrFO}_2\text{Na}$ 311.0053, 313.0034, Found 311.0051, 313.0029.


2-((2-but-en-1-yl)-4-fluorobenzyl)oxy)tetrahydro-2H-pyran **S22**



was obtained according to general procedure IV, using the corresponding acetal **S20** (1.13 g, 3.92 mmol) and crotylbromide (0.66 mL, 6.37 mmol, 85:15 *E/Z*). Purification by column chromatography afforded **S22** (0.84 g, 3.17 mmol, 81%, 77:23 *E/Z*) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.33 (dd, *J* = 8.4, 6.0 Hz, 1H, CH_{arom}), 6.94 – 6.85 (m, 2H, 2 x CH_{arom}), 5.66 – 5.43 (m, 2H, CH_{2,olef}), 4.79 – 4.74 (m, 1H, OCHH_{benzylic}), 4.70 – 4.67 (m, 1H, OCHO), 4.49 – 4.44 (m, 1H, OCHH_{benzylic}), 3.90 (ddd, *J* = 11.7, 8.5, 3.4 Hz, 1H, OCHH_{THP}), 3.57 – 3.53 (m, 1H, OCHH_{THP}), 3.45 (d, *J* = 7.8 Hz, 0.46H, CH_{2,benzylic,minor}), 3.39 – 3.34 (m, 1.54H, CH_{2,benzylic,major}), 1.89 – 1.82 (m, 1H, CHH_{THP}), 1.69 (d, *J* = 9.1 Hz, 4H, CHH_{THP}, CH₃), 1.66 – 1.53 (m, 4H, 2xCH_{2,THP}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 162.7 (d, *J* = 244.1 Hz, CF_{arom,minor}), 161.7 (d, *J* = 245.2 Hz, CF_{arom,major}), 142.4 (d, *J* = 7.7 Hz, C_{arom,minor}), 142.2 (d, *J* = 7.2 Hz, C_{arom,major}), 131.9 (C_{arom,minor}), 131.8 (d, *J* = 2.9 Hz, C_{arom,major}), 130.9 (d, *J* = 8.6 Hz, C_{arom,major}), 128.9 (CH_{olef,major}), 127.9 (CH_{olef,minor}), 127.3 (CH_{olef,major}), 125.9 (CH_{olef,minor}), 116.2 (d, *J* = 21.5 Hz, C_{arom,major}), 115.8 (d, *J* = 21.9 Hz, C_{arom,minor}), 112.8 (d, *J* = 20.9 Hz, C_{arom,major}), 112.7 (d, *J* = 21.0 Hz, C_{arom,minor}), 98.1 (OCHO_{major}), 98.1 (OCHO_{minor}), 66.6 (OCH_{2,benzylic,minor}), 66.5 (OCH_{2,benzylic,major}), 62.4 (OCH_{2,THP}), 35.5 (CH_{2,benzylic,major}), 30.8 (CH_{2,THP}), 29.9 (CH_{2,benzylic,minor}), 25.6 (CH_{2,THP}), 19.6 (CH_{2,THP}), 18.0 (CH_{3,major}), 13.0 (CH_{3,minor}) ppm. Due to the noise to signal ratio, the aromatic carbon atom of the minor isomer could not be detected. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -115.15 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3024 (w), 2941 (m), 2872 (w), 1612 (w), 1592 (m), 1498 (m), 1466 (w), 1453 (w), 1441 (w), 1385 (w), 1350 (w), 1323 (w), 1260 (m), 1201 (w), 1183 (w), 1150 (w), 1119 (m), 1078 (w), 1054 (w), 1035 (w), 1025 (s), 973 (m), 959 (w), 906 (w), 869 (m), 814 (m), 524 (w), 507 (w), 475 (w), 429 (w). **HRMS (APCI+)** *m/z*: [M+H]⁺ Calcd for C₁₆H₂₁FO₂H 265.1598, Found 265.1599.


2-(but-2-en-1-yl)-4-fluorophenyl)methanol **S23**



was obtained according to general procedure VI, using the corresponding acetal **S22** (587 mg, 2.03 mmol) Purification by column chromatography afforded **S23** (354 mg, 1.34 mmol, 66%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.34 – 7.30 (m, 1H, CH_{arom}), 6.95 – 6.87 (m, 2H, 2 x CH_{arom}), 5.67 – 5.44 (m, 2H, 2 x CH_{olef}), 4.69 – 4.64 (m, 2H, OCH₂), 3.46 (d, *J* = 7.2 Hz, 0.47H, CH_{2,benzylic,minor}), 3.38 (dt, *J* = 6.3, 1.5 Hz, 1.53H, CH_{2,benzylic,major}), 1.74 (ddt, *J* = 6.8, 1.9, 1.0 Hz, 0.72H, CH_{3,minor}), 1.68 (dq, *J* = 6.2, 1.5 Hz, 2.28H, CH_{3,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 162.7 (d, *J* = 246.0 Hz, CF_{arom,minor}), 162.6 (d, *J* = 245.6 Hz, CF_{arom,major}), 142.0 (d, *J* = 7.6 Hz, C_{arom,minor}), 141.6 (d, *J* = 7.6 Hz, C_{arom,major}), 134.4 (C_{arom,major}), 134.4 (C_{arom,minor}), 130.2 (d, *J* = 8.3 Hz, C_{arom,major}), 130.2 (d, *J* = 8.6 Hz, C_{arom,minor}), 129.2 (CH_{olef,major}), 128.1 (CH_{olef,minor}), 127.4 (CH_{olef,major}), 126.0 (CH_{olef,minor}), 116.6 (d, *J* = 21.9 Hz, C_{arom,major}), 116.2 (d, *J* = 21.0 Hz, C_{arom,minor}), 113.1 (d, *J* = 21.0 Hz, C_{arom,major}), 113.0 (d, *J* = 21.0 Hz, C_{arom,minor}), 62.8 (OCH_{2,benzylic,minor}), 62.8 (OCH_{2,benzylic,major}), 35.6 (CH_{2,benzylic,major}), 30.1 (CH_{2,benzylic,minor}), 18.1 (CH_{3,benzylic,major}), 13.1 (CH_{3,benzylic,minor}) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -114.80 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3365 (m), 3070 (w), 3024 (w), 2958 (w), 2920 (m), 2857 (w), 1612 (w), 1591 (s), 1495 (s), 1452 (w), 1419 (w), 1364 (w), 1243 (s), 1179 (w), 1148 (m), 1123 (w), 1084 (w), 1034 (w), 1010 (s), 969 (m), 959 (w), 865 (w), 816 (m), 753 (w), 684 (s), 609 (w), 568 (m), 528 (w), 517 (w), 467 (w), 449 (w), 433 (w), 419 (w). **HRMS (APCI+)** *m/z*: [M-H₂O]⁺ Calcd for C₁₁H₁₂F 163.0923, Found 163.0918.


2-(but-2-en-1-yl)-4-fluorobenzaldehyde **4c**



was obtained according to general procedure VI, using the corresponding alcohol **S23** (254 mg, 1.41 mmol) Purification by column chromatography (*n*-pentane/Et₂O, 10:1) afforded **4c** (143 mg, 0.80 mmol, 57%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.21 (s, 1H, CHO), 7.88 – 7.84 (m, 1H, CH_{arom}), 7.07 – 6.97 (m, 2H, 2 x CH_{arom}), 5.68 – 5.44 (m, 2H, CH_{2,olef}), 3.84 (dd, *J* = 7.2, 0.7 Hz, 0.48H, CH_{2,benzylic,minor}), 3.74 (dt, *J* = 6.3, 1.5 Hz, 1.62H, CH_{2,benzylic,major}), 1.73 (ddt, *J* = 6.8, 1.9, 0.9 Hz, 0.71H, CH_{3,minor}), 1.68 (dq, *J* = 6.3, 1.4 Hz, 2.29H, CH_{3,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 191.0 (CHO_{minor}), 190.8 (CHO_{major}), 166.1 (d, *J* = 256.5 Hz, CF_{arom,major}), 147.4 (d, *J* = 8.5 Hz, C_{arom,minor}), 147.1 (d, *J* = 8.6 Hz, C_{arom,major}), 134.8 (d, *J* = 9.5 Hz, C_{arom,minor}), 134.2 (d, *J* = 10.5 Hz, C_{arom,major}), 130.5 (d, *J* = 3.0 Hz, C_{arom,minor}), 130.5 (d, *J* = 2.9 Hz, C_{arom,major}), 128.7 (CH_{olef,major}), 128.2 (CH_{olef,major}), 127.4 (CH_{olef,minor}), 126.5 (CH_{olef,minor}), 117.8 (d, *J* = 21.9 Hz, C_{arom,major}), 117.4 (d, *J* = 21.9 Hz, C_{arom,minor}), 114.1 (d, *J* = 22.1 Hz, C_{arom,major}), 114.0 (d, *J* = 21.9 Hz, C_{arom,minor}), 35.3 (CH_{2,benzylic,major}), 30.0 (CH_{2,benzylic,minor}), 18.1 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. Due to the noise to signal ratio and ¹⁹F-coupling, the quaternary aromatic carbon atom of the minor isomer CF_{arom,major} could not be detected. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -103.58 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3026 (w), 2919 (w), 2858 (w), 2734 (w), 1693 (s), 1605 (m), 1582 (s), 1491 (w), 1432 (w), 1399 (w), 1310 (w), 1277 (w), 1243 (s), 1212 (w), 1200 (w), 1151 (w), 1109 (w), 1084 (w), 1026 (w), 965 (m), 869 (w), 818 (m), 616 (w), 466 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₁H₁₁FOH 179.0867, Found 179.0865.


2-(but-2-en-1-yl)-4-(pyrrolidin-1-yl)benzaldehyde **4S3**



aldehyde **4c** (89.1 mg, 0.50 mmol), K_2CO_3 (138 mg, 1.00 mmol, 2.00 equiv) and pyrrolidine (0.08 mL, 1.00 mmol, 2.00 equiv) were added to a Schlenk-flask under inert atmosphere. 4 mL DMF were added and the reaction mixture was stirred for 16 h at 80 °C. Sat.5CF3 NaHCO₃ solution (5 mL) was added and the mixture was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layers were washed with water (3 x 15 mL) and brine (15 mL), dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. Purification by column chromatography 10:1 (*n*-pentane/EtOAc) afforded **4S3** (92.0 mg, 0.40 mmol, 80%) as a blue oil.

¹H NMR: (300 MHz, CDCl₃) δ = 10.00 (s, 1H, CHO), 7.78 – 7.68 (m, 1H, CH_{arom}), 6.48 (dd, *J* = 8.6, 2.5 Hz, 1H, CH_{arom}), 6.41 – 6.33 (m, 1H, CH_{arom}), 5.73 – 5.45 (m, 2H, 2 x CH_{olef}), 3.81 (d, *J* = 5.6 Hz, 0.29H, CH_{2,benzylic,minor}), 3.71 (d, *J* = 7.3 Hz, 1.71H, CH_{2,benzylic,major}), 3.45 – 3.37 (m, 4H, 2 x CH₂), 12.11 – 2.03 (m, 4H, 2 x CH₂), 1.77 (d, *J* = 4.7 Hz, 0.43H, CH_{3,minor}), 1.68 (d, *J* = 6.5 Hz, 2.57H, CH_{3,major}) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 190.1 (CHO), 151.6 (C_{arom}), 146.0 (C_{arom}), 134.3 (C_{arom}), 130.2 (CH_{olef}), 126.6 (CH_{olef}), 122.6 (C_{arom}), 112.7 (C_{arom}), 109.6 (C_{arom}), 47.7 (CH_{2,major}), 36.3 (CH_{2,minor}), 25.6 (CH_{3,major}), 18.1 (CH_{3,minor}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 2923 (m), 2852 (w), 1668 (w), 1590 (s), 1544 (w), 1516 (w), 1484 (w), 1449 (w), 1384 (m), 1351 (w), 1263 (m), 1214 (w), 1179 (w), 1106 (w), 1023 (w), 968 (w), 803 (m), 733 (s), 701 (w), 666 (w), 595 (w), 456 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₅H₁₉NONa 252.1359, Found 252.1362.


2-((2-bromo-5-(trifluoromethyl)benzyl)oxy)tetrahydro-2H-pyran **S24**



was obtained according to general procedure IV, using the corresponding alcohol **S25** (1.00 g, 3.93 mmol). Purification by column chromatography afforded **S24** (1.32 mg, 3.89 mmol, 99%) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 7.79 (d, *J* = 2.6 Hz, 1H, CH_{arom}), 7.66 (d, *J* = 8.3 Hz, 1H, CH_{arom}), 7.40 (dd, *J* = 8.3, 2.5 Hz, 1H, CH_{arom}), 4.86 (d, *J* = 14.0 Hz, 1H, CHH_{benzylic}), 4.80 (t, *J* = 3.4 Hz, 1H, OCHO), 4.58 (d, *J* = 14.0 Hz, 1H, CHH_{benzylic}), 3.90 (ddd, *J* = 11.5, 8.5, 3.5 Hz, 1H, OCHH_{THP}), 3.58 (dtd, *J* = 11.3, 4.5, 1.7 Hz, 1H, OCHH_{THP}), 2.01 – 1.50 (m, 6H, 3 x CH_{2,THP}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 139.4 (C_{arom}), 133.0 (C_{arom}), 130.08 (q, ²*J* = 30.9 Hz, CF₃C_{arom}), 126.19 (q, ¹*J* = 276.0 Hz, CF₃), 125.58 (q, ³*J* = 3.9 Hz, CH_{arom}), 125.42 (q, ³*J* = 4.1 Hz, CF₃CCH_{arom}), 98.8 (OCHO), 68.2 (CH_{2,benzylic}), 62.4 (OCH_{2,THP}), 30.6 (CH_{2,THP}), 25.5 (CH_{2,THP}), 19.4 (CH_{2,THP}) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -62.73 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 2944 (w), 2872 (w), 1606 (w), 1583 (w), 1455 (w), 1442 (w), 1414 (w), 1387 (w), 1328 (s), 1258 (w), 1200 (w), 1168 (m), 1125 (s), 1081 (s), 1038 (m), 1025 (w), 972 (w), 907 (w), 871 (w), 824 (w), 750 (w), 438 (w), 423 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₄BrF₃O₂Na 361.0021, 363.0002, Found 361.0019, 362.9999.


2-((2-(but-2-en-1-yl)-5-(trifluoromethyl)benzyl)oxy)tetrahydro-2H-pyran **S26**



was obtained according to general procedure IV, using the corresponding acetal **S24** (0.66 g, 1.94 mmol) and crotylbromide (0.26 mL, 2.52 mmol, 85:15 *E/Z*). Purification by column chromatography afforded **S26** (0.36 g, 1.15 mmol, 60%, 75:25 *E/Z*) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.68 (s, 1H, CH_{arom}), 7.48 (d, *J* = 8.1 Hz, 1H, CH_{arom}), 7.30 (t, *J* = 8.8 Hz, 1H, CH_{arom}), 5.69 – 5.39 (m, 2H, 2 x CH_{olef}), 4.87 – 4.82 (m, 1H, OCHH_{benzylic}), 4.72 (d, *J* = 7.0 Hz, 1H, OCHO), 4.55 – 4.50 (m, 1H, OCHH_{benzylic}), 3.90 (ddd, *J* = 11.6, 8.6, 3.3 Hz, 1H, OCHH_{THP}), 3.60 – 3.54 (m, 1H, OCHH_{THP}), 3.47 (d, *J* = 7.1 Hz, 0.5H, CH_{2,benzylic,minor}), 3.40 (d, *J* = 7.5 Hz, 1.5H CH_{2,benzylic,major}), 1.91 – 1.84 (m, 1H, CHH_{THP}), 1.78 – 1.66 (m, 5H, CHH_{THP}, CH₃, CHH_{THP}), 1.65 – 1.55 (m, 3H, CHH_{THP}, CH_{2,THP}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 143.4 (C_{arom,minor}), 143.2 (C_{arom,major}), 137.1 (C_{arom,major}), 129.9 (C_{arom,major}), 129.4 (C_{arom,minor}), 128.6 (q, ²*J* = 31.9 Hz, CF₃C_{arom}), 128.5 (CH_{olef,major}), 127.6 (CH_{olef,minor}), 127.4 (CH_{olef,major}), 126.1 (CH_{olef,minor}), 125.3 (q, ³*J* = 3.8 Hz, C_{arom,major}), 125.2 (q, ¹*J* = 271.4 Hz, CF₃), 124.6 – 124.5 (m, 2C, 2 x C_{arom,major}), 98.4 (OCHO_{major}), 98.4 (OCHO_{minor}), 66.4 (OCH_{2,benzylic,minor}), 66.3 (OCH_{2,benzylic,major}), 62.4 (OCH_{2,THP}), 35.5 (CH_{2,benzylic,major}), 30.7 (CH_{2,THP}), 30.0 (CH_{2,benzylic,minor}), 25.6 (CH_{2,THP}), 19.5 (CH_{2,THP}), 18.1 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. **¹⁹F NMR:** (282 MHz, CDZCl₃) δ = -62.30 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 2943 (w), 2872 (w), 1620 (w), 1426 (w), 1384 (w), 1329 (s), 1268 (w), 1202 (w), 1161 (m), 1119 (s), 1080 (m), 1059 (w), 1031 (m), 971 (m), 945 (w), 907 (m), 871 (w), 835 (w), 816 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₇H₂₁F₃O₂Na 337,1397, Found 337.1386.


(2-(but-2-en-1-yl)-5-(trifluoromethyl)phenyl)methanol **S27**



was obtained according to general procedure VI, using the corresponding acetal **S26** (0.31 g, 0.97 mmol) and aqueous HCl solution (1 M, 0.1 mL) instead of PPTS. Purification by column chromatography (*n*-pentane/Et₂O, 20:1 → 10:1 → 4:1) afforded **S27** (0.20 g, 0.87 mmol, 89%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.69 (s, 1H, CH_{arom}), 7.49 (d, *J* = 7.9 Hz, 1H, CH_{arom}), 7.34 – 7.28 (m, 1H, CH_{arom}), 5.55 (s, 2H, 2 x CH_{2,olef}), 4.77 (t, *J* = 5.2 Hz, 2H, OCH₂), 3.48 (d, *J* = 7.2 Hz, 0.5H, CH_{2,benzylic,minor}), 3.41 (d, *J* = 6.3 Hz, 1.5H, CH_{2,benzylic,major}), 1.75 – 1.74 (m, 0.73H, CH_{3,minor}), 1.68 (dq, *J* = 6.2, 1.4 Hz, 2.24H, CH_{3,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 143.0 (C_{arom,minor}), 142.6 (C_{arom,major}), 139.4 (C_{arom,major}), 139.4 (C_{arom,minor}), 130.1 (C_{arom,major}), 129.7 (C_{arom,minor}), 128.9 (q, ²*J* = 32.4 Hz, CF₃C_{arom}), 128.7 (CH_{olef,major}), 127.7 (CH_{olef,minor}), 127.6 (CH_{olef,major}), 126.2 (CH_{olef,minor}), 125.0 (q, ¹*J* = 272.4 Hz, CF₃), 124.8 – 124.5 (m, 2 x C_{arom}), 123.3 (C_{arom,minor}), 62.7 (OCH_{2,benzylic,minor}), 62.6 (OCH_{2,benzylic,major}), 35.6 (CH_{2,benzylic,major}), 30.2 (CH_{2,benzylic,minor}), 18.0 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. Due to the noise to signal ratio and ¹⁹F-coupling, some aromatic carbon atom of the minor isomer could not be detected. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -62.37 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3365 (m), 3070 (w), 3024 (w), 2958 (w), 2920 (m), 2857 (w), 1612 (w), 1591 (s), 1495 (s), 1452 (w), 1419 (w), 1364 (w), 1243 (s), 1179 (w), 1148 (m), 1123 (w), 1084 (w), 1034 (w), 1010 (s), 969 (m), 959 (w), 865 (w), 816 (m), 753 (w), 684 (s), 609 (w), 568 (m), 528 (w), 517 (w), 467 (w), 449 (w), 433 (w), 419 (w). **HRMS (ESI-)** *m/z*: [M]⁻ Calcd for C₁₂H₁₂F₃O 229.0846, Found 229.0830.


2-(but-2-en-1-yl)-5-(trifluoromethyl)benzaldehyde **4b**



was obtained according to general procedure VI, using the corresponding alcohol **S27** (191 mg, 1.06 mmol) Purification by column chromatography (*n*-pentane/Et₂O, 50:1) afforded **4b** (64 mg, 0.36 mmol, 34%) as a pale-yellow oil.


¹H NMR: (500 MHz, CDCl₃) δ = 10.31 (s, 1H, CHO), 8.12 – 8.09 (m, 1H, CH_{arom}), 7.77 – 7.74 (m, 1H, CH_{arom}), 7.48 – 7.42 (m, 1H, CH_{arom}), 5.68 – 5.41 (m, 2H, 2 x CH_{2,olef}), 3.88 (d, *J* = 7.1 Hz, 0.5H, CH_{2,minor}), 3.79 (d, *J* = 6.4 Hz, 1.5H, CH_{2,major}), 1.75 (ddt, *J* = 6.9, 1.9, 1.0 Hz, 0.75H, CH_{3,minor}), 1.67 (dq, *J* = 6.4, 1.5 Hz, 2.25H, CH_{3,major}) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 191.1 (CHO_{minor}), 190.9 (CHO_{major}), 147.6 (C_{arom,minor}), 147.2 (C_{arom,major}), 134.1 (C_{arom,minor}), 134.1 (C_{arom,major}), 131.8 (C_{arom,major}), 131.4 (C_{arom,minor}), 130.3 (q, ³*J* = 3.8 Hz, 2 x C_{arom}), 129.6 (p, ²*J* = 33.3 Hz, C_{arom,major}), 129.1 (q, ²*J* = 33.5 Hz, C_{arom,minor}), 128.7 (CH_{olef,major}), 128.3 (CH_{olef,major}), 128.3 (q, ³*J* = 3.8 Hz C_{arom,minor}), 127.7 (q, ³*J* = 3.8 Hz C_{arom,major}), 127.3 (CH_{olef,minor}), 126.6 (CH_{olef,minor}), 124.3 (q, ¹*J* = 271.8 Hz, CF₃), 35.4 (CH_{2,benzylic,major}), 30.1 (CH_{2,benzylic,minor}), 18.1 (CH_{3,major}), 13.2 (CH_{3,minor}) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -62.79 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3027 (w), 2921 (w), 2860 (w), 2737 (w), 1697 (m), 1617 (w), 1577 (w), 1502 (w), 1453 (w), 1396 (w), 1330 (s), 1270 (w), 1165 (m), 1125 (s), 1083 (w), 1054 (w), 968 (w), 942 (w), 914 (w), 842 (w), 816 (w), 766 (w), 735 (w), 693 (w), 644 (w), 580 (w), 557 (w), 441 (w), 416 (w). **HRMS (APCI+)** *m/z*: [M+H]⁺ Calcd for C₁₂H₁₁FOH 229.0835, Found 229.0832.

2-(2-bromophenyl)-2-methylpropanenitrile **1S1**




was obtained following the procedure reported by ZHANG *et al.* starting from 2-brom-phenylacetonitrile **11**.^[13]
Spectral data was in agreement with the literature.^[14]

2-(2-bromophenyl)propanenitrile **1S2**



was obtained following the procedure reported by ZHANG *et al.* starting from 2-brom-phenylacetonitrile **11**.^[13]
Spectral data was in agreement with the literature.^[14]


1-(2-bromophenyl)cyclopropane-1-carbonitrile **1S3**



was obtained according to general procedure VII, using 2-brom-phenylacetonitrile **11** (0.59 g, 3.00 mmol) and 1,2-dibromoethane (0.34 mL, 3.90 mmol). Purification by column chromatography afforded **1S3** (0.47 mg, 2.10 mmol, 70%) as a colorless solid.

¹H NMR: (500 MHz, CDCl₃) δ = 7.62 (ddd, J = 7.9, 1.3, 0.4 Hz, 1H, CH_{arom}), 7.34 (dd, J = 7.7, 1.8 Hz, 1H, CH_{arom}), 7.30 (td, J = 7.5, 1.3 Hz, 1H, CH_{arom}), 7.22 (ddd, J = 7.9, 7.3, 1.8 Hz, 1H, CH_{arom}), 1.80 – 1.74 (m, 2H, 2 x CHH), 1.38 – 1.32 (m, 2H, 2 x CHH). ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 135.5 (C_{arom}), 133.6 (C_{arom}), 131.7 (C_{arom}), 130.4 (C_{arom}), 127.9 (C_{arom}), 126.8 (C_{arom}), 121.8 (CN), 17.0 (2 x CH₂), 15.7 (C_{quart}CN) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3060 (w), 3019 (w), 2234 (m), 1927 (w), 1590 (w), 1567 (w), 1472 (m), 1428 (m), 1319 (w), 1252 (w), 1163 (w), 1114 (w), 1075 (w), 1026 (s), 952 (w), 940 (w), 865 (w), 758 (s), 725 (m), 698 (w), 646 (w), 577 (m), 520 (w), 453 (w), 421 (w). **HRMS** (ESI+) m/z : [M+Na]⁺ Calcd for C₁₀H₈BrNNa 243.9732, 245.9711, Found 243.9733, 245.9712. **m.p.** 70.0 – 72.0 °C (ethyl acetate).


1-(2-bromophenyl)cyclopentane-1-carbonitrile **1S4**



was obtained according to general procedure VII, using 2-brom-phenylacetonitrile **11** (0.98 g, 5.00 mmol) and 1,4-dibromobutane (1.40 mL, 6.50 mmol). Purification by column chromatography (*n*-pentane/Et₂O 20:1) afforded **1S4** (1.33 g, 5.32 mmol, 83%) as a light brown oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.67 (dd, J = 7.9, 1.4 Hz, 1H, CH_{arom}), 7.42 (dd, J = 8.0, 1.7 Hz, 1H, CH_{arom}), 7.32 (ddd, J = 8.0, 7.3, 1.4 Hz, 1H, CH_{arom}), 7.19 (ddd, J = 8.0, 7.3, 1.7 Hz, 1H, CH_{arom}), 2.79 – 2.73 (m, 2H, 2 x ¹CHH), 2.24 – 2.17 (m, 2H, 2 x ¹CHH), 2.08 – 2.01 (m, 2H, 2 x ²CHH), 1.94 – 1.87 (m, 2H, 2 x ²CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 137.8 (C_{arom}), 135.4 (C_{arom}), 129.7 (C_{arom}), 127.9 (C_{arom}), 127.7 (C_{arom}), 123.9 (C_{arom}), 123.2 (CN), 47.8 (C_{quart}), 38.4 (2 x CH₂), 23.9 (2 x CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3066 (w), 2958 (m), 2876 (w), 2231 (w), 1926 (w), 1684 (w), 1587 (w), 1566 (w), 1468 (m), 1454 (w), 1434 (w), 1319 (w), 1275 (w), 1228 (w), 1167 (w), 1023 (m), 957 (w), 902 (w), 863 (w), 755 (s), 724 (w), 686 (w), 641 (w), 554 (w), 538 (w), 481 (w), 447 (w). **HRMS** (ESI+) m/z : [M+Na]⁺ Calcd for C₁₂H₁₂BrNNa 272.0056, Found 272.0039.


2-(2-bromophenyl)-2-methylpropanal **2S1**



was obtained according to general procedure VIII, using the corresponding nitrile **1S1** (2.94 g, 15.0 mmol). Purification by column chromatography afforded **2S1** (2.52 mg, 11.1 mmol, 74%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 9.80 (s, 1H, CHO), 7.61 (dd, J = 7.9, 1.4 Hz, 1H, CH_{arom}), 7.42 (dd, J = 7.9, 1.8 Hz, 1H, CH_{arom}), 7.37 (ddd, J = 7.8, 7.2, 1.3 Hz, 1H, CH_{arom}), 7.19 (ddd, J = 7.9, 7.2, 1.8 Hz, 1H, CH_{arom}), 1.52 (s, 6H, 2 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 203.1 (CHO), 142.4 (C_{arom}), 134.5 (C_{arom}), 129.1 (C_{arom}), 128.6 (C_{arom}), 127.9 (C_{arom}), 123.5 (C_{arom}), 51.8 (C_{quart}), 23.2 (2 x CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3067 (w), 2976 (w), 2935 (w), 2875 (w), 2803 (w), 2703 (w), 1721 (s), 1589 (w), 1565 (w), 1468 (m), 1426 (w), 1390 (w), 1361 (w), 1274 (w), 1239 (w), 1168 (w), 1112 (w), 1044 (w), 1023 (m), 983 (w), 948 (w), 907 (w), 886 (w), 839 (w), 756 (s), 733 (w), 722 (w), 670 (w), 653 (w), 637 (w), 617 (w), 550 (w), 452 (w), 422 (w). **HRMS** (ESI+) m/z : [M+H]⁺ Calcd for C₁₀H₁₁BrOH 227.0066, 229.0046, Found 227.0063, 229.0414.


2-(2-bromophenyl)propanal **2S2**



was obtained according to general procedure VIII, using the corresponding nitrile **1S2** (2.10 g, 10.0 mmol). Purification by column chromatography afforded **2S2** (1.22 g, 5.74 mmol, 57%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 9.74 (s, 1H, CHO), 7.64 (dd, *J* = 8.1, 1.3 Hz, 1H, CH_{arom}), 7.34 (dd, *J* = 7.7, 1.3 Hz, 1H, CH_{arom}), 7.18 (ddd, *J* = 8.1, 7.4, 1.7 Hz, 1H, CH_{arom}), 7.12 (dd, *J* = 7.7, 1.7 Hz, 1H, CH_{arom}), 4.17 (q, *J* = 7.1 Hz, 1H, CH), 1.44 (d, *J* = 7.1 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 200.4 (CHO), 138.0 (C_{arom}), 133.5 (C_{arom}), 129.4 (C_{arom}), 129.2 (C_{arom}), 128.2 (C_{arom}), 125.3 (C_{arom}), 52.1 (CH), 14.2 (CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3060 (w), 2979 (w), 2935 (w), 2874 (w), 2816 (w), 2722 (w), 1720 (s), 1589 (w), 1567 (w), 1471 (m), 1438 (w), 1389 (w), 1371 (w), 1278 (w), 1245 (w), 1194 (w), 1162 (w), 1126 (w), 1071 (w), 1047 (w), 1022 (s), 945 (w), 897 (w), 865 (w), 752 (s), 722 (w), 669 (w), 654 (w), 538 (w), 449 (m). **HRMS (ESI-)** *m/z*: [M]⁻ Calcd for C₉H₈BrO 210.9764, 212.9744, Found 210.9759, 212.9738.


1-(2-bromophenyl)cyclopropane-1-carbaldehyde **2S3**



was obtained according to general procedure VIII, using the corresponding nitrile **1S3** (1.11 g, 5.00 mmol). Purification by column chromatography afforded **2S3** (1.07 g, 4.74 mmol, 95%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 9.21 (s, 1H, CHO), 7.63 (ddd, *J* = 8.0, 1.3, 0.5 Hz, 1H, CH_{arom}), 7.31 (ddd, *J* = 7.7, 7.2, 1.3 Hz, 1H, CH_{arom}), 7.28 – 7.26 (m, 1H, CH_{arom}), 7.20 (ddd, *J* = 8.0, 7.2, 2.0 Hz, 1H, CH_{arom}), 1.75 – 1.72 (m, 1H, 2 x CHH), 1.42 – 1.39 (m, 1H, 2 x CHH). ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 199.9 (CHO), 137.5 (C_{arom}), 133.2 (C_{arom}), 132.4 (C_{arom}), 129.6 (C_{arom}), 127.7 (C_{arom}), 127.4 (C_{arom}), 38.3 (C_{quart}), 17.8 (2 x CH₂). ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3057 (w), 3006 (w), 2830 (w), 2749 (w), 2703 (w), 1712 (s), 1654 (w), 1590 (w), 1564 (w), 1473 (m), 1437 (w), 1395 (w), 1344 (w), 1246 (w), 1160 (w), 1111 (w), 1069 (w), 1039 (w), 1024 (m), 968 (w), 899 (w), 865 (w), 758 (m), 742 (w), 725 (w), 670 (w), 655 (w), 636 (w), 589 (w), 563 (w), 546 (w), 517 (w), 495 (w), 471 (w), 451 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₀H₉BrONa 246.9729, 248.9709, Found 246.9727, 248.9706.


1-(2-bromophenyl)cyclopentane-1-carbaldehyde **2S4**



was obtained according to general procedure VIII, using the corresponding nitrile **1S4** (1.04 g, 4.14 mmol). Purification by column chromatography afforded **2S4** (0.45 g, 1.76 mmol, 43%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 9.67 (s, 1H, CHO), 7.62 (dd, *J* = 7.9, 1.4 Hz, 1H, CH_{arom}), 7.40 (dd, *J* = 7.9, 1.7 Hz, 1H, CH_{arom}), 7.34 (td, *J* = 7.5, 1.4 Hz, 1H, CH_{arom}), 7.17 (ddd, *J* = 7.9, 7.2, 1.7 Hz, 1H, CH_{arom}), 2.47 – 2.35 (m, 2H, 2 x CHH), 2.12 – 2.07 (m, 2H, 2 x CHH), 1.81 – 1.73 (m, 2H, 2 x CH₂) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.9 (CHO), 141.7 (C_{arom}), 134.6 (C_{arom}), 129.1 (C_{arom}), 128.9 (C_{arom}), 127.6 (C_{arom}), 124.7 (C_{arom}), 64.0 (C_{quart}), 34.2 (2 x CH₂), 25.1 (2 x CH₂) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3063 (w), 2953 (m), 2871 (w), 2801 (w), 2717 (w), 1721 (s), 1587 (w), 1564 (w), 1467 (m), 1433 (w), 1385 (w), 1319 (w), 1268 (w), 1228 (w), 1102 (w), 1062 (w), 1042 (w), 1022 (m), 906 (w), 862 (w), 755 (m), 735 (w), 681 (w), 650 (w), 591 (w), 452 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₃BrONa 275.0047, 277.0022, Found 275.0032, 277.0007.


(*E*)-1-bromo-2-(2-methylpent-3-en-2-yl)benzene **5S1**



was obtained according to general procedure IX, using the corresponding aldehyde **2S1** (0.50 g, 2.20 mmol). Purification by column chromatography afforded **5S1** (246 mg, 1.03 mmol, 47%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.57 (dd, *J* = 7.9, 1.5 Hz, 1H, CH_{arom}), 7.52 (dd, *J* = 8.0, 1.7 Hz, 1H, CH_{arom}), 7.30 – 7.26 (m, 1H, CH_{arom}), 7.05 (ddd, *J* = 8.0, 7.3, 1.7 Hz, 1H, CH_{arom}), 5.75 (dq, *J* = 11.3, 1.8 Hz, 1H, CH_{olef}), 5.30 (dq, *J* = 11.3, 7.2 Hz, 1H, CH_{olef}), 1.54 (s, 6H, 2 x CH₃), 1.08 (dd, *J* = 7.2, 1.8 Hz, 3H, CH_{olef}CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 148.1 (C_{arom}), 139.3 (C_{olef}), 135.2 (C_{arom}), 127.6 (C_{arom}), 127.5 (C_{arom}), 127.3 (C_{arom}), 123.4 (C_{arom}), 122.9 (C_{olef}), 41.1 (C_{quart}), 29.7 (2 x CH₃), 13.5 (CH_{olef}CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3059 (w), 3013 (w), 2964 (w), 2870 (w), 1649 (w), 1588 (w), 1562 (w), 1466 (m), 1434 (w), 1423 (w), 1402 (w), 1381 (w), 1361 (w), 1289 (w), 1262 (w), 1227 (w), 1186 (w), 1167 (w), 1149 (w), 1105 (w), 1061 (w), 1045 (w), 1020 (s), 955 (w), 916 (w), 859 (w), 755 (s), 729 (m), 706 (s), 653 (m), 633 (m), 538 (w), 492 (w), 454 (m). **HRMS (EI+)** *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₅Br 238.03571, Found 238.03690.


1-bromo-2-(1-cyclopropylidene-2-methylpropan-2-yl)benzene **5S2**



was obtained by the following procedure. A mixture of 1-bromopropyl-3-triphenylphosphonium bromide (369 mg, 0.79 mmol, 1.50 equiv.) and KO^tBu (178 mg, 1.59 mmol, 3.00 equiv.) in anhydrous THF (1.5 mL) under inert atmosphere was stirred at 60 °C for 90 min. Then aldehyde **2S1** (120 mg, 0.53 mmol, 1.00 equiv.) in 1.5 mL THF was added and the reaction was stirred for 2 h at 60 °C. The mixture was cooled to rt, quenched with water and diluted with Et₂O. The mixture was extracted with Et₂O (15 mL x 3), washed with brine (20 mL), dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude was purified by column chromatography (*n*-pentane) and the product **5S2** (53.0 mg, 0.21 mmol, 40%) was obtained as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 7.56 (dd, *J* = 7.9, 1.4 Hz, 1H, CH_{arom}), 7.49 (dd, *J* = 8.0, 1.7 Hz, 1H, CH_{arom}), 7.29 – 7.23 (m, 1H, CH_{arom}), 7.04 (ddd, *J* = 7.9, 7.3, 1.7 Hz, 1H, CH_{arom}), 6.05 (p, *J* = 2.1 Hz, 1H, CH_{olef}), 1.61 (s, 6H, 2 x CH₃), 0.95 – 0.84 (m, 4H, 2 x CH₂) ppm. **¹³C NMR:** (76 MHz, CDCl₃) δ = 147.4 (C_{arom}), 135.4 (C_{arom}), 128.2 (C_{arom}), 127.6 (C_{arom}), 127.2 (C_{arom}), 126.6 (CH_{olef}), 123.7 (C_{arom}), 119.4 (C_{olef}), 43.0 (C_{quart}), 28.7 (2 x CH₃), 3.6 (CH₂), 0.5 (CH₂) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3080 (w), 3003 (w), 2965 (w), 2871 (w), 1914 (w), 1797 (w), 1691 (w), 1646 (w), 1588 (w), 1563 (w), 1466 (m), 1425 (w), 1380 (w), 1361 (w), 1317 (w), 1264 (w), 1232 (w), 1189 (w), 1157 (w), 1096 (w), 1045 (w), 1019 (s), 949 (m), 878 (w), 813 (w), 754 (s), 729 (m), 655 (w), 645 (m), 547 (w), 505 (w), 454 (m). **HRMS (EI+)** *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₄Br 249.02789, 251.02593, Found 249.02861, 251.02684.


1-bromo-2-(pent-3-en-2-yl)benzene **5S3**



was obtained according to general procedure IX, using the corresponding aldehyde **2S2** (490 mg, 2.30 mmol). Purification by column chromatography afforded **5S3** (303 mg, 1.34 mmol, 58%, *E/Z* 84:16) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.56 – 7.49 (m, 1H, CH_{arom}), 7.32 – 7.20 (m, 2H, 2 x CH_{arom}), 7.07 – 7.00 (m, 1H, CH_{arom}), 5.63 – 5.44 (m, 2H, 2 x CH_{olef}), 4.25 – 4.16 (m, 0.84H, CH_{major}), 3.91 (ddt, *J* = 7.0, 5.8, 1.3 Hz, 0.16H, CH_{minor}), 1.71 – 1.68 (m, 0.45H, CHCH_{3,minor}), 1.67 – 1.63 (m, 2.53H, CHCH_{3,major}), 1.33 – 1.27 (m, 3H, CH_{olef}CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 146.1 (C=O_{major}), 145.5 (C=O_{minor}), 134.6 (CH_{olef,major}), 134.5 (CH_{olef,minor}), 133.0 (C_{arom,minor}), 132.9 (C_{arom,major}), 128.3 (C_{arom,minor}), 128.1 (C_{arom,major}), 127.8 (C_{arom,major}), 127.7 (C_{arom,minor}), 127.6 (C_{arom,minor}), 127.5 (C_{arom,major}), 124.7 (CH_{olef,minor}), 124.5 (CH_{olef,major}), 124.4 (C_{arom,minor}), 124.0 (C_{arom,major}), 40.8 (CH_{minor}), 36.5 (CH_{major}), 22.2 (CH_{3,major}), 20.5 (CH_{3,minor}), 18.2 (CH_{3,minor}), 13.6 (CH_{3,major}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3060 (w), 3013 (w), 2967 (m), 2927 (w), 2870 (w), 1911 (w), 1795 (w), 1654 (w), 1590 (w), 1566 (w), 1469 (s), 1438 (w), 1401 (w), 1369 (w), 1319 (w), 1248 (w), 1194 (w), 1161 (w), 1110 (w), 1084 (w), 1022 (s), 999 (w), 971 (w), 938 (w), 859 (w), 789 (w), 752 (s), 731 (m), 712 (w), 660 (w), 618 (w), 583 (w), 551 (w), 517 (w), 448 (w). **HRMS (EI+)** *m/z*: [M]⁺ Calcd for C₁₁H₁₃Br 224.02006, 226.01808, Found 224.02018, 226.01819.


1-bromo-2-(1-(2-methylprop-1-en-1-yl)cyclopropyl)benzene **5S4**



was obtained according to general procedure IX, using the corresponding aldehyde **2S3** (563 mg, 2.50 mmol). Purification by column chromatography afforded **5S4** (537 mg, 2.14 mmol, 86%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.54 (dd, *J* = 7.9, 1.3 Hz, 1H, CH_{arom}), 7.41 (dd, *J* = 7.7, 1.8 Hz, 1H, CH_{arom}), 7.23 (td, *J* = 7.5, 1.4 Hz, 1H, CH_{arom}), 7.06 (ddd, *J* = 7.9, 7.3, 1.7 Hz, 1H, CH_{arom}), 5.72 – 5.67 (m, 1H, CH_{olef}), 1.67 (d, *J* = 1.5 Hz, 3H, CH₃), 1.65 (d, *J* = 1.6 Hz, 3H, CH₃), 1.09 – 1.05 (m, 2H, 2 x CHH), 1.03 – 0.99 (m, 2H, 2 x CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 145.1 (C_{olef}), 135.7 (C_{arom}), 133.1 (C_{arom}), 131.5 (C_{arom}), 127.6 (C_{arom}), 127.2 (CH_{olef}), 127.0 (C_{arom}), 126.5 (C_{arom}), 26.1 (CH₃), 18.9 (CH₃), 16.0 (2 x C_{cycprop}). **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3078 (w), 3001 (w), 2968 (w), 2912 (w), 2854 (w), 1662 (w), 1588 (w), 1562 (w), 1469 (w), 1435 (m), 1422 (w), 1374 (w), 1337 (w), 1308 (w), 1250 (w), 1197 (w), 1160 (w), 1113 (w), 1064 (w), 1032 (w), 1021 (m), 981 (w), 951 (w), 911 (w), 890 (w), 861 (w), 825 (m), 808 (w), 754 (s), 734 (w), 723 (w), 655 (m), 604 (w), 547 (w), 515 (w), 474 (w), 448 (w). **HRMS (EI+)** *m/z*: [M]⁺ Calcd for C₁₃H₁₅Br 250.03571, 252.03375, Found 250.03762, 252.03710.

1-bromo-2-(1-(2-methylprop-1-en-1-yl)cyclopentyl)benzene **5S5**




was obtained according to general procedure IX, using the corresponding aldehyde **2S4** (157 mg, 0.62 mmol) and isopropyl triphenylphosphonium iodide (348 mg, 0.81 mmol). Purification by column chromatography afforded **5S5** (136 mg, 0.54 mmol, 87%) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 7.54 (dd, *J* = 7.9, 1.5 Hz, 1H, CH_{arom}), 7.46 (dd, *J* = 7.9, 1.7 Hz, 1H, CH_{arom}), 7.25 – 7.18 (m, 1H, CH_{arom}), 7.05 – 6.97 (m, 1H, CH_{arom}), 5.66 (p, *J* = 1.4 Hz, 1H, CH_{olef}), 2.21 – 2.04 (m, 4H, 2 x CH₂), 1.76 – 1.62 (m, 4H, 2 x CH₂), 1.65 (d, *J* = 1.4 Hz, 3H, CH₃), 1.13 (d, *J* = 1.3 Hz, 3H, CH₃) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 147.9 (C_{arom}), 135.0 (C_{arom}),

133.4 (C_{olef}), 130.6 (C_{olef}), 128.3 (C_{arom}), 127.1 (C_{arom}), 126.6 (C_{arom}), 124.0 (C_{arom}), 52.8 ($C_{benzylic}$), 39.3 (2 x CH_2), 26.8 (CH_3), 23.5 (2 x CH_2), 18.4 (CH_3) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3057 (w), 2958 (m), 2912 (w), 2871 (w), 1661 (w), 1586 (w), 1563 (w), 1452 (m), 1434 (w), 1376 (w), 1321 (w), 1262 (w), 1233 (w), 1187 (w), 1165 (w), 1080 (w), 1020 (s), 964 (w), 939 (w), 823 (w), 753 (s), 736 (w), 670 (w), 651 (w), 622 (w), 592 (w), 541 (w), 451 (w), 420 (w). **HRMS** (EI+) m/z : $[M+Na]^+$ Calcd for $C_{15}H_{19}Br$ 278.06701, 280.06508, Found 278.06873, 280.06672.


(E)-2-(2-methylpent-3-en-2-yl)benzaldehyde **4r**



was obtained according to general procedure X, using the corresponding bromide **5S1** (244 mg, 1.02 mmol). Purification by column chromatography afforded **4r** (107 mg, 0.57 mmol, 56%) as a colorless oil.

1H NMR: (500 MHz, $CDCl_3$) δ = 10.64 (s, 1H, CHO), 7.91 (dd, J = 7.7, 2.1 Hz, 1H, CH_{arom}), 7.56 – 7.50 (m, 2H, 2 x CH_{arom}), 7.33 (dddd, J = 7.6, 6.8, 1.7, 0.8 Hz, 1H, CH_{arom}), 5.95 (dq, J = 11.2, 1.8 Hz, 1H, CH_{olef}), 5.35 (dq, J = 11.2, 7.2 Hz, 1H, CH_{olef}), 1.56 (s, 6H, 2 x CH_3), 0.98 (dd, J = 7.3, 1.8 Hz, 3H, $CH_{olef}CH_3$) ppm. **^{13}C NMR**: (126 MHz, $CDCl_3$) δ = 192.5 (CHO), 152.2 (C_{arom}), 142.2 (CH_{olef}), 134.5 (C_{arom}), 133.6 (C_{arom}), 129.2 (C_{arom}), 126.6 (C_{arom}), 125.6 (C_{arom}), 125.2 (CH_{olef}), 39.6 (C_{quat}), 32.2 (2 x CH_3), 13.7 ($CH_{olef}CH_3$) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3064 (w), 3008 (w), 2968 (w), 2933 (w), 2873 (w), 2771 (w), 1685 (s), 1645 (w), 1596 (m), 1469 (w), 1446 (w), 1399 (w), 1383 (w), 1363 (w), 1288 (w), 1270 (w), 1225 (w), 1195 (m), 1142 (w), 1120 (w), 1079 (w), 1064 (w), 1045 (w), 959 (w), 916 (w), 862 (w), 821 (m), 765 (s), 744 (w), 725 (w), 707 (m), 648 (w), 631 (m), 537 (w), 452 (w). **HRMS** (ESI+) m/z : $[M+Na]^+$ Calcd for $C_{13}H_{16}OH$ 189.1274, Found 189.1272.


2-(1-cyclopropylidene-2-methylpropan-2-yl)benzaldehyde **4x**



was obtained according to general procedure X, using the corresponding bromide **5S2** (37.7 mg, 0.15 mmol). Purification by column chromatography afforded **4x** (12.8 mg, 0.01 mmol, 43%) as a colorless oil.

1H NMR: (500 MHz, $CDCl_3$) δ = 10.59 (s, 1H, CHO), 7.88 (dt, J = 7.7, 1.2 Hz, 1H, CH_{arom}), 7.57 – 7.47 (m, 2H, 2 x CH_{arom}), 7.38 – 7.29 (m, 1H, CH_{arom}), 6.22 (p, J = 2.0 Hz, 1H, CH_{olef}), 1.61 (s, 6H, 2 x CH_3), 0.95 – 0.86 (m, 2H, 2 x CHH), 0.85 – 0.76 (m, 2H, 2 x CHH) ppm. **^{13}C NMR**: (126 MHz, $CDCl_3$) δ = 192.9 (CHO), 151.2 (C_{arom}), 135.4 (C_{arom}), 133.3 (C_{arom}), 129.5 (CH_{olef}), 128.9 (C_{arom}), 126.7 (C_{arom}), 126.2 (C_{arom}), 120.9 (C_{olef}), 41.8 (C_{quat}), 31.5 (CH_3), 3.6 (CH_2), 0.7 (CH_2) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3069 (w), 2963 (m), 2929 (w), 2869 (w), 2120 (w), 1796 (w), 1709 (s), 1602 (m), 1467 (m), 1387 (w), 1365 (w), 1323 (w), 1290 (w), 1274 (w), 1244 (m), 1221 (w), 1161 (w), 1109 (w), 1087 (w), 1066 (w), 1027 (m), 944 (w), 881 (w), 825 (w), 761 (s), 696 (w), 642 (w), 605 (w), 535 (w), 445 (w). **HRMS** (ESI+) m/z : $[M+Na]^+$ Calcd for $C_{14}H_{16}OH$ 201.1274, Found 201.1274.


2-(pent-3-en-2-yl)benzaldehyde **4n**



was obtained according to general procedure X, using the corresponding bromide **5S3** (293 mg, 1.30 mmol). Purification by column chromatography afforded **4n** (131 mg, 0.75 mmol, 58%, 86/14 *E/Z*) as a colorless oil.

1H NMR: (500 MHz, $CDCl_3$) δ = 10.37 (s, 1H, CHO), 7.84 – 7.77 (m, 1H, CH_{arom}), 7.54 (td, J = 7.6, 1.6 Hz, 1H, CH_{arom}), 7.46 (dd, J = 7.8, 1.4 Hz, 0.86H, $CH_{arom,major}$), 7.40 (dd, J = 7.9, 1.3 Hz, 0.14H, $CH_{arom,minor}$), 7.37 – 7.31 (m, 1H, CH_{arom}), 5.68 (ddq, J = 15.4, 6.2, 1.7 Hz, 0.14H, $CH_{olef,minor}$), 5.62 (ddq, J = 10.5, 8.7, 1.7 Hz, 0.86H, $CH_{olef,major}$), 5.52 – 5.41 (m, 1H, CH_{olef}), 4.80 (p, J = 7.4 Hz, 0.86H, CH_{major}), 4.46 (p, J = 7.0 Hz, 0.14H, CH_{minor}), 1.68 (dd, J = 6.5, 1.5 Hz, 0.41H, $CH_{3,minor}$), 1.63 (dd, J = 6.8, 1.7 Hz, 2.55H, $CH_{3,major}$), 1.39 (d, J = 7.0 Hz, 0.42H, $CH_{3,minor}$), 1.37 (d, J = 7.0 Hz, 2.58H, $CH_{3,major}$) ppm. **^{13}C NMR**: (126 MHz, $CDCl_3$) δ = 192.6 (CHO), 149.8 ($C_{arom,major}$), 149.1 ($C_{arom,minor}$), 135.6 ($CH_{olef,minor}$), 135.3 ($CH_{olef,major}$), 134.2 ($C_{arom,major}$), 134.1 ($C_{arom,minor}$), 133.3 ($C_{arom,minor}$), 133.2 ($C_{arom,major}$), 131.5 ($C_{arom,major}$), 131.2 ($C_{arom,minor}$), 127.9 ($C_{arom,minor}$), 127.6 ($C_{arom,major}$), 126.5 ($CH_{olef,minor}$), 126.4 ($C_{arom,major}$), 125.0 ($CH_{olef,minor}$), 124.3 ($CH_{olef,major}$), 36.1 (CH_{minor}), 31.7 (CH_{major}), 23.1 ($CH_{3,major}$), 21.6 ($CH_{3,minor}$), 18.1 ($CH_{3,minor}$), 13.3 ($CH_{3,major}$) ppm. **IR** (ATR) $\tilde{\nu}$ (cm^{-1}) = 3067 (w), 3014 (w), 2966 (w), 2926 (w), 2869 (w), 2731 (w), 1688 (s), 1598 (m), 1572 (w), 1484 (w), 1450 (m), 1403 (w), 1374 (w), 1294 (w), 1204 (w), 1193 (w), 1182 (m), 1162 (w), 1141 (w), 1080 (w), 1040 (w), 999 (w), 971 (w), 938 (w), 884 (w), 844 (m), 827 (w), 758 (s), 739 (w), 712 (w), 658 (w), 621 (w), 544 (w), 440 (w). **HRMS** (ESI+) m/z : $[M+H]^+$ Calcd for $C_{12}H_{14}OH$ 175.1117, Found 175.1117.


2-(1-(2-methylprop-1-en-1-yl)cyclopropyl)benzaldehyde **4w**



was obtained according to general procedure X, using the corresponding bromide **5S4** (535 mg, 2.13 mmol). Purification by column chromatography afforded **4w** (344 mg, 1.72 mmol, 81%) as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 10.80 (s, 1H, CHO), 7.91 – 7.86 (m, 1H, CH_{arom}), 7.53 – 7.48 (m, 2H, 2 x CH_{arom}), 7.34 (dddd, J = 7.7, 6.2, 2.3, 0.8 Hz, 1H, CH_{arom}), 5.45 (p, J = 1.4 Hz, 1H, CH_{olef}), 1.63 (d, J = 1.5 Hz, 3H, CH₃), 1.54 (d, J = 1.4 Hz, 3H, CH₃), 1.20 – 1.18 (m, 2H, 2 x CHH), 1.10 – 1.07 (m, 2H, CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 193.0 (CHO), 148.7 (C_{arom}), 136.2 (C_{olef}), 135.0 (C_{arom}), 133.9 (C_{arom}), 130.0 (C_{arom}), 129.9 (CH_{olef}), 128.2 (C_{arom}), 126.8 (C_{arom}), 26.2 (CH₃), 22.9 (C_{quart}), 18.8 (CH₃), 15.8 (2 x CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3066 (w), 2996 (w), 2965 (w), 2917 (w), 2853 (w), 2756 (w), 1689 (s), 1596 (m), 1569 (w), 1479 (w), 1450 (w), 1423 (w), 1394 (w), 1375 (w), 1341 (w), 1293 (w), 1261 (w), 1194 (m), 1161 (w), 1118 (w), 1086 (w), 1063 (w), 1029 (w), 982 (w), 960 (w), 913 (w), 891 (w), 825 (m), 763 (s), 743 (w), 723 (w), 642 (w), 593 (w), 543 (w), 447 (w), 420 (w). **HRMS** (ESI+) m/z: [M+Na]⁺ Calcd for C₁₄H₁₆ONa 223.1093, Found 223.1090.


2-(1-(2-methylprop-1-en-1-yl)cyclopentyl)benzaldehyde **4s**



was obtained according to general procedure X, using the corresponding bromide **5S5** (531 mg, 1.90 mmol). Purification by column chromatography (*n*-pentane/toluene 5:1, 1% Et₃N) afforded **4s** (378 mg, 1.66 mmol, 87%) as a colorless oil.


¹H NMR: (300 MHz, CDCl₃) δ = 10.58 (s, 1H, CHO), 7.91 (d, J = 7.6 Hz, 1H, CH_{arom}), 7.58 – 7.43 (m, 1H, CH_{arom}), 7.36 – 7.30 (m, 1H, CH_{arom}), 5.80 (s, 1H, CH_{olef}), 2.25 – 2.13 (m, 2H, CH₂), 2.10 – 2.00 (m, 2H, CH₂), 1.88 – 1.73 (m, 4H, 2 x CH₂), 1.64 (s, 3H, CH₃), 1.07 (s, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.9 (CHO), 151.9 (C_{arom}), 136.6 (CH_{olef}), 133.9 (C_{arom}), 134.8 (C_{arom}), 133.0 (C_{olef}), 129.1 (C_{arom}), 126.3 (C_{arom}), 126.3 (C_{arom}), 51.2 (C_{quart}), 41.9 (2 x CH₂), 26.6 (CH₃), 23.8 (2 x CH₂), 18.6 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3463 (w), 3068 (w), 3024 (w), 2953 (s), 2869 (w), 1688 (s), 1639 (w), 1597 (w), 1473 (w), 1451 (m), 1377 (w), 1271 (w), 1232 (w), 1199 (w), 1159 (w), 1095 (w), 1071 (m), 1020 (w), 965 (w), 890 (w), 825 (w), 757 (s), 726 (w), 702 (w), 540 (w), 445 (w). **HRMS** (ESI+) m/z: [M+Na]⁺ Calcd for C₁₆H₂₀OH 229.1587, Found 229.1585.

9 General Procedure XI: Photocyclization to Tetralones



The *o*-allyl benzaldehyde **4** (0.20 mmol, 1.00 equiv) was placed in a 25 mL round bottom flask. The flask was put under argon atmosphere and dry, degassed CH₂Cl₂ (13.5 mL, 15 mM or 20.0 mL, 10 mM) was added (unless otherwise noted). The reaction was stirred and irradiated 6 cm away from a 365 nm LED for the noted time. After completion of the reaction, the solvent was removed under reduced pressure. The afforded crude was applied onto a silica gel chromatography column and eluted with 100:1 *n*-pentane/Et₂O, unless otherwise indicated. After removal of the solvents under reduced pressure, the analytically pure tetralone **6** was isolated as an oil or solid.

2-methyl-3,4-dihydronaphthalen-1(2H)-one **6k**




was obtained following general procedure XI using the corresponding aldehyde **4k** (33.7 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6k** (29.8 mg, 18.6 mmol, 93%) was afforded as a colorless oil.

Yield at 10 mM: 91%

Spectral data was in agreement with the literature.^[15]

¹H NMR: (500 MHz, CDCl₃) δ = 8.04 (dd, *J* = 7.9, 1.7 Hz, 1H, CH_{arom}), 7.45 (td, *J* = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.30 (t, *J* = 7.6 Hz, 1H, CH_{arom}), 7.23 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 3.08 – 2.93 (m, 2H, CH_{2,benzylic}), 2.65 – 2.54 (m, 1H, CH), 2.20 (dq, *J* = 13.2, 4.5 Hz, 1H, CHH), 1.89 (dddd, *J* = 13.2, 11.9, 11.1, 4.8 Hz, 1H, CHH), 1.28 (d, *J* = 6.8 Hz, 3H, CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 200.9 (C=O), 144.3 (C_{arom}), 133.2 (C_{arom}), 132.6 (C_{arom}), 128.8 (C_{arom}), 127.6 (C_{arom}), 126.7 (C_{arom}), 42.8 (CH_{2,benzylic}), 31.5 (CH), 29.0 (CH₂), 15.6 (CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3067 (w), 2964 (w), 2931 (w), 2862 (w), 1716 (w), 1682 (s), 1601 (m), 1486 (w), 1455 (m), 1433 (w), 1375 (w), 1358 (w), 1323 (w), 1300 (w), 1267 (w), 1227 (s), 1157 (w), 1127 (w), 1077 (w), 1016 (w), 968 (m), 907 (w), 847 (w), 803 (w), 777 (w), 739 (s), 707 (w), 674 (w), 645 (w), 573 (w), 515 (w), 491 (w), 448 (w), 432 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₁H₁₂O 161.0961, Found 161.0959.

3,4-dihydronaphthalen-1(2H)-one **6l**




was obtained following general procedure XI using the corresponding aldehyde **4l** (36.7 mg, 0.2 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6l** (28.5 mg, 0.16 mmol, 82%) was afforded as a colorless oil.

Yield at 10 mM: 83%

Spectral data was in agreement with the literature.^[16]

¹H NMR: (500 MHz, CDCl₃) δ = 8.04 (ddd, *J* = 7.9, 1.5, 0.5 Hz, 1H, CH_{arom}), 7.45 (td, *J* = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.30 (dddt, *J* = 8.0, 7.3, 1.4, 0.7 Hz, 1H, CH_{arom}), 7.22 (dtd, *J* = 7.7, 1.5, 1.0 Hz, 1H, CH_{arom}), 2.99 (t, *J* = 6.4 Hz, 2H, CH_{2,benzylic}), 2.02 – 1.95 (m, 2H, CH₂), 1.22 (s, 6H, 2 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 203.1 (C=O), 143.7 (C_{arom}), 133.3 (C_{arom}), 131.5 (C_{arom}), 128.8 (C_{arom}), 128.1 (C_{arom}), 126.7 (C_{arom}), 41.7 (C_{quart}), 36.7 (CH₂), 25.8 (CH_{2,benzylic}), 24.5 (2 x CH₃) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2962 (w), 2925 (w), 2855 (w), 1681 (s), 1601 (m), 1474 (w), 1453 (m), 1383 (w), 1347 (w), 1308 (m), 1252 (w), 1218 (s), 1157 (w), 1128 (w), 1096 (w), 1016 (w), 994 (w), 968 (m), 897 (w), 798 (w), 775 (w), 740 (s), 697 (w), 676 (w), 625 (w), 573 (w), 524 (w), 489 (w), 455 (w), 431 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₄O 175.1111, Found 175.1113.

2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one **6m**




was obtained following general procedure XI using the corresponding aldehyde **4m** (29.6 mg, 0.19 mmol) and the reaction was carried out at a concentration of 15 mM for 24 h. The product **6m** (8.3 mg, 0.06 mmol, 30%) was afforded as a colorless oil.

Spectral data was in agreement with the literature.^[17]

¹H NMR: (500 MHz, CDCl₃) δ = 8.04 (d, J = 7.7 Hz, 1H, CH_{arom}), 7.47 (t, J = 7.3 Hz, 1H, CH_{arom}), 7.35 – 7.21 (m, 2H, 2 x CH_{arom}), 2.97 (t, J = 6.2 Hz, 2H, CH₂), 2.66 (t, J = 6.6 Hz, 2H, CH₂), 2.15 (p, J = 6.2 Hz, 2H, CH₂) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 198.5 (C=O), 144.6 (C_{arom}), 133.5 (C_{arom}), 132.8 (C_{arom}), 128.9 (C_{arom}), 127.3 (C_{arom}), 126.8 (C_{arom}), 39.3 (CH₂), 29.9 (CH₂), 23.4 (CH₂) ppm.


2,4,4-trimethyl-3,4-dihydronaphthalen-1(2H)-one **6r**



was obtained following general procedure XI using the corresponding aldehyde **4r** (43.6 mg, 0.25 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6r** (42.3 mg, 0.24 mmol, 97%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.03 (ddd, J = 7.8, 1.5, 0.5 Hz, 1H, CH_{arom}), 7.53 (ddd, J = 8.0, 7.1, 1.6 Hz, 1H, CH_{arom}), 7.43 (ddd, J = 7.9, 1.2, 0.5 Hz, 1H, CH_{arom}), 7.31 (ddd, J = 7.8, 7.2, 1.2 Hz, 1H, CH_{arom}), 2.85 (ddq, J = 10.4, 8.3, 6.6 Hz, 1H, CH), 1.95 – 1.92 (m, 2H, CH₃CCH₂), 1.45 (s, 3H, CH₃CCH₃), 1.41 (s, 3H, CHCH₃), 1.28 (d, J = 6.6 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.0 (C=O), 152.2 (C_{arom}), 133.6 (C_{arom}), 131.4 (C_{arom}), 127.6 (C_{arom}), 126.4 (C_{arom}), 126.1 (C_{arom}), 46.4 (CH₂), 38.6 (CH), 34.4 (C_{quar}), 30.8 (CH₃CCH₃), 29.9 (CH₃CCH₃), 15.6 (CHCH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3064 (w), 3008 (w), 2967 (w), 2931 (w), 2872 (w), 2772 (w), 1686 (s), 1645 (w), 1596 (m), 1469 (w), 1446 (w), 1399 (w), 1383 (w), 1363 (w), 1288 (w), 1270 (w), 1225 (w), 1195 (m), 1142 (w), 1120 (w), 1079 (w), 1064 (w), 1045 (w), 959 (w), 916 (w), 862 (w), 821 (m), 765 (s), 744 (w), 725 (w), 707 (m), 648 (w), 631 (m), 537 (w), 452 (w). **HRMS (ESI+)** m/z : [M+H]⁺ Calcd for C₁₃H₁₆OH 189.1274, Found 189.1272.


2,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one **6n**



was obtained following general procedure XI using the corresponding aldehyde **4n** (39.2 mg, 0.23 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6n** (39.1 mg, 0.22 mmol, 99%, d.r. 1:0.53) was afforded as a colorless oil.

major diastereomer **¹H NMR:** (500 MHz, CDCl₃) δ = 8.07 (dd, J = 7.8, 1.6 Hz, 1H, CH_{arom,major}), 8.04 (dd, J = 7.8, 1.5 Hz, 0H), 7.54 (td, J = 7.5, 1.7 Hz, 1H), 7.50 (td, J = 7.5, 1.5 Hz, 0H), 7.42 (dtd, J = 7.9, 1.2, 0.5 Hz, 1H), 7.36 – 7.27 (m, 0H), 3.22 – 3.12 (m, 0H), 2.92 – 2.81 (m, 0H), 2.65 (dq, J = 13.3, 6.7, 4.5 Hz, 1H), 2.20 – 2.10 (m, 1H), 2.02 (ddd, J = 13.4, 4.9, 3.8 Hz, 0H), 1.66 (td, J = 13.6, 12.0 Hz, 1H), 1.44 (d, J = 6.8 Hz, 3H), 1.44 (d, J = 7.2 Hz, 1H), 1.29 (d, J = 6.6 Hz, 3H), 1.28 (d, J = 6.8 Hz, 1H). ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.0 (C=O), 149.1 (C_{arom,minor}), 148.4 (C_{arom,major}), 133.5 (C_{arom,minor}), 133.4 (C_{arom,major}), 132.5 (C_{arom,major}), 131.5 (C_{arom,minor}), 128.4 (C_{arom,minor}), 127.6 (C_{arom,minor}), 127.5 (C_{arom,major}), 126.6 (C_{arom,minor}), 126.5 (C_{arom,major}), 126.5 (C_{arom,major}), 43.1 (CH_{major}), 41.2 (CH_{2,major}), 38.0 (CH_{2,minor}), 37.5 (CH_{minor}), 33.2 (COCH_{major}), 31.9 (COCH_{minor}), 21.8 (CH_{3,minor}), 20.4 (CH_{3,major}), 15.8 (CH_{3,minor}), 15.5 (CH_{3,major}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3063 (w), 2963 (m), 2929 (w), 2869 (w), 1686 (s), 1600 (w), 1480 (w), 1457 (w), 1388 (w), 1365 (w), 1331 (w), 1301 (w), 1254 (w), 1235 (m), 1162 (w), 1130 (w), 1092 (w), 1033 (w), 987 (w), 955 (w), 891 (w), 849 (w), 781 (w), 763 (m), 710 (w), 681 (w), 632 (w), 555 (w). **HRMS (ESI+)** m/z : [M+H]⁺ Calcd for C₁₃H₁₆OH 189.1274, Found 189.1272.

3',3'-dimethyl-2',3'-dihydro-4'H-spiro[cyclopropane-1,1'-naphthalen]-4'-one **6w**




was obtained following general procedure XI using the corresponding aldehyde **4w** (42.1 mg, 0.21 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6w** (25.3 mg, 0.13 mmol, 60%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.03 (ddd, J = 7.9, 1.6, 0.6 Hz, 1H, CH_{arom}), 7.44 (ddd, J = 8.1, 7.2, 1.6 Hz, 1H, CH_{arom}), 7.24 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H, CH_{arom}), 6.74 (dd, J = 8.1, 1.4 Hz, 1H, CH_{arom}), 1.87 (s, 2H, CH₂), 1.24 (s, 6H, 2 x CH₃), 1.15 – 1.10 (m, 2H, 2 x CHH), 1.01 – 0.97 (m, 2H, 2 x CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 203.30 (C=O), 147.82 (C_{arom}), 133.60 (C_{arom}), 131.50 (C_{arom}), 128.08 (C_{arom}), 125.69 (C_{arom}), 122.08 (C_{arom}), 46.59 (CH₂), 43.08 (C_{quar}(CH₃)₂), 24.93 (2 x CH₃), 18.40 (2 x CH_{2,cycprop}), 16.88 (C_{quar,cycprop}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3066 (w), 2963 (w), 2924 (w), 2867 (w), 2843 (w), 1679 (s), 1600 (m), 1571 (w), 1482 (m), 1469 (w), 1449

(w), 1383 (m), 1362 (w), 1298 (m), 1284 (w), 1246 (m), 1212 (m), 1170 (w), 1145 (w), 1110 (w), 1087 (m), 1053 (w), 1043 (w), 1021 (w), 994 (m), 979 (w), 956 (m), 938 (w), 905 (w), 876 (w), 846 (w), 807 (w), 796 (w), 756 (s), 706 (m), 688 (w), 628 (w), 566 (w), 552 (w), 459 (w), 409 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₆OH 201.1274, Found 201.1270.


4',4'-dimethyl-3',4'-dihydro-1'H-spiro[cyclopropane-1,2'-naphthalen]-1'-one **6x**



was obtained following general procedure XI using the corresponding aldehyde **4x** (41.1 mg, 0.21 mmol) and the reaction was carried out at a concentration of 15 mM for 12 h. The product **6x** (38.9 mg, 0.19 mmol, 95%) was afforded as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 8.00 (dd, *J* = 7.8, 1.6 Hz, 1H, CH_{arom}), 7.52 (ddd, *J* = 7.9, 7.1, 1.6 Hz, 1H, CH_{arom}), 7.43 (dd, *J* = 7.9, 1.8 Hz, 1H, CH_{arom}), 7.31 (ddd, *J* = 7.8, 7.1, 1.4 Hz, 1H, CH_{arom}), 1.94 (s, 2H, CH₃), 1.53 (q, *J* = 3.3 Hz, 2H, 2 x CHH), 1.41 (s, 6H, 2 x CH₃), 0.83 (q, *J* = 3.4 Hz, 2H, 2 x CHH) ppm. **¹³C NMR**: (75 MHz, CDCl₃) δ = 199.8 (C=O), 152.5 (C_{arom}), 133.6 (C_{arom}), 131.9 (C_{arom}), 127.4 (C_{arom}), 126.4 (C_{arom}), 125.1 (C_{arom}), 46.0 (CH₂), 35.3 (C_{quant}(CH₃)₂), 29.9 (2 x CH₃), 25.3 (C_{quant}(CH₂)_{cycprop}), 19.9 (2 x CH_{2,cycprop}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3064 (w), 2998 (w), 2963 (w), 2916 (w), 2865 (w), 1671 (s), 1599 (m), 1465 (w), 1448 (w), 1416 (w), 1387 (w), 1358 (s), 1336 (w), 1297 (w), 1228 (s), 1173 (w), 1148 (w), 1111 (w), 1088 (w), 1061 (w), 1044 (w), 1030 (w), 1001 (m), 968 (w), 910 (w), 875 (w), 808 (w), 782 (w), 764 (m), 707 (m), 636 (w), 552 (w), 520 (w), 477 (w), 435 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₆OH 201.1274, Found 201.1270.


3',3'-dimethyl-2',3'-dihydro-4'H-spiro[cyclopentane-1,1'-naphthalen]-4'-one **6s**



was obtained following general procedure XI using the corresponding aldehyde **4s** (40.8 mg, 0.18 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6s** (17.2 mg, 0.08 mmol, 42%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.96 (dd, *J* = 7.8, 1.6 Hz, 1H, CH_{arom}), 7.51 (ddd, *J* = 8.0, 7.2, 1.6 Hz, 1H, CH_{arom}), 7.35 (dd, *J* = 8.0, 1.4 Hz, 1H, CH_{arom}), 7.30 – 7.26 (m, 1H, CH_{arom}), 2.01 – 1.82 (m, 10H, 5 x CH₂), 1.24 (s, 6H, 3 x CH₃) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 204.3 (C=O), 152.5 (C_{arom}), 133.5 (C_{arom}), 130.9 (C_{arom}), 127.6 (C_{arom}), 126.9 (C_{arom}), 126.2 (C_{arom}), 49.5 (CH₂), 45.0 (C_{quant}), 44.4 (2 x CH_{2,pent}), 42.2 (C_{quant}), 27.1 (2 x CH₃), 25.9 (2 x CH_{2,pent}) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3063 (w), 2954 (m), 2870 (w), 1682 (s), 1598 (m), 1474 (w), 1449 (m), 1383 (w), 1361 (w), 1308 (w), 1225 (m), 1167 (w), 1138 (w), 1104 (w), 996 (w), 963 (m), 909 (w), 878 (w), 800 (w), 759 (s), 712 (m), 543 (w), 457 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₆H₂₀OH 229.1587, Found 229.1585.


5,6,7,8-tetrahydro-9H-5,8-methanobenzo[7]annulen-9-one **6o**



was obtained following general procedure XI using the corresponding aldehyde **4o** (30.4 mg, 0.18 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6o** (21.8 mg, 0.13 mmol, 72%) was afforded as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 8.04 – 7.98 (m, 1H, CH_{arom}), 7.32 (td, *J* = 7.6, 1.3 Hz, 1H, CH_{arom}), 7.28 – 7.26 (m, 1H, CH_{arom}), 3.41 (t, *J* = 4.7 Hz, 1H, ⁴CH), 3.19 – 3.14 (m, 1H, ¹CH), 2.27 – 2.14 (m, 3H, ²CHH, ³CHH, ⁵CHH), 1.88 (dt, *J* = 11.7, 4.5 Hz, 1H, ⁵CHH), 1.74 – 1.69 (m, 1H, ³CHH), 1.68 – 1.61 (m, 1H, ²CHH) ppm. **¹³C NMR**: (126 MHz, CDCl₃) δ = 201.9 (C=O), 151.1 (C_{arom}), 133.8 (C_{arom}), 130.5 (C_{arom}), 127.7 (C_{arom}), 126.9 (C_{arom}), 126.7 (C_{arom}), 50.0 (C=O¹CH), 42.4 (⁴CH_{benz}), 39.6 (⁵CH₂), 31.9 (²CH₂), 24.9 (³CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3067 (w), 2947 (m), 2870 (w), 1686 (s), 1602 (m), 1478 (w), 1457 (w), 1326 (w), 1302 (w), 1279 (m), 1243 (w), 1198 (w), 1152 (w), 1132 (w), 1099 (w), 1011 (w), 947 (w), 924 (w), 904 (w), 824 (w), 772 (w), 734 (w), 674 (w), 561 (w), 540 (w), 517 (w), 499 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₂H₁₂OH 173.0961, Found 178.0960.

6,7,8,9-tetrahydro-5,9-methanobenzo[8]annulen-10(5H)-one **6p**




was obtained following general procedure XI using the corresponding aldehyde **4p** (39.2 mg, 0.2 mmol) and the reaction was carried out at a concentration of 10 mM for 3 h. The product **6p** (23.3 mg, 0.13 mmol, 63%) was afforded as a colorless oil.

Yield at 15 mM: 53%

¹H NMR: (300 MHz, CDCl₃) δ = 8.07 (dd, *J* = 7.8, 1.6 Hz, 1H, CH_{arom}), 7.54 (td, *J* = 7.4, 1.6 Hz, 1H, CH_{arom}), 7.36 (td, *J* = 7.5, 1.3 Hz, 1H, CH_{arom}), 7.27 (dd, *J* = 7.6, 1.4 Hz, 1H, CH_{arom}), 3.20 (p, *J* = 3.7 Hz, 1H, ⁵CH_{benzylic}), 2.78 (p, *J* = 4.0 Hz, 1H, ¹CH), 2.40 (dtd, *J* = 13.4, 3.9, 2.0 Hz, 1H, ⁶CHH), 2.06 – 1.87 (m, 3H, ²CHH, ⁴CHH, ⁶CHH), 1.84 – 1.68 (m, 2H, ²CHH, ⁴CHH), 1.55 – 1.46 (m, 1H, ³CHH), 1.26 (qt, *J* = 13.9, 4.4 Hz, 1H, ³CHH) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 202.4 (C=O), 147.7 (C_{arom}), 134.4 (C_{arom}), 134.0 (C_{arom}), 128.3 (C_{arom}), 126.7 (C_{arom}), 126.3 (C_{arom}), 43.3 (C=O¹CH), 35.3 (⁵CH_{benz}), 33.7 (⁶CH₂), 31.1 (⁴CH₂), 29.8 (²CH₂), 18.1 (³CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 927 (m), 2856 (w), 1714 (w), 1682 (s), 1600 (m), 1455 (w), 1365 (w), 1347 (w), 1316 (w), 1286 (m), 1228 (w), 1187 (w), 1147 (w), 1122 (w), 1081 (w), 1017 (w), 990 (w), 914 (w), 863 (w), 796 (w), 761 (m), 737 (w), 709 (w), 558 (w), 534 (w), 514 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₄O₁Na 187.1114, Found 187.1117.


5,6,7,8,9,10-hexahydro-11H-5,10-methanobenzo[9]annulen-11-one **6q**



was obtained following general procedure XI using the corresponding aldehyde **4q** (40.0 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6q** (8.00 mg, 0.04 mmol, 20%) was afforded as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 8.01 (d, *J* = 7.8 Hz, 1H, CH_{arom}), 7.50 (t, *J* = 7.7 Hz, 1H, CH_{arom}), 7.31 (t, *J* = 7.4 Hz, 1H, CH_{arom}), 7.26 – 7.22 (m, 1H, CH_{arom}), 3.38 – 3.27 (m, 1H, ⁶CH), 2.93 – 2.81 (m, 1H, ¹CH), 2.45 (dt, *J* = 12.7, 6.1 Hz, 1H, ⁷CHH), 2.16 – 2.09 (m, 1H, ⁷CHH), 2.07 – 1.91 (m, 4H, ³CH₂, ⁴CH₂), 1.76 – 1.65 (m, 2H, ²CHH), 1.64 – 1.46 (m, 2H, ²CHH, ⁵CHH), 1.13 – 1.00 (m, 1H, ⁵CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 203.2 (C=O), 148.6 (C_{arom}), 133.7 (C_{arom}), 132.7 (C_{arom}), 128.7 (C_{arom}), 127.1 (C_{arom}), 126.7 (C_{arom}), 43.1 (¹CH), 39.1 (³CH₂), 36.4 (⁶CH), 32.6 (⁴CH₂), 29.6 (⁷CH₂), 26.3 (²CH₂), 24.4 (⁵CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3065 (w), 3023 (w), 2917 (m), 2857 (w), 2686 (w), 1672 (s), 1599 (m), 1478 (w), 1452 (m), 1366 (w), 1323 (w), 1293 (m), 1234 (w), 1205 (w), 1158 (w), 1119 (w), 1062 (w), 1029 (w), 970 (m), 840 (w), 817 (w), 763 (s), 695 (w), 676 (w), 593 (w), 557 (w), 502 (w), 427 (w). **HRMS** (EI+) *m/z*: [M]⁺ Calcd for C₁₄H₁₆O 200.12011, Found 200.12066.


1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]naphthalen-4-one **6t**



was obtained following general procedure XI using the corresponding aldehyde **4t** (38.7 mg, 0.21 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6t** (38.2 mg, 0.21 mmol, 99%, 2:1 *cis/trans*) was afforded as a colorless oil.

Major isomer (*cis*):^[18] **¹H NMR:** (300 MHz, CDCl₃) δ = 7.98 (d, *J* = 8.0 Hz, 1H, CH_{arom}), 7.47 (t, *J* = 7.2 Hz, 1H, CH_{arom}), 7.33 – 7.27 (m, 1H, CH_{arom}), 7.22 (d, *J* = 7.1 Hz, 1H, CH_{arom}), 3.00 (dd, *J* = 16.2, 5.6 Hz, 1H, ⁶CHH), 2.92 – 2.76 (m, 2H, ⁶CHH, ¹CH), 2.76 – 2.66 (m, 1H, ⁵CH), 2.12 – 2.00 (m, 2H, ²CH₂), 1.90 – 1.79 (m, 1H, ⁴CHH), 1.73 (d, *J* = 4.8 Hz, 2H, ³CH₂), 1.58 – 1.41 (m, 1H, ⁴CHH) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.2 (C=O), 142.8 (C_{arom}), 133.6 (C_{arom}), 132.3 (C_{arom}), 129.1 (C_{arom}), 127.4 (C_{arom}), 126.8 (C_{arom}), 50.7 (¹CH), 38.9 (⁵CH), 31.3 (⁴CH₂), 31.1 (⁶CH₂), 28.7 (²CH₂), 23.5 (³CH₂) ppm. Minor isomer (*trans*):^[18] **¹H NMR:** (300 MHz, CDCl₃) δ = 8.05 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 7.46 (t, *J* = 7.7 Hz, 1H, CH_{arom}), 7.34 – 7.27 (m, 2H, 2 x CH_{arom}), 3.21 (dd, *J* = 16.1, 3.7 Hz, 1H, ⁶CHH), 2.91 – 2.76 (m, 1H, ⁶CHH), 2.49 – 2.34 (m, 1H, ¹CH), 2.12 – 1.99 (m, 3H, ⁵CH, ⁴CHH, ²CHH), 1.93 – 1.73 (m, 3H, ²CHH, ³CHH, ³CHH), 1.49 – 1.41 (m, 1H, ⁴CHH) ppm. **¹³C NMR:** 200.2 (C=O), 144.5 (C_{arom}), 133.8 (C_{arom}), 133.1 (C_{arom}), 129.3 (C_{arom}), 127.3 (C_{arom}), 126.6 (C_{arom}), 55.7 (¹CH), 44.6 (⁵CH), 36.9 (⁶CH), 32.3 (⁴CH₂), 23.7 (²CH₂), 22.4 (³CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 1684 (s), 1597 (m), 1472 (w), 1450 (m), 1366 (w), 1349 (w), 1331 (w), 1293 (w), 1250 (m), 1199 (w), 1151 (w), 1132 (w), 1111 (w), 1020 (w), 977 (w), 957 (w), 869 (w), 823 (w), 802 (w), 759 (m), 725 (w), 674 (w), 633 (w), 592 (w), 505 (w), 460 (w). **HRMS** (ESI+) *m/z*: [M]⁺ Calcd for C₁₃H₁₄O_H 187.1117, Found 187.1115.

1,3,4,4a,9a,10-hexahydroanthracen-9(2H)-one **6u**




was obtained following general procedure XI using the corresponding aldehyde **4u** (40.0 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6u** (39.4 mg, 0.19 mmol, 98%, 73:27 *cis/trans*) was afforded as a colorless solid. The *trans* isomer could not be obtained separately.

¹H NMR: (300 MHz, CDCl₃) δ = 8.05 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 7.47 (t, *J* = 7.5 Hz, 1H, CH_{arom}), 7.30 (d, *J* = 7.4 Hz, 1H, CH_{arom}), 7.22 (d, *J* = 7.7 Hz, 1H, CH_{arom}), 3.00 (qd, *J* = 16.7, 5.9 Hz, 2H, ⁷CH_{2,benzylic}), 2.74 – 2.67 (m, 1H, ¹CH), 2.47 – 2.37 (m, 1H, ⁶CH), 2.26 – 2.14 (m, 1H, ⁵CHH), 1.69 – 1.58 (m, 1H, ²CHH), 1.52 – 1.36 (m, 6H, ⁵CHH, ²CHH, ³CH₂, ⁴CH₂) ppm.

¹³C NMR: (126 MHz, CDCl₃) δ = 200.5 (C=O), 143.0 (C_{arom}), 133.5 (C_{arom}), 132.0 (C_{arom}), 129.4 (C_{arom}), 127.4 (C_{arom}), 126.6 (C_{arom}), 48.5 (¹CH), 36.0 (⁶CH), 33.5 (⁷CH₂), 29.1 (^{3/4}CH₂), 25.6 (⁵CH₂), 24.0 (²CH₂), 23.6 (^{3/4}CH₂) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3063 (w), 2922 (s), 2851 (w), 1676 (s), 1598 (m), 1480 (w), 1450 (m), 1366 (w), 1334 (w), 1307 (w), 1287 (w), 1265 (w), 1231 (m), 1209 (w), 1156 (w), 1138 (w), 1105 (w), 1024 (w), 1003 (w), 958 (w), 940 (w), 912 (w), 882 (w), 843 (w), 819 (w), 792 (w), 750 (m), 670 (w), 617 (w), 580 (w), 492 (w), 446 (w). **HRMS** (EI+) *m/z*: [M]⁺ Calcd for C₁₄H₁₆O 200.12011, Found 200.12027. **m.p.** 76.7 – 81.7 °C (Et₂O).


8-fluoro-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one **6d**



was obtained following general procedure XI using the corresponding aldehyde **4d** (34.9 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6d** (28.8 mg, 0.16 mmol, 83%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.39 (td, *J* = 8.0, 5.1 Hz, 1H, CH_{arom}), 7.01 (d, *J* = 7.6 Hz, 1H, CH_{arom}), 6.96 (ddd, *J* = 11.5, 8.2, 1.1 Hz, 1H, CH_{arom}), 3.01 – 2.97 (m, 2H, CH_{2,benzylic}), 1.99 – 1.92 (m, 2H, CH₂), 1.21 (s, 6H, 2 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.18 (d, *J* = 1.2 Hz, C=O), 162.94 (d, *J* = 264.9 Hz, FC_{arom}), 146.0 (C_{arom}), 134.00 (d, *J* = 10.3 Hz, C_{arom}), 124.40 (d, *J* = 4.1 Hz, C_{arom}), 120.60 (d, *J* = 5.0 Hz, C_{arom}), 115.08 (d, *J* = 22.4 Hz, C_{arom}), 42.75 (C_{quart}), 36.30 (CH₂), 26.10 (CH_{2,benzylic}), 24.47 (2 x CH₃) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -111.93 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 2964 (w), 2928 (w), 2867 (w), 1687 (s), 1609 (s), 1572 (w), 1454 (m), 1384 (w), 1350 (w), 1300 (w), 1256 (m), 1221 (w), 1203 (w), 1161 (w), 1072 (w), 1043 (w), 1024 (w), 1000 (m), 960 (w), 889 (w), 862 (w), 801 (m), 778 (w), 748 (w), 692 (w), 641 (w), 605 (w), 560 (w), 482 (w), 461 (w), 433 (w). **HRMS** (ESI+) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₃FO_{Na} 215.0800, Found 215.0847.


6-fluoro-2-methyl-3,4-dihydronaphthalen-1(2H)-one **6c**



was obtained following general procedure XI using the corresponding aldehyde **4c** (35.1 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6c** (29.8 mg, 0.17 mmol, 85%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.06 (dd, *J* = 8.7, 6.0 Hz, 1H, CH_{arom}), 6.98 (td, *J* = 8.5, 2.6 Hz, 1H, CH_{arom}), 6.94 – 6.87 (m, 1H, CH_{arom}), 3.06 – 2.93 (m, 2H, CH_{2,benzylic}), 2.58 (dq, *J* = 11.3, 6.8, 4.5 Hz, 1H, CH), 2.23 – 2.17 (m, 1H, CHH), 1.93 – 1.84 (m, 1H, CHH), 1.27 (d, *J* = 6.8 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 199.4 (C=O), 165.7 (d, *J* = 254.6 Hz, C_{arom}), 147.3 (d, *J* = 8.6 Hz, C_{arom}), 130.7 (d, *J* = 9.5 Hz, C_{arom}), 129.3 – 129.2 (m, C_{arom}), 115.1 (d, *J* = 21.0 Hz, C_{arom}), 114.4 (d, *J* = 21.9 Hz, C_{arom}), 42.6 (CH), 31.4 (CH₂), 29.1 (CH_{2,benzylic}), 15.5 (CH₃) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -105.58 ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3063 (w), 2930 (m), 2861 (w), 1683 (s), 1607 (s), 1584 (m), 1487 (w), 1457 (w), 1432 (w), 1375 (w), 1358 (w), 1318 (w), 1243 (s), 1141 (w), 1115 (w), 1082 (w), 1023 (w), 973 (m), 902 (w), 869 (m), 829 (w), 801 (w), 757 (w), 727 (w), 662 (w), 601 (w), 574 (w), 522 (w), 449 (w), 424 (w). **HRMS** (ESI+) *m/z*: [M+H]⁺ Calcd for C₁₁H₁₂FOH 179.0867, Found 179.0867.


2-methyl-7-(trifluoromethyl)-3,4-dihydronaphthalen-1(2H)-one **6b**



was obtained following general procedure XI using the corresponding aldehyde **4b** (45.6 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6b** (23.9 mg, 0.13 mmol, 67%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.33 (s, 1H, CH_{arom}), 7.71 (dd, *J* = 8.0, 2.7 Hz, 1H, CH_{arom}), 7.40 (d, *J* = 8.0 Hz, 1H, CH_{arom}), 3.17 – 3.02 (m, 2H, CH_{2,benzylic}), 2.71 – 2.60 (m, 1H, CH), 2.26 (dq, *J* = 13.4, 4.5 Hz, 1H, CHH), 1.93 (dddd, *J* = 13.5, 12.2, 10.8, 5.2 Hz, 1H, CHH), 1.31 (d, *J* = 6.8 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 199.6 (C=O), 147.8 (C_{arom}), 132.8 (C_{arom}), 129.8 – 128.9 (m, C_{arom}), 129.7 (C_{arom}), 129.3 (q, *J* = 3.3 Hz, C_{arom}), 124.8 (q, *J* = 3.8 Hz, C_{arom}), 124.0 (q, *J* = 272.1 Hz, CF₃), 42.7 (CH), 31.0 (CH₂), 28.9 (CH_{2,benzylic}), 15.4 (CH₃) ppm. **¹⁹F NMR:** (282 MHz, CDCl₃) δ = -62.71 ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 2936 (w), 2869 (w), 1692 (s), 1619 (m), 1457 (w), 1434 (w), 1377 (w), 1332 (s), 1318 (w), 1260 (m), 1242 (w), 1208 (m), 1165 (m), 1124 (s), 1091 (w), 1071 (m), 988 (w), 926 (w), 861 (w), 842 (w), 815 (w), 760 (w), 745 (w), 717 (w), 693 (w), 651 (w), 613 (w), 532 (w), 514 (w), 436 (w), 418 (w). **HRMS (ESI-)** m/z: [M]⁻ Calcd for C₁₂H₁₀FO 227.0689, Found 227.0690.


2,2,6-trimethyl-3,4-dihydronaphthalen-1(2H)-one **6e**



was obtained following general procedure XI using the corresponding aldehyde **4e** (37.7 mg, 0.2 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6e** (33.2 mg, 0.18 mmol, 88%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 7.94 (d, *J* = 8.0 Hz, 1H, CH_{arom}), 7.13 – 7.08 (m, 1H, CH_{arom}), 7.02 (dp, *J* = 1.6, 0.8 Hz, 1H, CH_{arom}), 2.94 (t, *J* = 6.4 Hz, 2H, CH_{2,benzylic}), 2.37 (s, 3H, C_{arom}CH₃), 1.96 (dd, *J* = 6.8, 5.9 Hz, 2H, CH₂), 1.21 (s, 6H, 2 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 202.8 (C=O), 143.9 (C_{arom}), 143.6 (C_{arom}), 129.3 (C_{arom}), 129.2 (C_{arom}), 128.3 (C_{arom}), 127.8 (C_{arom}), 41.7 (C_{quart}), 36.9 (CH₂), 25.8 (CH₂), 24.6 (2 x CH₃), 21.8 (C_{arom}CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 2962 (w), 2924 (m), 2855 (w), 1679 (s), 1609 (m), 1471 (w), 1452 (w), 1383 (w), 1362 (w), 1348 (w), 1306 (m), 1227 (s), 1110 (w), 1036 (w), 1022 (w), 994 (w), 967 (w), 903 (w), 835 (w), 772 (w), 724 (w), 698 (w), 665 (w), 569 (w), 518 (w), 460 (w), 437 (w). **HRMS (ESI+)** m/z: [M+Na]⁺ Calcd for C₁₃H₁₆ONa 211.1093, Found 211.1095.


7-chloro-2-methyl-3,4-dihydronaphthalen-1(2H)-one **6a**



was obtained following general procedure XI using the corresponding aldehyde **4a** (40.4 mg, 0.21 mmol) and the reaction was carried out at a concentration of 15 mM for 8 h. The product **6a** (39.8 mg, 0.21 mmol, 99%) was afforded as a colorless solid.

¹H NMR: (500 MHz, CDCl₃) δ = 7.99 (d, *J* = 2.3 Hz, 1H, CH_{arom}), 7.41 (dd, *J* = 8.1, 2.3 Hz, 1H, CH_{arom}), 7.19 (d, *J* = 8.1 Hz, 1H, CH_{arom}), 3.05 – 2.90 (m, 2H, CH_{2,benzylic}), 2.63 – 2.52 (m, 1H, CH), 2.20 (dq, *J* = 13.3, 4.4 Hz, 1H, CHH), 1.87 (dddd, *J* = 13.4, 12.2, 10.9, 5.1 Hz, 1H, CHH), 1.27 (d, *J* = 6.8 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 199.7 (C=O), 142.5 (C_{arom}), 133.8 (C_{arom}), 133.1 (C_{arom}), 132.9 (C_{arom}), 130.4 (C_{arom}), 127.3 (C_{arom}), 42.6 (CH), 31.3 (CH₂), 28.4 (CH_{2,benzylic}), 15.5 (CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3060 (w), 2964 (w), 2932 (w), 2863 (w), 1688 (s), 1595 (w), 1568 (w), 1476 (m), 1455 (w), 1433 (w), 1410 (w), 1375 (w), 1356 (w), 1318 (w), 1293 (w), 1257 (w), 1215 (s), 1136 (w), 1097 (w), 1020 (w), 985 (w), 905 (w), 855 (w), 830 (w), 804 (m), 758 (w), 707 (w), 685 (w), 651 (w), 527 (w), 468 (w), 436 (w). **HRMS (EI+)** m/z: [M]⁺ Calcd for C₁₁H₁₁ClO 194.04984, 196.04713, Found 194.04851, 196.04624.

Irradiation of **4j**




was obtained following general procedure XI for 5 h using the corresponding aldehyde **6j** (47.8 mg, 0.20 mmol) and the reaction was carried out at a concentration of 10 mM. The resulting product **6k** (15.5 mg, 0.06 mmol, 32%) was

afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.04 (dd, *J* = 7.9, 1.7 Hz, 1H, CH_{arom}), 7.46 (td, *J* = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.30 (t, *J* = 7.6 Hz, 1H, CH_{arom}), 7.24 (d, *J* = 7.6 Hz, 1H), 3.10 – 2.93 (m, 2H), 2.65 – 2.54 (m, 1H), 2.20 (dq, *J* = 13.2, 4.4 Hz, 1H), 1.89 (dtd, *J* = 13.2, 11.5, 4.7 Hz, 1H), 1.28 (d, *J* = 6.7 Hz, 3H) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.0 (C=O), 144.4 (C_{arom}), 133.2 (C_{arom}), 132.5 (C_{arom}), 128.9 (C_{arom}), 127.5 (C_{arom}), 126.7 (C_{arom}), 42.8 (CH), 31.5 (CH₂), 29.0 (CH_{2,benzylic}), 15.6 (CH₃) ppm.


2-methyl-8-(trimethylsilyl)-3,4-dihydronaphthalen-1(2H)-one **6f**



was obtained following general procedure XI using the corresponding aldehyde **4f** (45.6 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 5 h. The product **6f** (38.0 mg, 0.16 mmol, 83%) was afforded as a colorless solid.

¹H NMR: (500 MHz, CDCl₃) δ = 7.60 (d, *J* = 7.3 Hz, 1H, CH_{arom}), 7.42 (t, *J* = 7.5 Hz, 1H, CH_{arom}), 7.26 – 7.24 (m, 1H, CH_{arom}), 3.11 – 2.94 (m, 2H, CH_{2,benzylic}), 2.66 – 2.57 (m, 1H, CHCH₃), 2.20 (dq, *J* = 13.3, 4.6 Hz, 1H, CHH), 1.88 (dtd, *J* = 13.2, 11.2, 4.7 Hz, 1H, CHH), 1.27 (d, *J* = 6.8 Hz, 3H, CH₃), 0.29 (s, 9H, Si(CH₃)₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 202.0 (C=O), 144.7 (C_{arom}), 143.1 (C_{arom}), 137.1 (C_{arom}), 134.3 (C_{arom}), 131.9 (C_{arom}), 130.1 (C_{arom}), 42.9 (CHCH₃), 31.3 (CH_{2,benzylic}), 29.8 (CH₂), 15.9 (CH₃), 0.7 (Si(CH₃)₃) ppm. **²⁹Si NMR:** (60 MHz, CDCl₃) δ = 5.35. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3043 (w), 2934 (w), 1680 (s), 1575 (w), 1458 (w), 1414 (w), 1375 (w), 1359 (w), 1319 (w), 1286 (w), 1245 (m), 1225 (w), 1198 (w), 1147 (w), 1106 (w), 1081 (w), 1022 (w), 967 (w), 939 (w), 859 (w), 838 (s), 783 (w), 760 (m), 690 (w), 674 (w), 625 (w), 581 (w), 529 (w), 481 (w), 452 (w), 429 (w). **HRMS (ESI+)** *m/z*: [M+Na]⁺ Calcd for C₁₄H₂₀OSiNa 255.1176, Found 255.1168.


2-methyl-3,4-dihydrophenanthren-1(2H)-one **6g**



was obtained following general procedure XI using the corresponding aldehyde **4g** (45.2 mg, 0.19 mmol) and the reaction was carried out at a concentration of 15 mM for 8 h. The crude was purified by column chromatography (*n*-pentane/toluene 6:1). **6g** (11.8 mg, 0.05 mmol, 26%) was afforded as a colorless solid.

¹H NMR: (500 MHz, CDCl₃) δ = 8.19 – 8.11 (m, 2H, 2 x CH_{arom}), 7.91 – 7.88 (m, 1H, CH_{arom}), 7.78 (d, *J* = 8.6 Hz, 1H, CH_{arom}), 7.64 – 7.60 (m, 2H, 2 x CH_{arom}), 3.59 (dt, *J* = 17.3, 4.4 Hz, 1H, CHH_{benzylic}), 3.32 (ddd, *J* = 16.8, 10.9, 5.0 Hz, 1H, CHH_{benzylic}), 2.79 – 2.68 (m, 1H, CH), 2.47 – 2.38 (m, 1H, CHH), 2.09 – 2.00 (m, 1H, CHH), 1.35 (d, *J* = 6.8 Hz, 3H, CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 201.2 (C=O), 142.5 (C_{arom}), 135.7 (C_{arom}), 131.6 (C_{arom}), 129.9 (C_{arom}), 128.9 (C_{arom}), 128.3 (C_{arom}), 127.1 (C_{arom}), 126.8 (C_{arom}), 124.9 (C_{arom}), 123.2 (C_{arom}), 41.8 (CH), 30.9 (CH₂), 25.2 (CH_{2,benzylic}), 15.5 (CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3061 (w), 2961 (w), 2930 (w), 2862 (w), 1677 (s), 1621 (w), 1596 (w), 1458 (w), 1430 (w), 1374 (w), 1328 (w), 1265 (w), 1231 (m), 1177 (w), 1124 (w), 1072 (w), 1025 (w), 964 (w), 905 (w), 868 (w), 824 (w), 758 (m), 718 (w), 666 (w), 576 (w), 542 (w), 523 (w), 413 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₅H₁₄OH 211.1117, Found 211.1120. **m.p.** 49.7 – 54.7 °C (Et₂O).


6,6-dimethyl-7,8-dihydroquinolin-5(6H)-one **6h**



was obtained following general procedure XI using the corresponding aldehyde **4h** (39.1 mg, 0.23 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The crude was purified by column chromatography (*n*-pentane/EtOAc 2:1). The product **6h** (38.8 mg, 0.23 mmol, 99%) was afforded as a yellow oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.67 (dd, *J* = 4.8, 1.9 Hz, 1H, CH_{arom}), 8.29 (dd, *J* = 7.9, 1.9 Hz, 1H, CH_{arom}), 7.30 – 7.25 (m, 1H, CH_{arom}), 3.17 (t, *J* = 6.4 Hz, 2H, CH₂), 2.04 (t, *J* = 6.5 Hz, 2H, CH₂), 1.23 (s, 6H, 2 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 202.5 (C=O), 162.7 (C_{arom}), 153.4 (C_{arom}), 136.1 (C_{arom}), 127.1 (C_{arom}), 122.3 (C_{arom}), 41.6 (C_{quart}), 35.4 (CH₂), 29.0 (CH₂), 24.2 (2 x CH₃) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3367 (w), 3054 (w), 2963 (w), 2929 (w), 2867 (w), 1686 (s), 1582 (s), 1472 (w), 1457 (m), 1438 (w), 1423 (w), 1385 (m), 1364 (w), 1347 (w), 1310 (m), 1261 (w), 1247 (w), 1222 (m), 1159 (w), 1094 (m), 1058 (w), 1019 (w), 994 (w), 966 (m), 897 (w), 826 (w), 802 (w), 784 (w), 756 (m), 717 (w), 672 (w), 632 (w), 574 (w), 536 (w), 491 (w), 455 (w), 437 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₁H₁₃NOH 176.1063, Found 176.1070.


6,6-dimethyl-7,8-dihydroisoquinolin-5(6H)-one **6i**



was obtained following general procedure XI using the corresponding aldehyde **4i** (33.8 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The crude was purified by column chromatography (*n*-pentane/EtOAc 2:1). The product **6i** (33.0 mg, 0.19 mmol, 98%) was afforded as a yellow oil.

¹H NMR: (300 MHz, CDCl₃) δ = 8.64 (s, 1H, CH_{arom}), 8.61 (d, *J* = 5.0 Hz, 1H, CH_{arom}), 7.78 (d, *J* = 5.1 Hz, 1H, CH_{arom}), 2.99 (t, *J* = 6.3 Hz, 2H, CH_{2,benzylic}), 2.03 (t, *J* = 6.4 Hz, 2H, CH₂), 1.23 (s, 9H, 3 x CH₃) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 202.4 (C=O), 151.5 (C_{arom}), 148.6 (C_{arom}), 136.8 (C_{arom}), 136.7 (C_{arom}), 120.1 (C_{arom}), 42.2 (C_{quart}), 36.3 (CH₂), 24.1 (2 x CH₃), 22.6 (CH_{2,benzylic}) ppm. **IR (ATR)** $\tilde{\nu}$ (cm⁻¹) = 3026 (w), 2965 (w), 2929 (w), 2868 (w), 1695 (s), 1590 (w), 1563 (w), 1472 (w), 1452 (w), 1433 (w), 1412 (w), 1385 (w), 1364 (w), 1349 (w), 1314 (m), 1228 (m), 1172 (w), 1137 (w), 1050 (w), 1034 (w), 996 (w), 976 (w), 911 (w), 896 (w), 849 (w), 823 (w), 787 (w), 707 (w), 693 (w), 630 (w), 528 (w), 424 (w). **HRMS (ESI+)** *m/z*: [M+H]⁺ Calcd for C₁₁H₁₃NOH 176.1070, Found 176.1064.

9.1 Limitation of the Substrate Scope



scheme 1: Irradiation experiments that have not led to the corresponding cyclized photo-hydroacylation products.

The observed absence of conversion of substrates bearing electron donating substituents indicates the inhibition of required mechanistic steps. However, after irradiation isomerization of the olefine can be observed. It is reasonable to suggest that 1,5-HAT does not occur.

9.2 Isomerisation of Olefin in Substrates bearing EDG-substituents




Figure 5: ¹H-NMR spectrum before and after irradiation of 4S2 showing isomerization of the olefin.





Figure 6: ¹H-NMR spectrum before and after irradiation of S13 showing isomerization of the olefin.


10 Synthesis of Prolonged Sidechain

2-vinylbenzaldehyde **4y**



was obtained following the procedure reported by OH *et al.* starting from 2-bromo benzaldehyde.^[19]

1-bromo-2-(but-3-en-1-yl)benzene **S29**,




To a solution of 1-bromo-2-(bromomethyl)benzene (300 mg, 1.20 mmol) in anhydrous THF (0.87 mL) allyl magnesium bromide (1.83 mL, 0.79 M, 1.20 equiv) in anhydrous THF (1.45 mL) were added slowly at 0 °C and the mixture was stirred at rt overnight. HCl aq. (1 M, 5 mL) was added, the organic layer was extracted with CH₂Cl₂ (3

x 15 mL) and dried over Na₂SO₄. The solvent was removed under reduced pressure. Purification by column chromatography (*n*-pentane) afforded **S29** (113 mg, 0.54 mmol, 44%) as a pale yellow oil. Spectral data was in agreement with the literature.^[20]

¹H NMR: (300 MHz, CDCl₃) δ = 7.56 – 7.51 (m, 1H, CH_{arom}), 7.25 – 7.18 (m, 2H, 2xCH_{arom}), 7.03 (d, J = 3.3 Hz, 1H, CH_{arom}), 5.89 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, CH=CH₂), 5.11 – 4.98 (m, 1H, CH=CH₂), 2.87 – 2.80 (m, 2H, CH_{2,benzylic}), 2.43 – 2.34 (m, 2H, CH₂) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 141.2 (C_{arom}), 137.8 (CH_{olef}), 132.3 (C_{arom}), 130.5 (C_{arom}), 127.7 (C_{arom}), 127.5 (C_{arom}), 124.6 (C_{arom}), 114.8 (CH_{2,olef}), 35.8 (CH_{2,benzylic}), 34.0 (CH₂) ppm.


2-(but-3-en-1-yl)benzaldehyde **S30**,



was obtained according to general procedure X, using the corresponding bromide **S29** (113 mg, 0.54 mmol). Purification by column chromatography afforded **S30** (20.8 mg, 0.13 mmol, 24%) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 10.27 (s, 1H, CHO), 7.83 (dd, J = 7.6, 1.6 Hz, 1H, CH_{arom}), 7.51 (td, J = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.38 (td, J = 7.5, 1.3 Hz, 1H, CH_{arom}), 7.28 (d, J = 7.6 Hz, 1H, CH_{arom}), 5.87 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, CH_{olef}), 5.04 (dq, J = 17.0, 1.5 Hz, 1H, CH_{olef}), 5.00 (ddt, J = 10.2, 2.0, 1.2 Hz, 1H, CH_{olef}), 3.16 – 3.12 (m, 2H, CH_{2,benzylic}), 2.41 – 2.35 (m, 2H, CH₂) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 192.5 (CHO), 144.7 (C_{arom}), 137.6 (CH_{olef}), 134.0 (C_{arom}), 133.9 (C_{arom}), 132.2 (C_{arom}), 131.2 (C_{arom}), 126.8 (C_{arom}), 115.6 (CH_{2,olef}), 36.1 (CH₂), 32.2 (CH_{2,benzylic}). **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3074 (w), 2927 (w), 2860 (w), 2733 (w), 1695 (s), 1640 (w), 1600 (w), 1574 (w), 1486 (w), 1451 (w), 1403 (w), 1293 (w), 1206 (w), 1192 (w), 1161 (w), 1112 (w), 996 (w), 913 (w), 870 (w), 827 (w), 803 (w), 756 (m), 661 (w), 636 (w), 585 (w), 447 (w). **HRMS (ESI+)** m/z: [M+H]⁺ Calcd for C₁₁H₁₂O 161.0961; Found 161.0953.


2-methyl-3,4-dihydronaphthalen-1(2H)-one **6k**,



was obtained via irradiation of homoallyl aldehyde **S30** (20 mg, 0.12 mmol, 0.015 M) in CH₂Cl₂ (9.5 mL) with 365 nm UV-Light for 3 h. Purification by column chromatography afforded **6k** (5.0 mg, 0.03 mmol, 25%) as a colorless oil.


11 Synthesis of Deuterated Compounds

2-Bromobenzaldehyde-d **S31**




was obtained following the procedure reported by YOU *et al.* starting from 2-Bromobenzaldehyde.^[21]

1-bromo-2-(dimethoxymethyl-d)benzene **S32**



was obtained according to general procedure I using the corresponding aldehyde **S31** (967 mg, 5.20 mmol). The crude was used in the following steps without further purification.


2-(but-2-en-1-yl)-benzaldehyde-d **4v**,



was obtained according to general procedure II A, using corresponding aryl bromide **S32** (74.3 mg, 0.32 mmol) and crotyl bromide (0.05 mL, 0.37 mmol, 85:15 *E/Z*). The crude was then used according to general procedure III. Purification by column chromatography using 100:1 (*n*-pentane/Et₂O) afforded **4v** (27.6 mg, 0.17 mmol, 67:33 *E/Z*, 53% over two steps) as a colorless oil.

¹H NMR: (300 MHz, CDCl₃) δ = 7.84 (dt, *J* = 7.6, 2.3 Hz, 1H, CH_{arom}), 7.52 (tt, *J* = 7.6, 1.4 Hz, 1H, CH_{arom}), 7.40 – 7.27 (m, 2H, 2 x CH_{arom}), 5.69 – 5.38 (m, 2H, 2 x CH_{olef}), 3.83 (d, *J* = 5.7 Hz, 0.68H, CH_{2,minor}), 3.74 (dt, *J* = 6.2, 1.6 Hz, 1.32H, CH_{2,major}), 1.74 (dt, *J* = 6.4, 1.2 Hz, 1H, CH_{3,minor}), 1.66 (dq, *J* = 6.3, 1.6 Hz, 2H, CH_{3,major}) ppm. **¹³C NMR:** (75 MHz, CDCl₃) δ = 192.0 (t, *J* = 26.7 Hz, COD), 143.9 (C_{arom,minor}), 143.6 (C_{arom,major}), 134.1 (2C, C_{arom,major}, C_{arom,minor}), 133.9 (d, *J* = 3.7 Hz, C_{arom,major}), 131.8 (C_{arom,minor}), 131.1 (C_{arom,major}), 131.0 (C_{arom,major}), 130.7 (C_{arom,minor}), 129.8 (CH_{olef,major}), 128.6 (CH_{olef,minor}), 127.3 (CH_{olef,major}), 126.9 (C_{arom,major}), 126.8 (C_{arom,minor}), 125.5 (CH_{olef,minor}), 35.5 (CH_{2,major}), 30.2 (CH_{2,minor}), 18.0 (CH_{3,major}), 13.1 (CH_{3,minor}) ppm. Due to the noise to signal ratio, the quaternary carbon atom C_{arom}COD could not be detected. **²H-NMR:** (77 MHz, CHCl₃) δ = 10.13 (s, 1D, C=D) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3402 (w), 3067 (w), 3024 (w), 2976 (w), 2932 (w), 1768 (w), 1715 (w), 1679 (s), 1598 (m), 1572 (w), 1481 (w), 1451 (w), 1368 (w), 1286 (w), 1217 (m), 1158 (w), 1121 (w), 1057 (w), 1022 (w), 969 (m), 859 (w), 753 (s), 656 (w), 632 (w), 549 (w), 526 (w), 492 (w), 462 (w), 427 (w). **HRMS (ESI+)** *m/z*: [M+NH]⁺ Calcd for C₁₁H₁₂D₁O₁ 162.1024; Found 162.1018.

2-methyl-3,4-dihydronaphthalen-1(2H)-one-3-d **6v**,




was obtained following general procedure XI using the corresponding aldehyde **4v** (31.4 mg, 0.20 mmol) and the reaction was carried out at a concentration of 15 mM for 3 h. The product **6v** (18.5 mg, 0.11 mmol, 59%) was afforded as a colorless oil.

¹H NMR: (500 MHz, CDCl₃) δ = 8.04 (dd, *J* = 7.8, 1.6 Hz, 1H, CH_{arom}), 7.45 (td, *J* = 7.5, 1.5 Hz, 1H, CH_{arom}), 7.33 – 7.27 (m, 1H, CH_{arom}), 7.25 – 7.21 (m, 1H, CH_{arom}), 3.02 (d, *J* = 11.2 Hz, 0.5H, CDH), 2.63 – 2.54 (m, 0.5H, CHD) ppm. **¹³C NMR:** (126 MHz, CDCl₃) δ = 200.9 (C=O), 144.3 (C_{arom}), 133.2 (C_{arom}), 132.6 (C_{arom}), 128.9 (C_{arom}), 127.6 (C_{arom}), 126.7 (C_{arom}), 42.7 (CHCH₃), 31.4 – 30.9 (m, CDH), 28.9 (CH₂), 15.57 (CH₃) ppm. **²H-NMR:** (77 MHz, CHCl₃) δ = 2.00 (s, 0.5 D, CDH), 1.69 (s, 0.5 D, CHD) ppm. **IR** (ATR) $\tilde{\nu}$ (cm⁻¹) = 3351 (w), 3068 (w), 2967 (w), 2931 (w), 1683 (s), 1600 (m), 1455 (m), 1434 (w), 1375 (w), 1292 (w), 1248 (m), 1221 (w), 1158 (w), 1125 (w), 1093 (w), 1032 (w), 969 (m), 914 (w), 897 (w), 848 (w), 792 (w), 782 (w), 732 (m), 708 (w), 697 (w), 673 (w), 561 (w), 517 (w), 489 (w), 448 (w). **HRMS (ESI+)** *m/z*: [M+NH]⁺ Calcd for C₁₁H₁₂D₁O₁ 162.1024; Found 162.1019.

12 Mechanistic Studies

12.1 Deuteration Studies



Deuterated benzaldehyde **4v** (31.4 mg, 0.20 mmol, 1.00 equiv) was placed in a 25 mL round bottom flask. The flask was put under argon atmosphere and dry, degassed CH_2Cl_2 (13 mL, 15 mM) was added. The reaction was irradiated 6-7 cm away from a 365 nm LED for 3 h at rt. The entire reaction mixture was filtered through a short pad of silica gel and washed with CH_2Cl_2 (100 mL). After removal of the solvents under reduced pressure, tetralone **6v** (18.5 mg, 0.11 mmol, 59%, 100% deuteration) was isolated as a colorless oil. The deuterium atom insertion occurred both in *cis* and *trans* position (1:1 H/D), in relation to the α -methyl group.





Figure S7: $^1\text{H-NMR}$ spectrum of **6v** in CDCl_3 , 500 MHz.

12.2 Deuterium Scrambling Experiment



Deuterated benzaldehyde **4v** (17.9 mg, 0.11 mmol, 0.50 equiv) and **4d** (19.8 mg, 0.11 mmol, 0.50 equiv) was placed in a 25 mL round bottom flask. The flask was put under argon atmosphere and dry, degassed CH_2Cl_2 (14.8 mL, 15 mM) was added. The reaction was irradiated 6-7 cm away from a 365 nm LED for 3 h at rt. The entire reaction mixture was filtered through a short pad of silica gel and washed with CH_2Cl_2 (100 mL) and concentrated under reduced pressure. The crude was purified by column chromatography (*n*-pentane/ Et_2O 100:1→10:1

) to give tetralone **6v** (10.1 mg, 0.06 mmol, 56%, 100% deuteration) and tetralone **6d** (17.2 mg, 0.09 mmol, 81%, 0% deuteration). No deuterium scrambling was observed.




Figure S8: $^1\text{H-NMR}$ spectrum of **6v** and **6d** after deuterium scrambling experiment in CDCl_3 , 300 MHz.

12.3 Quantum Yield Determination

The quantum yield measurement was carried out according to a procedure reported by MEGGERS *et al.*^[22]

As a light source a 365 nm LED used. A Powermeter was employed as a detector. The measurement was carried out in a dark room with a 1.1 W red LED. The quantum yield was determined for the reaction **4k** → **6k**. The setup is explained in the following:

- Step 1:** To determine the radiant power of light transmitted, the cuvette was measured containing a blank solution (CH₂Cl₂). The measurement gave the value of $P_{blank} = 286 \text{ mW}$.
- Step 2:** The solution of **4k** (7.2 mg, 0.045 mmol) in CH₂Cl₂ (3 mL, 15 mm) was added into the fluorescence cuvette containing a stirring bar under a stream of nitrogen. The cuvette was irradiated in the set-up and irradiated with a 365 nm LED. The measured transmitted radiant power $P^0_{sample} = 270 \text{ mW}$ was observed at the beginning of the reaction.
- Step 3:** After irradiation of 300 s the transmitted radiant power of $P^1_{sample} = 220.2 \text{ mW}$ was measured. Resulting in $P^{\varnothing}_{sample} = 245.1 \text{ mW}$. Using ¹H-NMR spectroscopy, the amount of formed product **6k** was determined to be $1.04 \times 10^{-5} \text{ mol}$.
- Step 4:** Using the following formula, the quantum yield of the reaction was determined to be 0.28:

$$\text{Quantum Yield} = \frac{N_{product}}{N_{photon}} = \frac{N_A \times n_{product}}{\frac{P_{absorbed} \times t}{\frac{h \times c}{\lambda}}} = \frac{h \times c \times N_A \times n_{product}}{(P_{blank} - P^{\varnothing}_{sample}) \times t \times \lambda}$$

$$= \frac{6.626 \times 10^{-34} \text{ Js} \times 2.998 \times 10^8 \text{ ms}^{-1} \times 6.022 \times 10^{23} \text{ mol}^{-1} \times 1.04 \times 10^{-5} \text{ mol}}{(286 - 245.1) \times 10^{-3} \text{ Js}^{-1} \times 300 \text{ s} \times 365 \times 10^{-9}} = 0.28$$

With the quantum yield being QY < 1, a chain reaction process for the reported photoreaction can be discarded.

12.4 UV-Vis Measurements








Figure S9: Absorption spectra of aldehyde **4k** and tetralone **6k** in CH₂Cl₂ (0.05 mM).




S2
(500 MHz, CDCl₃)





S2
(126 MHz, CDCl₃)






S3


(500 MHz, CDCl₃)



S3



(126 MHz, CDCl₃)






4h


(500 MHz, CDCl₃)





4h

(126 MHz, CDCl₃)







S4
(500 MHz, CDCl₃)





S4
(126 MHz, CDCl₃)






S5


(500 MHz, CDCl₃)



S5



(126 MHz, CDCl₃)






4i


(500 MHz, CDCl₃)



4i



(126 MHz, CDCl₃)






4k


(500 MHz, CDCl₃)



4k



(126 MHz, CDCl₃)






41


(300 MHz, CDCl₃)



41



(75 MHz, CDCl₃)






4m


(500 MHz, CDCl₃)



4m



(126 MHz, CDCl₃)






4o





(500 MHz, CDCl₃)




4o



(126 MHz, CDCl₃)









(500 MHz, CDCl₃)



4q



(126 MHz, CDCl₃)






4t


(300 MHz, CDCl₃)



4t



(75 MHz, CDCl₃)






4u


(300 MHz, CDCl₃)



4u



(75 MHz, CDCl₃)






S13


(500 MHz, CDCl₃)



S13



(126 MHz, CDCl₃)






S14


(500 MHz, CDCl₃)





S14

(126 MHz, CDCl₃)







(500 MHz, CDCl₃)





(75 MHz, CDCl₃)







(500 MHz, CDCl₃)





(126 MHz, CDCl₃)






3S3


(500 MHz, CDCl₃)



3S3


(126 MHz, CDCl₃)






3S3



(282 MHz, CDCl₃)






4d


(500 MHz, CDCl₃)



4d


(126 MHz, CDCl₃)






4d



(282 MHz, CDCl₃)






3S4


(500 MHz, CDCl₃)



3S4



(126 MHz, CDCl₃)






4e


(500 MHz, CDCl₃)



4e



(126 MHz, CDCl₃)






3S5


(500 MHz, CDCl₃)



3S5



(126 MHz, CDCl₃)






S18





(300 MHz, CDCl₃)




S18

(75 MHz, CDCl₃)










3S6


(500 MHz, CDCl₃)



3S6



(126 MHz, CDCl₃)






3S7


(500 MHz, CDCl₃)



3S7



(126 MHz, CDCl₃)






4S1


(500 MHz, CDCl₃)



4S1



(126 MHz, CDCl₃)






4S2

(500 MHz, CDCl₃)



4S2



(126 MHz, CDCl₃)






3S9


(500 MHz, CDCl₃)





3S9

(126 MHz, CDCl₃)







4g
(500 MHz, CDCl₃)





4g
(126 MHz, CDCl₃)






S20


(300 MHz, CDCl₃)



S20


(75 MHz, CDCl₃)






S20



(282 MHz, CDCl₃)






S22


(500 MHz, CDCl₃)



S22


(126 MHz, CDCl₃)






S22



(282 MHz, CDCl₃)






S23


(500 MHz, CDCl₃)



S23


(126 MHz, CDCl₃)






S23



(500 MHz, CDCl₃)






4c


(500 MHz, CDCl₃)



4c


(126 MHz, CDCl₃)








4c

(282 MHz, CDCl₃)







4S3
(300 MHz, CDCl₃)





4S3
(75 MHz, CDCl₃)






S24


(300 MHz, CDCl₃)



S24


(75 MHz, CDCl₃)






S24



(282 MHz, CDCl₃)






S26


(500 MHz, CDCl₃)



S26


(126 MHz, CDCl₃)






S26



(282 MHz, CDCl₃)






S27


(500 MHz, CDCl₃)



S27


(126 MHz, CDCl₃)










S27


(282 MHz, CDCl₃)










(282 MHz, CDCl₃)






1S3





(500 MHz, CDCl₃)




1S3

(126 MHz, CDCl₃)










2S1


(500 MHz, CDCl₃)



2S1



(126 MHz, CDCl₃)






2S2


(500 MHz, CDCl₃)



2S2



(126 MHz, CDCl₃)






2S3


(500 MHz, CDCl₃)



2S3



(126 MHz, CDCl₃)






2S4


(500 MHz, CDCl₃)



2S4



(126 MHz, CDCl₃)






5S1


(500 MHz, CDCl₃)



5S1



(126 MHz, CDCl₃)






5S2


(300 MHz, CDCl₃)



5S2



(76 MHz, CDCl₃)






5S3


(500 MHz, CDCl₃)



5S3



(126 MHz, CDCl₃)






5S4


(500 MHz, CDCl₃)



5S4



(126 MHz, CDCl₃)






5S5


(300 MHz, CDCl₃)



5S5



(75 MHz, CDCl₃)






4r


(500 MHz, CDCl₃)



4r



(126 MHz, CDCl₃)






4x


(500 MHz, CDCl₃)



4x



(126 MHz, CDCl₃)






4n


(500 MHz, CDCl₃)



4n



(126 MHz, CDCl₃)






4w


(500 MHz, CDCl₃)



4w



(126 MHz, CDCl₃)






4s


(300 MHz, CDCl₃)



4s



(126 MHz, CDCl₃)






6k


(500 MHz, CDCl₃)



6k



(126 MHz, CDCl₃)






6i


(500 MHz, CDCl₃)





6i

(126 MHz, CDCl₃)







6m
(300 MHz, CDCl₃)





6m
(75 MHz, CDCl₃)






6r


(500 MHz, CDCl₃)



6r



(126 MHz, CDCl₃)






6n



(500 MHz, CDCl₃)






6w


(500 MHz, CDCl₃)





6x

(300 MHz, CDCl₃)



D (ddd)
7.31
J(7.84, 7.13, 1.42)

B (ddd)
7.52
J(7.93, 7.13, 1.61)

A (dd)
8.00
J(7.79, 1.56)



C (dd)
7.43
J(7.88, 1.84)

E (s)
1.94

F (q)
1.53
J(3.26)


G (s)
1.41

H (q)
0.83
J(3.45)






6x

(75 MHz, CDCl₃)




6s

(500 MHz, CDCl₃)





6s

(126 MHz, CDCl₃)




6o


(500 MHz, CDCl₃)



6o



(126 MHz, CDCl₃)






6p



(300 MHz, CDCl₃)








6q

(300 MHz, CDCl₃)







6t (cis)
(300 MHz, CDCl₃)





6t (cis)
(126 MHz, CDCl₃)







6t (trans)
(300 MHz, CDCl₃)





6t (trans)
(126 MHz, CDCl₃)






6u


(300 MHz, CDCl₃)



6u



(126 MHz, CDCl₃)






6d


(500 MHz, CDCl₃)



6d


(126 MHz, CDCl₃)






6d



(282 MHz, CDCl₃)






6c


(500 MHz, CDCl₃)



6c


(126 MHz, CDCl₃)






6c



(282 MHz, CDCl₃)






6b


(500 MHz, CDCl₃)






6b



(282 MHz, CDCl₃)






6e



(500 MHz, CDCl₃)






6a


(500 MHz, CDCl₃)



6a



(126 MHz, CDCl₃)








6f


(500 MHz, CDCl₃)







6g
(500 MHz, CDCl₃)






6h


(300 MHz, CDCl₃)



6h



(126 MHz, CDCl₃)






6i





(300 MHz, CDCl₃)




6i

(126 MHz, CDCl₃)










S30


(500 MHz, CDCl₃)



S30



(126 MHz, CDCl₃)






4v

(300 MHz, CDCl₃)





Hz, CDCl₃)




6v


(500 MHz, CDCl₃)



6v



(126 MHz, CDCl₃)






S30


(500 MHz, CDCl₃)



S30



(126 MHz, CDCl₃)






S31

(500 MHz, CDCl₃)



S31

(126 MHz, CDCl₃)



References

- [1] L. Pitzer, F. Schäfers, F. Glorius, *Angew. Chem. Int. Ed.* **2019**, *58*, 8572-8576.
- [2] H. Park, P. Verma, K. Hong, J.-Q. Yu, *Nature Chemistry* **2018**, *10*, 755-762.
- [3] J. A. P. Maitland, J. A. Leitch, K. Yamazaki, K. E. Christensen, D. J. Cassar, T. A. Hamlin, D. J. Dixon, *Angew. Chem. Int. Ed.* **2021**, *60*, 24116-24123.
- [4] V. Srinivas, M. Koketsu, *J. Org. Chem.* **2013**, *78*, 11612-11617.
- [5] M. Shibata, K. Nakajima, Y. Nishibayashi, *Chem. Commun.* **2014**, *50*, 7874-7877.
- [6] X.-Y. Cui, Y. Ge, S. M. Tan, H. Jiang, D. Tan, Y. Lu, R. Lee, C.-H. Tan, *J. Am. Chem. Soc.* **2018**, *140*, 8448-8455.
- [7] F. J. Geffers, F. R. Kurth, P. G. Jones, D. B. Werz, *Chem. Eur. J.* **2021**, *27*, 14846-14850.
- [8] I. R. Hazelden, X. Ma, T. Langer, J. F. Bower, *Angew. Chem. Int. Ed.* **2016**, *55*, 11198-11202.
- [9] H. Mao, D. W. Kim, H. Y. Shin, C. E. Song, J. W. Yang, *Org. Biomol. Chem.* **2017**, *15*, 1355-1362.
- [10] J. Bhangu, R. M. Whittal, D. G. Hall, *Org. Biomol. Chem.* **2020**, *18*, 3492-3500.
- [11] M. Mohankumar, B. Chattopadhyay, R. Hadji, L. Sanguinet, A. R. Kennedy, V. Lemaure, J. Cornil, O. Fenwick, P. Samori, Y. Geerts, *ChemPlusChem* **2019**, *84*, 1263-1269.
- [12] J. Großkopf, M. Plaza, A. Seitz, S. Breitenlechner, G. Storch, T. Bach, *J. Am. Chem. Soc.* **2021**, *143*, 21241-21245.
- [13] B. Wan, Z. Lu, Z. Wu, C. Cheng, Y. Zhang, *Org. Lett.* **2021**, *23*, 1269-1274.
- [14] C. Pascal, J. Dubois, D. Guénard, F. Guéritte, *J. Org. Chem.* **1998**, *63*, 6414-6420.
- [15] P. Kukula, V. Matoušek, T. Mallat, A. Baiker, *Chem. Eur. J.* **2008**, *14*, 2699-2708.
- [16] E. Hasegawa, N. Yamaguchi, H. Muraoka, H. Tsuchida, *Org. Lett.* **2007**, *9*, 2811-2814.
- [17] H.-C. Shen, H.-L. Su, Y.-C. Hsueh, R.-S. Liu, *Organometallics* **2004**, *23*, 4332-4334.
- [18] R. J. Moss, R. O. White, B. Rickborn, *J. Org. Chem.* **1985**, *50*, 5132-5139.
- [19] J. Lee, H. Y. Kim, K. Oh, *Org. Lett.* **2020**, *22*, 474-478.
- [20] G. F. Meijjs, J. F. Bunnett, A. L. J. Beckwith, *J. Am. Chem. Soc.* **1986**, *108*, 4899-4904.
- [21] A. R. Jagdale, S. W. Youn, *Eur. J. Org. Chem.* **2011**, *2011*, 3904-3910.
- [22] P. S. Steinlandt, W. Zuo, K. Harms, E. Meggers, *Chem. Eur. J.* **2019**, *25*, 15333-15340.

13 Author Contributions

U. Koert administered the project. U. Koert & V. Schmalz conceived and planned the project. V. Schmalz conducted the experimental work.t